Teleflex (TFX) 10-Q 29 Oct 14 2014 Q3 Quarterly report Financial data

Document_and_Entity_Informatio

Document and Entity Information	9 Months Ended
	Sep. 28, 2014	Oct. 20, 2014
Document And Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	28-Sep-14	'
Document Fiscal Year Focus	'2014	'
Document Fiscal Period Focus	'Q3	'
Trading Symbol	'TFX	'
Entity Registrant Name	'TELEFLEX INC	'
Entity Central Index Key	'0000096943	'
Current Fiscal Year End Date	'--12-31	'
Entity Filer Category	'Large Accelerated Filer	'
Entity Common Stock, Shares Outstanding	'	41,413,981

CONDENSED_CONSOLIDATED_STATEME

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (USD $)	3 Months Ended		9 Months Ended
In Thousands, except Per Share data, unless otherwise specified	Sep. 28, 2014	Sep. 29, 2013	Sep. 28, 2014	Sep. 29, 2013
Income Statement [Abstract]	'	'	'	'
Net revenues	$457,173	$413,796	$1,363,824	$1,245,732
Cost of goods sold	221,007	209,804	662,411	631,730
Gross profit	236,166	203,992	701,413	614,002
Selling, general and administrative expenses	138,252	115,228	425,392	358,431
Research and development expenses	14,871	15,638	43,803	47,169
Restructuring and other impairment charges	1,108	7,084	16,511	29,205
Income from continuing operations before interest, loss on extingushments of debt and taxes	81,935	66,042	215,707	179,197
Interest expense	17,184	13,948	48,650	42,566
Interest income	-161	-144	-494	-458
Loss on extinguishments of debt	0	1,250	0	1,250
Income from continuing operations before taxes	64,912	50,988	167,551	135,839
Taxes on income from continuing operations	9,684	5,209	28,224	18,958
Income from continuing operations	55,228	45,779	139,327	116,881
Operating income (loss) from discontinued operations	-247	38	-1,866	-1,746
Taxes (benefit) on income (loss) from discontinued operations	24	-991	-345	-1,547
Income (loss) from discontinued operations	-271	1,029	-1,521	-199
Net income	54,957	46,808	137,806	116,682
Less: Income from continuing operations attributable to noncontrolling interest	126	234	765	629
Net income attributable to common shareholders	54,831	46,574	137,041	116,053
Basic:	'	'	'	'
Income from continuing operations (in dollars per share)	$1.33	$1.11	$3.35	$2.83
Income (loss) from discontinued operations (in dollars per share)	($0.01)	$0.02	($0.04)	($0.01)
Net income (in dollars per share)	$1.32	$1.13	$3.31	$2.82
Diluted:	'	'	'	'
Income from continuing operations (in dollars per share)	$1.18	$1.05	$3	$2.69
Income (loss) from discontinued operations (in dollars per share)	$0	$0.03	($0.04)	($0.01)
Net income (in dollars per share)	$1.18	$1.08	$2.96	$2.68
Dividends per share	$0.34	$0.34	$1.02	$1.02
Weighted average common shares outstanding	'	'	'	'
Basic (in shares)	41,399	41,132	41,347	41,087
Diluted (in shares)	46,628	43,264	46,256	43,246
Amounts attributable to common shareholders:	'	'	'	'
Income from continuing operations, net of tax	55,102	45,545	138,562	116,252
Income (loss) from discontinued operations, net of tax	-271	1,029	-1,521	-199
Net income attributable to common shareholders	$54,831	$46,574	$137,041	$116,053

CONDENSED_CONSOLIDATED_STATEME1

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2014	Sep. 29, 2013	Sep. 28, 2014	Sep. 29, 2013
Statement of Comprehensive Income [Abstract]	'	'	'	'
Net income	$54,957	$46,808	$137,806	$116,682
Other comprehensive income (loss), net of tax:	'	'	'	'
Foreign currency translation, net of tax of $12,721, $(6,520), $13,252 and $(5,167) for the three and nine month periods, respectively	-46,395	23,530	-41,105	-9,275
Pension and other postretirement benefit plans adjustment, net of tax of $(526), $(502), $(1,235) and $(1,525) for the three and nine month periods, respectively	1,094	779	2,336	2,735
Derivatives qualifying as hedges, net of tax of $(34), $23, $(117) and $30 for the three and nine month periods, respectively	60	-40	203	-52
Other comprehensive income (loss), net of tax:	-45,241	24,269	-38,566	-6,592
Comprehensive income	9,716	71,077	99,240	110,090
Less: comprehensive income attributable to non-controlling interest	86	128	793	372
Comprehensive income attributable to common shareholders	$9,630	$70,949	$98,447	$109,718

CONDENSED_CONSOLIDATED_STATEME2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (Parenthetical) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2014	Sep. 29, 2013	Sep. 28, 2014	Sep. 29, 2013
Statement of Comprehensive Income [Abstract]	'	'	'	'
Foreign Currency translation tax	$12,721	($6,520)	$13,252	($5,167)
Pension and other postretirement benefits plans adjustment, tax	-526	-502	-1,235	-1,525
Derivatives qualifying as hedges, tax	($34)	$23	($117)	$30

CONDENSED_CONSOLIDATED_BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 28, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Current assets	'	'
Cash and cash equivalents	$286,382	$431,984
Accounts receivable, net	287,179	295,290
Inventories, net	353,227	333,621
Prepaid expenses and other current assets	43,283	39,810
Prepaid taxes	51,319	36,504
Deferred tax assets	48,141	52,917
Assets held for sale	7,672	10,428
Total current assets	1,077,203	1,200,554
Property, plant and equipment, net	347,233	325,900
Goodwill	1,352,045	1,354,203
Intangible assets, net	1,208,252	1,255,597
Investments in affiliates	1,079	1,715
Deferred tax assets	1,706	943
Other assets	70,274	70,095
Total assets	4,057,792	4,209,007
Current liabilities	'	'
Current borrowings	365,356	356,287
Accounts payable	71,034	71,967
Accrued expenses	77,333	74,868
Current portion of contingent consideration	2,957	4,131
Payroll and benefit-related liabilities	76,781	73,090
Accrued interest	13,848	8,725
Income taxes payable	26,735	23,821
Other current liabilities	42,272	22,231
Total current liabilities	676,316	635,120
Long-term borrowings	700,000	930,000
Deferred tax liabilities	494,884	514,715
Pension and postretirement benefit liabilities	97,007	109,498
Noncurrent liability for uncertain tax provisions	56,448	55,152
Other liabilities	49,221	48,506
Total liabilities	2,073,876	2,292,991
Commitments and contingencies	'	'
Total common shareholders' equity	1,981,728	1,913,527
Noncontrolling interest	2,188	2,489
Total equity	1,983,916	1,916,016
Total liabilities and equity	$4,057,792	$4,209,007

CONDENSED_CONSOLIDATED_STATEME3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2014	Sep. 29, 2013
Cash Flows from Operating Activities of Continuing Operations	'	'
Net income	$137,806	$116,682
Adjustments to reconcile net income to net cash provided by operating activities:	'	'
Loss from discontinued operations	1,521	199
Depreciation expense	37,409	30,735
Amortization expense of intangible assets	47,053	37,072
Amortization expense of deferred financing costs and debt discount	11,792	11,228
Loss on extinguishments of debt	0	1,250
Impairment of long-lived assets	0	3,354
Changes in contingent consideration	-7,670	-12,927
Stock-based compensation	9,125	8,426
Deferred income taxes, net	-2,808	-1,286
Other	-4,310	-8,223
Changes in operating assets and liabilities, net of effects of acquisitions and disposals:	'	'
Accounts receivable	2,442	-12,395
Inventories	-23,084	-23,576
Prepaid expenses and other current assets	-4,087	-5,420
Accounts payable and accrued expenses	14,258	1,573
Income taxes receivable and payable, net	-10,649	-10,820
Net cash provided by operating activities from continuing operations	208,798	135,872
Cash Flows from Investing Activities of Continuing Operations:	'	'
Expenditures for property, plant and equipment	-48,220	-54,640
Proceeds from sale of assets and investments	5,251	0
Payments for businesses and intangibles acquired, net of cash acquired	-28,535	-40,450
Investment in affiliates	-40	-50
Net cash used in investing activities from continuing operations	-71,544	-95,140
Cash Flows from Financing Activities of Continuing Operations:	'	'
Proceeds from long-term borrowings	250,000	382,000
Repayment of long-term borrowings	-480,009	-375,000
Debt extinguishment, issuance and amendment fees	-3,689	-6,365
Proceeds from share based compensation plans and the related tax impacts	2,936	4,740
Payments to noncontrolling interest shareholders	-1,094	-736
Payments for contingent consideration	0	-16,367
Dividends	-42,174	-41,915
Net cash used in financing activities from continuing operations	-274,030	-53,643
Cash Flows from Discontinued Operations:	'	'
Net cash used in operating activities	-1,946	-2,167
Net cash used in discontinued operations	-1,946	-2,167
Effect of exchange rate changes on cash and cash equivalents	-6,880	4,476
Net increase (decrease) in cash and cash equivalents	-145,602	-10,602
Cash and cash equivalents at the beginning of the period	431,984	337,039
Cash and cash equivalents at the end of the period	$286,382	$326,437

CONDENSED_CONSOLIDATED_STATEME4

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (USD $)	Total	Common Stock	Additional Paid in Capital	Retained Earnings	Accumulated Other Comprehensive Income (Loss)	Treasury Stock	Noncontrolling Interest
In Thousands, unless otherwise specified
Beginning Balance at Dec. 31, 2012	$1,781,537	$43,102	$394,384	$1,601,460	($132,048)	($127,948)	$2,587
Beginning Balance (in shares) at Dec. 31, 2012	'	43,102	'	'	'	2,130	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'	'
Net income	116,682	'	'	116,053	'	'	629
Cash dividends ($1.02 per share)	-41,915	'	'	-41,915	'	'	'
Other comprehensive income (loss)	-6,592	'	'	'	-6,335	'	-257
Distributions to noncontrolling interest shareholders	-736	'	'	'	'	'	-736
Shares issued under compensation plans (in shares)	'	116	'	'	'	55	'
Shares issued under compensation plans	13,240	116	10,416	'	'	2,708	'
Deferred compensation (in shares)	'	'	'	'	'	-1	'
Deferred compensation	46	'	-9	'	'	55	'
Ending Balance at Sep. 29, 2013	1,862,262	43,218	404,791	1,675,598	-138,383	-125,185	2,223
Ending Balance (in shares) at Sep. 29, 2013	'	43,218	'	'	'	2,074	'
Beginning Balance at Dec. 31, 2013	1,916,016	43,243	409,338	1,696,424	-110,855	-124,623	2,489
Beginning Balance (in shares) at Dec. 31, 2013	'	43,243	'	'	'	2,064	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'	'	'	'	'	'
Net income	137,806	'	'	137,041	'	'	765
Cash dividends ($1.02 per share)	-42,174	'	'	-42,174	'	'	'
Other comprehensive income (loss)	-38,566	'	'	'	-38,594	'	28
Distributions to noncontrolling interest shareholders	-1,094	'	'	'	'	'	-1,094
Settlements of convertible notes	0	'	4	'	'	-4	'
Settlements of note hedges associated with convertible notes	-1	'	-7	'	'	6	'
Shares issued under compensation plans (in shares)	'	158	'	'	'	75	'
Shares issued under compensation plans	11,843	158	9,001	'	'	2,684	'
Deferred compensation (in shares)	'	'	'	'	'	-2	'
Deferred compensation	86	'	'	'	'	86	'
Ending Balance at Sep. 28, 2014	$1,983,916	$43,401	$418,336	$1,791,291	($149,449)	($121,851)	$2,188
Ending Balance (in shares) at Sep. 28, 2014	'	43,401	'	'	'	1,987	'

CONDENSED_CONSOLIDATED_STATEME5

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY (parenthetical) (USD $)	3 Months Ended		9 Months Ended
	Sep. 28, 2014	Sep. 29, 2013	Sep. 28, 2014	Sep. 29, 2013
Statement of Stockholders' Equity [Abstract]	'	'	'	'
Common Stock, Dividends, Per Share, Declared	$0.34	$0.34	$1.02	$1.02

Basis_of_presentation

Basis of presentation	9 Months Ended
	Sep. 28, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]	'
Basis of presentation	'
	Basis of presentation
	The accompanying unaudited condensed consolidated financial statements of Teleflex Incorporated are prepared on the same basis as the Company's annual consolidated financial statements.
	In the opinion of management, the financial statements reflect all adjustments, which are of a normal recurring nature, necessary for the fair presentation of financial statements for interim periods in accordance with U.S. generally accepted accounting principles (GAAP) and with Rule 10-01 of SEC Regulation S-X, which sets forth the instructions for financial statements included in Form 10-Q. The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
	In accordance with applicable accounting standards, the accompanying condensed consolidated financial statements do not include all of the information and footnote disclosures that are required to be included in the Company's annual consolidated financial statements. The year-end condensed balance sheet data was derived from the Company's audited financial statements, but, as permitted by Rule 10-01 of SEC Regulation S-X, does not include all disclosures required by GAAP for complete financial statements. Accordingly, the Company's quarterly condensed consolidated financial statements should be read in conjunction with the consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2013.
	Effective January 1, 2014, the Company realigned its operating segments to reflect changes in the Company’s internal financial reporting structure. See Note 14 for additional information on the Company’s changed reporting structure.
	The Company’s share-based compensation plan permits employees to elect to have shares withheld by the Company to satisfy their minimum statutory tax withholding obligations arising from the exercise or vesting of share-based awards.  The Company then remits, in cash, the withholding taxes to the appropriate tax authorities on behalf of the employee.  For the nine months ended September 28, 2014, the Company has classified such payments as a cash outflow from financing activities under the line item “Proceeds from share-based compensation plans and the related tax impacts” within the condensed consolidated statement of cash flows (i.e., the payment by the Company of the withholding taxes offsets, in part, increases in cash flow from financing activities resulting from the proceeds of the exercise and vesting of share-based awards and tax benefits related to such exercise and vesting).  The Company views the activity as, in effect, a repurchase of the employee’s shares.  The Company’s payments were previously reported as a cash outflow from operating activities; therefore, the Company reclassified the cash outflow for the nine months ended September 29, 2013 of $2.5 million to conform to the presentation for the nine months ended September 28, 2014 within the condensed consolidated statement of cash flows as well as the condensed consolidating statement of cash flows included in Note 15. The Company’s future filings incorporating financial periods prior to 2014 will also reflect this reclassification.
	Additionally, the Company made certain revisions to the prior year condensed consolidating statements of cash flows included in the condensed consolidated guarantor financial information included in Note 15 to correct errors identified in the fourth quarter 2013.
	As used in this report, the terms “we,” “us,” “our,” “Teleflex” and the “Company” mean Teleflex Incorporated and its subsidiaries, unless the context indicates otherwise. The results of operations for the periods reported are not necessarily indicative of those that may be expected for a full year.

New_accounting_standards

New accounting standards	9 Months Ended
	Sep. 28, 2014
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]	'
New accounting standards	'
	New accounting standards
	In April 2014, the Financial Accounting Standards Board (FASB) issued guidance for the reporting of discontinued operations. Under the new guidance, only those disposals of components of an entity that represent a strategic shift that has or will have a major effect on an entity's operations and financial results will be reported as discontinued operations in an entity's financial statements. In addition, the new guidance requires additional disclosures for discontinued operations designed to provide users of financial statements with more information about the assets, liabilities, revenues and expenses of discontinued operations. The new guidance also requires disclosures regarding disposals of a significant component of an entity that does not qualify for discontinued operations reporting.This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2014 with early adoption permitted. The Company does not believe the adoption of this guidance will have a material impact on the Company’s results of operations, cash flows or financial position.
	In May 2014, the FASB, in a joint effort with the International Accounting Standards Board, issued new accounting guidance to clarify the principles for recognizing revenue.  The new guidance is designed to enhance the comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets, and will affect any entity that enters into contracts with customers or enters into contracts for the transfer of nonfinancial assets, unless those contracts are within the scope of other standards.  The new guidance establishes principles for reporting information to users of financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from an entity's contracts with customers.  The core principle of the new guidance is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The new guidance is effective prospectively for annual periods beginning after December 15, 2016, and interim periods within those years.  Early application is not permitted. The Company is currently evaluating this guidance to determine the impact on the Company’s results of operations, cash flows, and financial position.
	From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date or, in some cases where early adoption is permitted, in advance of the specified effective date. The Company has assessed the recently issued standards that are not yet effective and, unless otherwise discussed, believes these standards will not have a material impact on the Company’s results of operations, cash flows or financial position.

Acquisitions

Acquisitions	9 Months Ended
	Sep. 28, 2014
Business Combinations [Abstract]	'
Acquisitions	'
	Acquisitions
	On February 3, 2014, the Company acquired Mayo Healthcare Pty Limited, (“Mayo Healthcare”), a distributor of medical devices and supplies primarily in the Australian market. The total fair value of consideration for the Mayo Healthcare acquisition was $28.5 million, which included an initial payment of $29.0 million in cash, partially offset by a $0.5 million favorable working capital adjustment. Transaction expenses associated with the acquisition, which are included in selling, general and administrative expenses on the condensed consolidated statements of income were $0.3 million for the nine months ended September 28, 2014. The results of operations of the Mayo Healthcare business are included in the condensed consolidated statements of income from the acquisition date. For the three months ended September 28, 2014, the Company recorded revenue and loss from continuing operations before taxes related to the Mayo Healthcare business of $6.5 million and $0.7 million, respectively.  For the nine months ended September 28, 2014, the Company recorded revenue and income from continuing operations before taxes related to the Mayo Healthcare business of $19.9 million and $3.1 million, respectively. Pro forma information is not presented as the Mayo Healthcare operations are not significant to the overall operations of the Company.
	The following table presents the preliminary fair value determination of the assets acquired and liabilities assumed in the Mayo Healthcare acquisition.
		(Dollars in thousands)
	Assets
	Current assets	$	10,393
	Property, plant and equipment	306
	Customer lists intangible asset	9,335
	Goodwill	15,986
	Total assets acquired	36,020
	Liabilities
	Current liabilities	4,685
	Deferred tax liabilities	2,800
	Liabilities assumed	7,485
	Net assets acquired	$	28,535
	The Company is continuing to evaluate the Mayo Healthcare acquisition. Further adjustments to the fair value determination may be necessary as a result of the Company’s assessment of additional information related to the fair values of assets acquired and liabilities assumed, primarily with respect to deferred tax assets and liabilities and goodwill.
	Among the acquired assets, customer lists have a useful life of 10 years. The goodwill resulting from the acquisition primarily reflects the synergies expected to be realized from integration of the acquired business. Goodwill and the increase in carrying value resulting from the step-up in basis of the intangible assets in connection with stock acquisitions such as the Mayo Healthcare acquisition are not deductible for tax purposes.
	The Company made the following acquisitions during 2013, all of which were accounted for as business combinations:
	•	On December 2, 2013, the Company acquired Vidacare Corporation, (“Vidacare”), a provider of intraosseous, or inside the bone, access devices. This acquisition complements the Company’s vascular access and specialty product portfolios.
	•	On June 11, 2013, the Company acquired the assets of Ultimate Medical Pty. Ltd. and its affiliates (“Ultimate”), a supplier of airway management devices and related products. This acquisition complements the Company’s anesthesia product portfolio.
	•	On June 6, 2013, the Company acquired Eon Surgical, Ltd. (“Eon”), a developer of a minimally invasive microlaparoscopy surgical platform technology designed to enhance a surgeon’s ability to perform scarless surgery while producing better patient outcomes. This technology complements the Company’s surgical product portfolio.
	The total fair value of consideration for the 2013 acquisitions was $307.0 million. The results of operations of the acquired businesses and assets are included in the consolidated statements of income from their respective acquisition dates. Pro forma information is not presented as the operations of the acquired businesses are not significant to the overall operations of the Company.

Restructuring_and_other_impair

Restructuring and other impairment charges	9 Months Ended
	Sep. 28, 2014
Restructuring and Related Activities [Abstract]	'
Restructuring and other impairment charges	'
	Restructuring and other impairment charges
	2014 Manufacturing Footprint Realignment Plan
	On April 28, 2014, the Board of Directors approved a restructuring plan (the “2014 Manufacturing Footprint Realignment Plan”) involving the consolidation of operations and a related reduction in workforce at certain of the Company’s facilities, and the relocation of manufacturing operations from certain higher-cost locations to existing lower-cost locations. These actions commenced in the quarter ended June 29, 2014 and are expected to be substantially completed by the end of 2017.
	The Company estimates that it will incur aggregate pre-tax charges in connection with these restructuring activities of approximately $42 to $53 million, most of which are expected to be incurred prior to the end of 2016. In addition, the Company estimates that $32 million to $40 million of the aggregate pre-tax charges will result in future cash outlays, most of which are expected to be incurred prior to the end of 2016.
	The following table provides a summary of the Company’s current cost estimates by major type of cost associated with the 2014 Manufacturing Footprint Realignment Plan:
	Type of cost	Total estimated amount expected to be incurred
	Termination benefits	$12 million to $15 million
	Facility closure and other exit costs(1)	$2 million to $5 million
	Accelerated depreciation charges	$10 million to $12 million
	Other (2)	$18 million to $21 million
		$42 million to $53 million
	-1	Includes costs to transfer product lines among facilities and outplacement and employee relocation costs.
	-2	Consists of other costs directly related to the Plan, including project management, legal and regulatory costs.
	The Company recorded expenses of $2.1 million and $11.6 million for the three and nine months ended September 28, 2014, respectively, related to the 2014 Manufacturing Footprint Realignment Plan. Of these amounts, $0.2 million and $8.7 million were recorded as restructuring expense for the three and nine months ended September 28, 2014, respectively, and $1.9 million and $2.9 million, which related to accelerated depreciation and other costs resulting from the plan for the three and nine months ended September 28, 2014, respectively, were recorded as cost of sales. As of September 28, 2014, the Company has a restructuring reserve of $8.7 million in connection with the 2014 Manufacturing Footprint Realignment Plan all of which relates to termination benefits.
	As the 2014 Manufacturing Footprint Realignment Plan progresses, management will reevaluate the estimated costs set forth above, and may revise its estimates and the accounting charges relating to these actions, as appropriate, consistent with generally accepted accounting principles.
	2014 European Restructuring Plan
	On February 27, 2014, the Company committed to a restructuring plan (the “2014 European Restructuring Plan”), which impacts certain administrative functions in Europe and involves the consolidation of operations and a related reduction in workforce at certain of the Company’s European facilities.
	The Company estimates that it will record pre-tax charges of approximately $9 million in connection with implementation of the 2014 European Restructuring Plan, of which $8.7 million was incurred through September 28, 2014, primarily related to termination benefits. As of September 28, 2014, the Company had a reserve of $3.2 million in connection with the 2014 European Restructuring Plan.  The Company expects to complete this plan in 2014.
	Other 2014 Restructuring Programs
	In June 2014, the Company initiated programs to consolidate locations in Australia and terminate certain European distributor agreements in an effort to reduce costs. As a result of these actions, the Company estimates that it will incur an aggregate of approximately $3 million in restructuring and other impairment charges over the term of these restructuring programs, of which $2.1 million was incurred through September 28, 2014. These programs include costs related to termination benefits, contract termination costs and other exit costs. As of September 28, 2014, the Company has a reserve of $0.4 million in connection with these programs. The Company expects to complete the programs in 2014.
	LMA Restructuring Program
	In connection with the acquisition of substantially all of the assets of LMA International N.V. (the “LMA business”) in 2012, the Company commenced a program (the "LMA Restructuring Program") related to the integration of the LMA business and the Company’s other businesses. The program focuses on the closure of the LMA business’ corporate functions and the consolidation of manufacturing, sales, marketing, and distribution functions in North America, Europe and Asia.
	A reconciliation of the changes in accrued liabilities associated with the LMA Restructuring Program from December 31, 2013 through September 28, 2014 is set forth in the following table:
		Termination Benefits			Facility Closure Costs			Contract Termination Costs			Other Exit Costs		Total
		(Dollars in thousands)
	Balance at December 31, 2013	$	552		$	427		$	3,686		$	16	$	4,681
	Subsequent accruals (reversals)	(29		)	(112		)	(3,211		)	—		(3,352		)
	Cash payments	(533		)	(317		)	(104		)	—		(954		)
	Foreign currency translation	10			2			(14		)	—		(2		)
	Balance at September 28, 2014	$	—		$	—		$	357		$	16	$	373
	During the nine months ended September 28, 2014, the Company reversed approximately $3.2 million in contract termination costs related to the favorable settlement of a terminated distributor agreement.
	The Company expects future restructuring expenses associated with this program, if any, to be nominal. The Company expects to complete the program in 2015.
	2013 Restructuring Programs
	In 2013, the Company initiated programs to consolidate manufacturing facilities in North America and warehouse facilities in Europe and terminate certain European distributor agreements in an effort to reduce costs. As a result of these actions, the Company estimates that it will incur an aggregate of up to $11.0 million in restructuring and other impairment charges over the term of these restructuring programs, of which $10.9 million was incurred through September 28, 2014. These programs entail costs related to termination benefits, contract termination costs and charges related to post-closing obligations associated with its acquired businesses. As of September 28, 2014, the Company has a reserve of $1.3 million in connection with these programs. The Company expects to complete the programs in 2015.
	2012 Restructuring Program
	In 2012, the Company identified opportunities to improve its supply chain strategy by consolidating its three North American warehouses into one centralized warehouse; and lower costs and improve operating efficiencies through the termination of certain distributor agreements in Europe, the closure of certain North American facilities and workforce reductions. The Company expects future restructuring expenses associated with this program, if any, to be nominal. As of September 28, 2014, the Company has a reserve of $0.6 million in connection with these projects. The Company expects to complete this program in 2015.
	Impairment Charges
	In the first quarter 2013, the Company recorded a $4.5 million in-process research and development (IPR&D) charge pertaining to a research and development project associated with the May 2012 acquisition of the assets of Axiom Technology Partners LLP because technological feasibility had not yet been achieved and the Company determined that the subject technology had no future alternative use.
	In the third quarter of 2013, the Company recorded $3.4 million in impairment charges related to assets held for sale that had a carrying value in excess of their appraised fair value.
	There were no impairment charges recorded for the three and nine months ended September 28, 2014.
	The restructuring and other impairment charges recognized for the three and nine months ended September 28, 2014 and September 29, 2013 consisted of the following:
	Three Months Ended September 28, 2014
	(in thousands)	Termination Benefits			Facility Closure Costs			Contract Termination Costs			Other Exit Costs		Total
	2014 Manufacturing footprint realignment plan	$	129		$	—		$	—		$	42	$	171
	2014 European restructuring plan	537			1			1			27		566
	Other 2014 restructuring programs	25			—			202			62		289
	LMA restructuring program	—			—			20			—		20
	2013 Restructuring programs	(124		)	—			186			—		62
	Total restructuring and other impairment charges	$	567		$	1		$	409		$	131	$	1,108
	Three Months Ended September 29, 2013
	(in thousands)	Termination Benefits			Facility			Contract Termination Costs			Other Exit Costs		Total
					Closure
					Costs
	LMA restructuring program	$	492		$	162		$	1,097		$	17	$	1,768
	2013 Restructuring programs	891			—			(65		)	—		826
	2012 Restructuring program	559			539			—			—		1,098
	2007 Arrow integration program	—			38			—			—		38
		1,942			739			1,032			17		3,730
	Impairment charges	—			—			—			3,354		3,354
	Total restructuring and other impairment charges	$	1,942		$	739		$	1,032		$	3,371	$	7,084
	Nine Months Ended September 28, 2014
	(in thousands)	Termination Benefits			Facility			Contract Termination Costs			Other Exit Costs		Total
					Closure
Costs
2014 Manufacturing footprint realignment plan	$	8,706		$	—		$	—		$	42	$	8,748
2014 European restructuring plan	8,289			1			306			76		8,672
Other 2014 restructuring programs	501			—			1,376			193		2,070
LMA restructuring program	(29		)	(112		)	(3,211		)	—		(3,352		)
2013 Restructuring programs	361			—			243			22		626
2012 Restructuring program	(619		)	354			—			—		(265		)
2011 Restructuring program	—			12			—			—		12
Total restructuring and other impairment charges	$	17,209		$	255		$	(1,286	)	$	333	$	16,511
Nine Months Ended September 29, 2013
(in thousands)	Termination Benefits			Facility Closure Costs			Contract Termination Costs			Other Exit Costs		Total
LMA restructuring program	$	3,318		$	536		$	4,378		$	132	$	8,364
2013 Restructuring programs	2,443			—			3,326			2,887		8,656
2012 Restructuring program	3,225			641			293			5		4,164
2007 Arrow integration program	—			173			—			—		173
	8,986			1,350			7,997			3,024		21,357
Impairment charges	—			—			—			7,848		7,848
Total restructuring and other impairment charges	$	8,986		$	1,350		$	7,997		$	10,872	$	29,205
Termination benefits include employee retention payments and severance payments and benefits for terminated employees.
Facility closure costs include general operating costs incurred subsequent to production shut-down as well as equipment relocation and other associated costs.
Contract termination costs include costs associated with terminating existing leases and distributor agreements.
Other costs include legal, outplacement and employee relocation costs and other employee-related costs.
Restructuring and other impairment charges by reportable segment for the three and nine months ended September 28, 2014 and September 29, 2013 are set forth in the following table:
	Three Months Ended						Nine Months Ended
	September 28, 2014			September 29, 2013			September 28, 2014			September 29, 2013
	(Dollars in thousands)
Restructuring and other impairment charges
Vascular North America	$	(54	)	$	2,233		$	5,908		$	2,860
Anesthesia/Respiratory North America	15			332			1,193			3,001
Surgical North America	—			—			—			7,294
EMEA	849			2,221			7,164			11,428
Asia	111			202			708			447
OEM	—			—			—			588
All other	187			2,096			1,538			3,587
Total restructuring and other impairment charges	$	1,108		$	7,084		$	16,511		$	29,205

Inventories_net

Inventories, net	9 Months Ended
	Sep. 28, 2014
Inventory Disclosure [Abstract]	'
Inventories, net	'
	Inventories, net
	Inventories as of September 28, 2014 and December 31, 2013 consisted of the following:
		28-Sep-14			31-Dec-13
		(Dollars in thousands)
	Raw materials	$	73,170		$	70,209
	Work-in-process	59,282			53,672
	Finished goods	254,120			242,113
		386,572			365,994
	Less: Inventory reserve	(33,345		)	(32,373		)
	Inventories, net	$	353,227		$	333,621

Goodwill_and_other_intangible_

Goodwill and other intangible assets, net	9 Months Ended
	Sep. 28, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Goodwill and other intangible assets, net	'
	Goodwill and other intangible assets, net
	The following table provides information relating to changes in the carrying amount of goodwill by reportable segment for the nine months ended September 28, 2014:
		Vascular			Anesthesia/			Surgical			EMEA			Asia			All			Total
		North America			Respiratory			North America									Other
					North America
		(Dollars in thousands)
	Balance as of December 31, 2013
	Goodwill	$	474,044		$	167,195		$	250,506		$	373,417		$	136,946		$	284,223		$	1,686,331
	Accumulated impairment losses	(219,527		)	(107,073		)	—			—			—			(5,528		)	(332,128		)
		254,517			60,122			250,506			373,417			136,946			278,695			1,354,203
	Goodwill related to acquisitions	—			—			—			—			15,986			—			15,986
	Translation adjustment	—			(300		)	—			(17,467		)	(585		)	208			(18,144		)
	Balance at September 28, 2014
	Goodwill	474,044			166,895			250,506			355,950			152,347			284,431			1,684,173
	Accumulated impairment losses	(219,527		)	(107,073		)	—			—			—			(5,528		)	(332,128		)
		$	254,517		$	59,822		$	250,506		$	355,950		$	152,347		$	278,903		$	1,352,045
	The following table provides information as of September 28, 2014 and December 31, 2013 regarding the gross carrying amount of, and accumulated amortization relating to, intangible assets, net:
		Gross Carrying Amount						Accumulated Amortization
		September 28,			31-Dec-13			September 28,			31-Dec-13
		2014						2014
		(Dollars in thousands)
	Customer relationships	$	631,983		$	628,020		$	(188,261	)	$	(168,223	)
	In-process research and development	68,766			68,786			—			—
	Intellectual property	433,227			435,869			(140,606		)	(118,086		)
	Distribution rights	16,406			16,797			(14,466		)	(14,592		)
	Trade names	403,460			407,879			(2,425		)	(1,148		)
	Noncompete agreements	337			337			(169		)	(42		)
		$	1,554,179		$	1,557,688		$	(345,927	)	$	(302,091	)
	During the first quarter 2013, the Company recorded an IPR&D charge of $4.5 million. See Note 4 for additional information.
	In May 2012, the Company acquired Semprus BioSciences, a biomedical research and development company that developed a polymer surface treatment technology intended to reduce thrombus related complications.  The Company experienced unexpected difficulties with respect to the development of the Semprus technology, which the Company is currently attempting to resolve through further research and testing. Failure to resolve these issues may result in a reduction of the expected future cash flows related to the Semprus technology and could result in the recognition of impairment charges with respect to the related assets, which could be material.  As of September 28, 2014, the Company has recorded assets at risk of approximately $41.0 million related to this investment.
	Amortization expense related to intangible assets was $15.0 million and $12.5 million for the three months ended September 28, 2014 and September 29, 2013, respectively, and 47.1 million and 37.1 million for the nine months ended September 28, 2014 and September 29, 2013, respectively.  Estimated annual amortization expense for the remainder of 2014 and the next five succeeding years is as follows (dollars in thousands):
	2014	$	13,700
	2015	54,100
	2016	53,700
	2017	53,300
	2018	53,000
	2019	52,600

Borrowings

Borrowings	9 Months Ended
	Sep. 28, 2014
Debt Disclosure [Abstract]	'
Borrowings	'
	Borrowings
	The components of long-term debt at September 28, 2014 and December 31, 2013 are as follows:
		28-Sep-14			31-Dec-13
		(Dollars in thousands)
	Senior Credit Facility:
	Revolving credit facility, at a rate of 1.90% at September 28, 2014, due 7/16/2018	$	200,000		$	680,000
	3.875% Convertible Senior Subordinated Notes due 2017	399,991			400,000
	6.875% Senior Subordinated Notes due 2019	250,000			250,000
	5.25% Senior Notes due 2024	250,000			—
	Total borrowings	1,099,991			1,330,000
	Less: Unamortized debt discount on 3.875% Convertible Senior Subordinated Notes	(39,335		)	(48,413		)
		1,060,656			1,281,587
	Current portion of borrowings	(360,656		)	(351,587		)
		$	700,000		$	930,000
	5.25% Senior Notes due 2024
	On May 21, 2014, the Company issued $250 million of 5.25% Senior Notes due 2024 (the “2024 Notes”). The Company will pay interest on the 2024 Notes semi-annually on June 15 and December 15, commencing on December 15, 2014, at a rate of 5.25% per year. The 2024 Notes will mature on June 15, 2024, unless earlier redeemed or purchased by the Company at the holder’s option under specified circumstances following a Change of Control or Asset Sale (each as defined in the Indenture related to the 2024 Notes) or upon the Company’s election to exercise its optional redemption rights, as described below. The Company incurred transaction fees of approximately $4.5 million, including underwriters’ discounts and commissions, in connection with the offering of the 2024 Notes, which were recorded as a deferred asset and are being amortized over the term of the 2024 Notes. The Company used $245.0 million of the proceeds to repay borrowings under its revolving credit facility.
	The Company's obligations under the 2024 Notes are fully and unconditionally guaranteed, jointly and severally, by each of the Company’s existing and future wholly-owned domestic subsidiaries that is a guarantor or other obligor under the Company’s revolving credit facility and by certain of the Company’s other wholly-owned domestic subsidiaries.
	At any time on or after June 15, 2019, the Company may, on one or more occasions, redeem some or all of the 2024 Notes at a redemption price of 102.625% of the principal amount of the 2024 Notes subject to redemption, declining, in annual increments of 0.875%, to 100% of the principal amount on June 15, 2022, plus accrued and unpaid interest.  In addition, at any time prior to June 15, 2019, the Company may, on one or more occasions, redeem some or all of the 2024 Notes at a redemption price equal to 100% of the principal amount of the 2024 Notes redeemed, plus a “make-whole” premium and any accrued and unpaid interest.  The “make-whole” premium is the greater of (a) 1.0% of the principal amount of the 2024 Notes subject to redemption or (b) the excess, if any, over the principal amount of the 2024 Notes of the present value, on the redemption date, of the sum of (i) the June 15, 2019 optional redemption price  plus (ii) all required interest payments on the 2024 Notes through June 15, 2019 (other than accrued and unpaid interest to the redemption date), calculated based on a specified Treasury rate, generally for the period most nearly equal to the period from the redemption date to June 15, 2019, plus 50 basis points.
	In addition, at any time prior to June 15, 2017, the Company may, on one or more occasions, redeem up to 35% of the aggregate principal amount of the 2024 Notes, using the proceeds of specified types of Company equity offerings and subject to specified conditions, at a redemption price equal to 105.25% of the principal amount of the Notes redeemed, plus accrued and unpaid interest.
	The 2024 Notes contain covenants that, among other things, limit or restrict the Company’s ability, and the ability of its subsidiaries, to incur debt, create liens, consolidate, merge or dispose of certain assets, make certain investments, engage in acquisitions, pay dividends on, repurchase or make distributions in respect of capital stock and enter into swap agreements.
	Classification of 3.875% Convertible Notes as a Current Liability
	The Company’s 3.875% Convertible Senior Subordinated Notes due 2017 (the “Convertible Notes”) are convertible under certain circumstances, including in any fiscal quarter following an immediately preceding fiscal quarter in which the last reported sales price per share of our common stock for at least 20 days during a period of 30 consecutive trading days ending on the last day of such fiscal quarter exceeds 130% of the $61.32 per share conversion price of the Convertible Notes (approximately $79.72). Since the fourth quarter of 2013, the Company’s closing stock price has exceeded the 130% threshold described above and, accordingly, the Convertible Notes have been classified as a current liability as of September 28, 2014 and December 31, 2013. The determination of whether or not the Convertible Notes are convertible under such circumstances is made each quarter until maturity or conversion. Consequently, the Convertible Notes may not be convertible in one or more future quarters if the common stock price-based contingent conversion threshold is not met in such quarters, in which case the Convertible Notes would again be classified as long-term debt unless another conversion event set forth in the Convertible Notes has occurred. The Company has elected a net settlement method to satisfy the conversion obligation, under which it may settle the principal amount of the Convertible Notes in cash and settle the excess of the conversion value of the Convertible Notes over the principal amount of the notes in shares; however, cash will be paid in lieu of fractional shares. While the Company believes it has sufficient liquidity to repay the principal amounts due through a combination of its existing cash on hand and borrowings under its credit facility, the Company’s use of these funds could adversely affect its results of operations and liquidity. The classification of the Convertible Notes as a current liability had no impact on the Company's financial covenants.
	Fair Value of Long-Term Debt
	The carrying amount of long-term debt reported in the consolidated balance sheet as of September 28, 2014 is $1,060.7 million. The Company uses quoted market prices to estimate the fair value of its publicly traded debt. To estimate the fair value of debt for which there are no quoted market prices, the Company uses a discounted cash flow technique that incorporates a market interest yield curve with adjustments for duration, optionality and risk profile. The Company’s implied credit rating is a factor in determining the market interest yield curve. The following table provides the fair value of the Company’s debt as of September 28, 2014, categorized by fair value hierarchy level (see Note 10, “Fair value measurement,” in the Company’s annual report on Form 10-K for the year ended December 31, 2013 for further information):
		Fair value of debt
		(Dollars in thousands)
	Level 1	$	955,567
	Level 2	442,337
	Total	$	1,397,904

Financial_instruments

Financial instruments	9 Months Ended
	Sep. 28, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Financial instruments	'
	Financial instruments
	The Company uses derivative instruments for risk management purposes. Foreign currency forward contracts are used to manage foreign currency transaction exposure. These derivative instruments are designated as cash flow hedges and are recorded on the balance sheet at fair market value. The effective portion of the gains or losses on derivatives is reported as a component of other comprehensive income and thereafter is recognized in the condensed consolidated statement of income in the period or periods during which the hedged transaction affects earnings. Gains and losses on the derivatives representing either hedge ineffectiveness or hedge components excluded from the assessment of effectiveness are recognized in the condensed consolidated statement of earnings in the period in which such gains and losses occur.
	The following table presents the location and fair values of derivative instruments designated as hedging instruments in the condensed consolidated balance sheet as of September 28, 2014 and December 31, 2013:
		September 28,			December 31,
		2014			2013
		Fair Value			Fair Value
		(Dollars in thousands)
	Asset derivatives:
	Foreign currency forward contracts:
	Prepaid expenses and other current assets	$	959		$	—
	Total asset derivatives	$	959		$	—
	Liability derivatives:
	Foreign currency forward contracts:
	Other current liabilities	$	471		$	—
	Total liability derivatives	$	471		$	—
	The total notional amount for all open foreign currency forward contracts as of September 28, 2014 is approximately $20.5 million. As of December 31, 2013, the Company had no open foreign currency forward contracts.
	The following table provides information as to the gains and losses attributable to derivatives in cash flow hedging relationships that were reported in other comprehensive income (“OCI”) for the three and nine months ended September 28, 2014 and September 29, 2013:
		After Tax Gain/(Loss)
		Recognized in OCI
		Three Months Ended						Nine Months Ended
		28-Sep-14			September 29,			September 28,		September 29,
					2013			2014		2013
		(Dollars in thousands)
	Foreign currency forward contracts	$	60		$	(40	)	$	203	$	(52	)
	Total	$	60		$	(40	)	$	203	$	(52	)
	See Note 10 for information on the location and amount of gains and losses attributable to derivatives that were reclassified from accumulated other comprehensive income (“AOCI”) to expense (income), net of tax.
	There was no ineffectiveness related to the Company’s derivatives used during the three and nine months ended September 28, 2014 and September 29, 2013.
	Based on exchange rates at September 28, 2014, approximately $0.2 million of unrealized gains, net of tax, within AOCI are expected to be reclassified from AOCI to the condensed consolidated statement of income during the remainder of 2014. However, the actual amount reclassified from AOCI could vary due to future changes in exchange rates.
	Concentration of Credit Risk
	Concentrations of credit risk with respect to trade accounts receivable is generally limited due to the Company’s large number of customers and their diversity across many geographic areas. A portion of the Company’s trade accounts receivable outside the United States, however, include sales to government-owned or supported healthcare systems in several countries which are subject to payment delays. Payment is dependent upon the financial stability and creditworthiness of those countries’ economies.
	In the ordinary course of business, the Company grants non-interest bearing trade credit to its customers on normal credit terms. In an effort to reduce its credit risk, the Company (i) establishes credit limits for all of its customer relationships, (ii) performs ongoing credit evaluations of its customers’ financial condition, (iii) monitors the payment history and aging of its customers’ receivables, and (iv) monitors open orders against an individual customer’s outstanding receivable balance.
	An allowance for doubtful accounts is maintained for accounts receivable based on the Company’s historical collection experience and expected collectability of the accounts receivable, considering the period an account is outstanding, the financial position of the customer and information provided by credit rating services. The adequacy of this allowance is reviewed each reporting period and adjusted as necessary. The allowance for doubtful accounts was $10.4 million and $10.7 million at September 28, 2014 and December 31, 2013, respectively.
	In light of the disruptions in global economic markets in recent years, the Company instituted enhanced measures, within countries where the Company has collectability concerns, to facilitate customer-by-customer risk assessment when estimating the allowance for doubtful accounts. Such measures include, among others, monthly credit control committee meetings, at which customer credit risks are identified after review of, among other things, accounts that exceed specified credit limits, payment delinquencies and other customer issues. In addition, for some of the Company’s non-government customers, the Company instituted measures designed to reduce its risk exposures, including issuing dunning letters, reducing credit limits, requiring that payments accompany orders and instituting legal action with respect to delinquent accounts. With respect to government customers, the Company evaluates receivables for potential collection risks associated with the availability of government funding and reimbursement practices.
	Some of the Company’s customers, particularly in Europe, have extended or delayed payments for products and services already provided. Collectability concerns regarding the Company’s accounts receivable from these customers, for the most part in Greece, Italy, Spain and Portugal, resulted in an increase in the allowance for doubtful accounts related to these countries. If the financial condition of these customers or the healthcare systems in these countries deteriorate such that the ability of an increasing number of customers to make payments is uncertain, additional allowances may be required in future periods. The aggregate net current and long-term accounts receivable for Spain, Italy, Greece and Portugal as a percentage of the Company’s net current and long-term accounts receivable at September 28, 2014 and December 31, 2013 are as follows:
		September 28,			December 31,
		2014			2013
		(Dollars in thousands)
	Current and long-term accounts receivable (net of allowances of $8.9 million and $7.9 million at September 28, 2014 and December 31, 2013, respectively) in Spain, Italy, Greece and Portugal (1)	$	87,733		$	97,852
	Percentage of total net current and long-term accounts receivable	29.4		%	31		%
	(1)The long-term portion of accounts receivable, net at September 28, 2014 and December 31, 2013 was $15.5 million and $17.6 million, respectively.
	For the nine months ended September 28, 2014 and September 29, 2013, net revenues from customers in Spain, Italy, Greece and Portugal were $114.8 million and $106.3 million, respectively.

Fair_value_measurement

Fair value measurement	9 Months Ended
	Sep. 28, 2014
Fair Value Disclosures [Abstract]	'
Fair value measurement	'
	Fair value measurement
	For a description of the fair value hierarchy, see Note 10 to the Company’s 2013 consolidated financial statements included in its annual report on Form 10-K for the year ended December 31, 2013.
	The following tables provide information regarding the financial assets and liabilities measured at fair value on a recurring basis as of September 28, 2014 and December 31, 2013:
		Total carrying			Quoted prices in		Significant other		Significant
		value at			active markets		observable		unobservable
		September 28,			(Level 1)		Inputs (Level 2)		Inputs (Level 3)
		2014
		(Dollars in thousands)
	Investments in marketable securities	$	6,540		$	6,540	$	—	$	—
	Derivative assets	959			—		959		—
	Derivative liabilities	471			—		471		—
	Contingent consideration liabilities	12,643			—		—		12,643
		Total carrying			Quoted prices in		Significant other		Significant
		value at			active markets		observable		unobservable
		December 31, 2013			(Level 1)		Inputs (Level 2)		Inputs (Level 3)
		(Dollars in thousands)
	Investments in marketable securities	$	6,150		$	6,150	$	—	$	—
	Contingent consideration liabilities	20,313			—		—		20,313
	There were no transfers of financial assets or liabilities carried at fair value among Level 1, Level 2 or Level 3 within the fair value hierarchy during the nine months ended September 28, 2014.
	The following table provides information regarding changes in Level 3 financial liabilities related to contingent consideration in connection with various Company acquisitions during the nine months ended September 28, 2014:
		Contingent consideration
		2014
		(Dollars in thousands)
	Balance - December 31, 2013	$	20,313
	Revaluations	(7,670		)
	Balance - September 28, 2014	$	12,643
	For the three and nine months ended September 28, 2014, the Company recorded net reductions to contingent consideration liabilities of $1.5 million and $8.2 million, respectively, and for the three and nine months ended September 29, 2013, the Company recorded reductions to contingent consideration liabilities of $4.4 million and $12.4 million, respectively.   These reductions were the result of changes in probabilities associated with certain regulatory and sales milestones.
	Valuation Techniques
	The Company’s financial assets valued based upon Level 1 inputs are comprised of investments in marketable securities held in trust, which are available to pay benefits under certain deferred compensation plans and other compensatory arrangements. The investment assets of the trust are valued using quoted market prices.
	The Company’s financial assets and financial liabilities valued based upon Level 2 inputs are comprised of foreign currency forward contracts. The Company uses foreign currency forward contracts to manage currency transaction exposure. The fair value of the foreign currency forward contracts represents the amount required to enter into offsetting contracts with similar remaining maturities based on quoted market prices. The Company has taken into account the creditworthiness of the counterparties in measuring fair value.
	The Company’s financial liabilities valued based upon Level 3 inputs are comprised of contingent consideration arrangements pertaining to the Company’s acquisitions. The Company accounts for contingent consideration in accordance with applicable accounting guidance related to business combinations. In connection with several of its acquisitions, the Company agreed to pay contingent consideration upon the achievement of specified objectives, including receipt of regulatory approvals, achievement of sales targets and, in some instances, the passage of time (collectively, “milestone payments”), and therefore recorded contingent consideration liabilities at the time of the acquisitions. The Company is required to reevaluate the fair value of contingent consideration each reporting period based on new developments and record changes in fair value until such consideration is satisfied through payment upon the achievement of the specified objectives or is no longer payable due to failure to achieve the specified objectives.
	In connection with the Company's contingent consideration arrangements, the Company estimates that it will make payments in 2015 and may make payments until 2018 or later. As of September 28, 2014, the range of undiscounted amounts the Company could be required to pay under contingent consideration arrangements is between zero and $56.5 million. The Company determines the fair value of the liabilities for the contingent consideration based on a probability-weighted discounted cash flow analysis. This fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement within the fair value hierarchy. The fair value of the contingent consideration liability associated with future payments under contingent consideration arrangements is based on several factors including:
	l	estimated cash flows projected from the success of market launches;
	l	the estimated time and resources needed to complete the development of acquired technologies;
	l	the uncertainty of obtaining regulatory approvals within the required time periods; and
	l	the risk adjusted discount rate for fair value measurement.
	The following table provides information regarding the valuation techniques and inputs used in determining the fair value of assets or liabilities categorized as Level 3 measurements as of September 28, 2014:
		Valuation Technique		Unobservable Input	Range (Weighted Average)
	Contingent consideration	Discounted cash flow		Discount rate	2.3% - 10% (8.6%)
				Probability of payment	0% - 100% (28.3%)
	As of September 28, 2014, of the $12.6 million of total recorded liabilities for contingent consideration, the Company has recorded approximately $3.0 million of contingent consideration as a current liability, and the remaining $9.6 million within other liabilities.

Changes_in_shareholders_equity

Changes in shareholders' equity Changes in shareholders' equity	9 Months Ended
	Sep. 28, 2014
Equity [Abstract]	'
Changes in shareholders' equity	'
	Changes in shareholders’ equity
	In 2007, the Company’s Board of Directors authorized the repurchase of up to $300 million of outstanding Company common stock. Repurchases of Company stock under the Board authorization may be made from time to time in the open market and may include privately-negotiated transactions as market conditions warrant and subject to regulatory considerations. The stock repurchase program has no expiration date and the Company’s ability to execute on the program will depend on, among other factors, cash requirements for acquisitions, cash generated from operations, debt repayment obligations, market conditions and regulatory requirements. In addition, under the Company’s senior credit agreements, the Company is subject to certain restrictions relating to its ability to repurchase shares in the event the Company’s consolidated leverage ratio (generally, the ratio of Consolidated Total Indebtedness to Consolidated EBITDA, as defined in the senior credit agreements) exceeds certain levels, which may limit the Company’s ability to repurchase shares under this Board authorization. Through September 28, 2014, no shares have been purchased under this Board authorization.
	The following table provides a reconciliation of basic to diluted weighted average shares outstanding:
		Three Months Ended						Nine Months Ended
		September 28, 2014			September 29, 2013			September 28, 2014		September 29, 2013
		(Shares in thousands)
	Basic	41,399			41,132			41,347		41,087
	Dilutive effect of share-based awards	440			383			441		383
	Dilutive effect of 3.875% Convertible Notes and warrants	4,789			1,749			4,468		1,776
	Diluted	46,628			43,264			46,256		43,246
	Weighted average shares that were antidilutive and therefore not included in the calculation of earnings per share were approximately 6.3 million and 6.4 million for the three and nine months ended September 28, 2014 respectively, and approximately 8.0 million and 7.9 million for the three and nine months ended September 29, 2013, respectively.
	The Convertible Notes are included in the diluted net income per share calculation during periods in which the average market price of the Company's common stock is above the applicable conversion price of the Convertible Notes, or $61.32 per share, and, therefore, the impact of conversion would be dilutive. In these periods, under the treasury stock method, we calculate the number of shares issuable under the terms of the Convertible Notes based on the average market price of the stock during the period, and include that number in the total diluted shares outstanding for the period.
	In connection with the issuance of the Convertible Notes, the Company entered into convertible note hedge and warrant agreements. The convertible note hedge economically reduces the dilutive impact of the Convertible Notes. However, because applicable accounting guidance requires the Company to separately analyze the impact of the convertible note hedge agreements and the impact of the warrant agreements on diluted weighted average shares outstanding, the impact of the convertible note hedge agreements are excluded from the calculation of earnings per share because it would be anti-dilutive. The anti-dilutive shares associated with the convertible note hedges are 2.8 million and 2.7 million for the three and nine months ended September 28, 2014, respectively and 1.4 million for both the three and nine months ended September 29, 2013. The treasury stock method is applied when the warrants are in-the-money and assumes the proceeds from the exercise of the warrants are used to repurchase shares based on the average stock price during the period. The strike price of the warrants is approximately $74.65 per share of common stock. Shares issuable upon exercise of the warrants that were included in the total diluted shares outstanding were 2.0 million and 1.8 million for the three and nine months ended September 28, 2014, respectively and 0.3 million or both the three and nine months ended September 29, 2013.
	For additional information regarding the convertible notes and convertible note hedge and warrant agreements see Note 8 to the consolidated financial statements included in the Company’s annual report on Form 10-K for the year ended December 31, 2013.
	The following tables provide information relating to the changes in accumulated other comprehensive income (loss), net of tax, for the nine months ended September 28, 2014 and September 29, 2013:
		Cash Flow Hedges				Pension and Other Postretirement Benefit Plans			Foreign Currency Translation Adjustment			Accumulated Other Comprehensive Income (Loss)
		(Dollars in thousands)
	Balance as of December 31, 2013	$	—			$	(97,037	)	$	(13,818	)	$	(110,855	)
	Other comprehensive income (loss) before reclassifications	641				131			(41,133		)	(40,361		)
	Amounts reclassified from accumulated other comprehensive income (loss)	(438		)		2,205			—			1,767
	Net current-period other comprehensive income (loss)	203				2,336			(41,133		)	(38,594		)
	Balance at September 28, 2014	$	203			$	(94,701	)	$	(54,951	)	$	(149,449	)
		Cash Flow Hedges				Pension and Other Postretirement Benefit Plans			Foreign Currency Translation Adjustment			Accumulated Other Comprehensive Income (Loss)
		(Dollars in thousands)
	Balance at December 31, 2012	$	(381	)		$	(127,257	)	$	(4,410	)	$	(132,048	)
	Other comprehensive income (loss) before reclassifications	(370		)		(762		)	(9,018		)	(10,150		)
	Amounts reclassified from accumulated other comprehensive income (loss)	318				3,497			—			3,815
	Net current-period other comprehensive income (loss)	(52		)		2,735			(9,018		)	(6,335		)
	Balance at September 29, 2013	$	(433	)		$	(124,522	)	$	(13,428	)	$	(138,383	)
	The following table provides information relating to the reclassifications of losses/(gain) in accumulated other comprehensive income into expense/(income), net of tax, for the three and nine months ended September 28, 2014 and September 29, 2013:
		Three Months Ended							Nine Months Ended
		28-Sep-14				29-Sep-13			28-Sep-14			29-Sep-13
		(Dollars in thousands)
	(Gains) losses on foreign exchange contracts:
	Cost of goods sold	$	(397	)		$	850		$	(526	)	$	154
	Total before tax	(397		)		850			(526		)	154
	Tax benefit	49				(158		)	88			164
	Net of tax	$	(348	)		$	692		$	(438	)	$	318
	Amortization of pension and other postretirement benefit items:
	Actuarial losses/(gains) (1)	$	1,090			$	1,696		$	3,295		$	5,460
	Prior-service costs(1)	(5		)		(4		)	(16		)	(15		)
	Transition obligation(1)	—				1			—			4
	Total before tax	1,085				1,693			3,279			5,449
	Tax expense	(378		)		(604		)	(1,074		)	(1,952		)
	Net of tax	$	707			$	1,089		$	2,205		$	3,497
	Total reclassifications, net of tax	$	359			$	1,781		$	1,767		$	3,815
	-1	These accumulated other comprehensive income components are included in the computation of net benefit cost of pension and other postretirement benefit plans (see Note 12 for additional information).

Taxes_on_income_from_continuin

Taxes on income from continuing operations	9 Months Ended
	Sep. 28, 2014
Income Tax Disclosure [Abstract]	'
Taxes on income from continuing operations	'
	Taxes on income from continuing operations
		Three Months Ended		Nine Months Ended
		28-Sep-14	29-Sep-13	28-Sep-14	29-Sep-13
	Effective income tax rate	14.90%	10.20%	16.80%	14.00%
	The effective income tax rate for the three and nine months ended September 28, 2014 was 14.9% and 16.8%, respectively, and 10.2% and 14.0% for the three and nine months ended September 29, 2013, respectively. The effective tax rate for the three and nine months ended September 28, 2014 benefited from a shift in the mix of taxable income to jurisdictions that have lower statutory rates.  Nevertheless, the effective tax rate for the three and nine months ended September 29, 2013 was lower than the effective income tax rate in the 2014 periods, reflecting the realization of net tax benefits resulting from the resolution of a foreign tax matter and the expiration of statutes of limitation for U.S. federal and state matters.

Pension_and_other_postretireme

Pension and other postretirement benefits	9 Months Ended
	Sep. 28, 2014
Compensation and Retirement Disclosure [Abstract]	'
Pension and other postretirement benefits	'
	Pension and other postretirement benefits
	The Company has a number of defined benefit pension and postretirement plans covering eligible U.S. and non-U.S. employees. The defined benefit pension plans are noncontributory. The benefits under these plans are based primarily on years of service and employees’ pay near retirement. The Company’s funding policy for U.S. plans is to contribute annually, at a minimum, amounts required by applicable laws and regulations. Obligations under non-U.S. plans are systematically provided for by depositing funds with trustees or by book reserves. As of September 28, 2014, the Company’s U.S. defined benefit pension plans and the Company’s other postretirement benefit plans, except certain postretirement benefit plans covering employees subject to a collective bargaining agreement, are frozen.
	The Company and certain of its subsidiaries provide medical, dental and life insurance benefits to pensioners and survivors. The associated plans are unfunded and approved claims are paid from Company funds.
	Net benefit cost of pension and postretirement benefit plans consisted of the following:
		Pension						Other Postretirement Benefits					Pension						Other Postretirement Benefits
		Three Months Ended						Three Months Ended					Nine Months Ended						Nine Months Ended
		28-Sep-14			29-Sep-13			28-Sep-14			29-Sep-13		28-Sep-14			29-Sep-13			28-Sep-14			29-Sep-13
		(Dollars in thousands)
	Service cost	$	453		$	432		$	42		$	176	$	1,350		$	1,361		$	318		$	501
	Interest cost	4,548			4,333			434			543		13,517			12,614			1,627			2,084
	Expected return on plan assets	(6,240		)	(5,784		)	—			—		(18,764		)	(17,328		)	—			—
	Net amortization and deferral	1,143			1,556			(58		)	137		3,284			4,380			(5		)	1,069
	Net benefit expense (income)	$	(96	)	$	537		$	418		$	856	$	(613	)	$	1,027		$	1,940		$	3,654
	The Company’s pension contributions are expected to be approximately $9.4 million during 2014, of which $2.7 million and $7.4 million were made during the three and nine months ended September 28, 2014, respectively.

Commitments_and_contingent_lia

Commitments and contingent liabilities	9 Months Ended
	Sep. 28, 2014
Commitments and Contingencies Disclosure [Abstract]	'
Commitments and contingent liabilities	'
	Commitments and contingent liabilities
	Operating leases: The Company uses various leased facilities and equipment in its operations. The terms for these leased assets vary depending on the terms of the applicable lease agreement. At September 28, 2014, the Company had no residual value guarantee obligations related to its operating leases.
	As of September 28, 2014, the Company recorded $28.2 million in property, plant and equipment representing the estimated fair value of the Company’s percentage of the costs to construct a building under a build-to-suit lease. The build-to-suit lease, which relates to a U.S. operating facility, was entered into in August 2013 and amended in March of 2014. Construction on the build-to-suit facility commenced in September 2013 and is expected to be completed in the fourth quarter of 2014. The estimated fair value of the Company’s percentage of the construction costs to complete the build-to-suit lease is approximately $28.3 million. For accounting purposes, the Company is deemed the owner of the asset during the construction period and is required to record the estimated fair value of the Company’s percentage of the construction costs as construction in progress during the construction period and a related liability in the same amount. This noncash activity is not reflective of the Company’s cash obligations, but represent the landlord’s costs to construct the Company’s portion of the building and tenant improvements. Based on current expectations, the Company believes that there are no continuing involvement requirements that would prohibit the Company from derecognizing the assets and related liabilities upon the completion of the construction period.
	Environmental: The Company is subject to contingencies as a result of environmental laws and regulations that in the future may require the Company to take further action to correct the effects on the environment of prior disposal practices or releases of chemical or petroleum substances by the Company or other parties. Much of this liability results from the U.S. Comprehensive Environmental Response, Compensation and Liability Act, often referred to as Superfund, the U.S. Resource Conservation and Recovery Act and similar state laws. These laws require the Company to undertake certain investigative and remedial activities at sites where the Company conducts or once conducted operations or at sites where Company-generated waste was disposed.
	Remediation activities vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, the regulatory agencies involved and their enforcement policies, as well as the presence or absence of other potentially responsible parties. At September 28, 2014 and December 31, 2013, the Company has recorded $2.2 million and $2.5 million, respectively, in accrued liabilities and $5.3 million and $5.8 million, respectively, in other liabilities relating to these matters. Considerable uncertainty exists with respect to these liabilities and, if adverse changes in circumstances occur, the potential liability may exceed the amount accrued as of September 28, 2014. The time frame, over which the accrued amounts may be paid out, based on past history, is estimated to be 15-20 years.
	Litigation: The Company is a party to various lawsuits and claims arising in the normal course of business. These lawsuits and claims include actions involving product liability, intellectual property, employment and environmental matters. As of September 28, 2014 and December 31, 2013, the Company has recorded reserves of approximately $4.2 million and $6.8 million, respectively, in connection with such contingencies, representing what it believes to be a better estimate of the cost than any other amount within the range of estimated possible losses that will be incurred to resolve these matters. Based on information currently available, advice of counsel, established reserves and other resources, the Company does not believe that any such actions likely will have, individually or in the aggregate, a material adverse effect on its business, financial condition, results of operations or liquidity. However, in the event of unexpected future developments, it is possible that the ultimate resolution of these matters, or other similar matters, if unfavorable, may have such a material adverse effect.
	Tax audits and examinations: The Company and its subsidiaries are routinely subject to tax examinations by various taxing authorities. As of September 28, 2014, the most significant tax examinations in process are in Austria, Canada, the Czech Republic, Germany and the United States. In conjunction with these examinations and as a regular and routine practice, the Company may establish reserves or adjust existing reserves with respect to uncertain tax positions. Accordingly, developments occurring with respect to these examinations, including resolution of uncertain tax positions, could result in increases or decreases to the Company’s recorded tax liabilities, which could impact the Company’s financial results.
	Other: The Company has various purchase commitments for materials, supplies and items of permanent investment incident to the ordinary conduct of its business. On average, such commitments are not at prices in excess of current market prices.

Business_segment_information_B

Business segment information Business segment information	9 Months Ended
	Sep. 28, 2014
Segment Reporting [Abstract]	'
Business segment information	'
	Business segment information
	An operating segment is a component of the Company (a) that engages in business activities from which it may earn revenues and incur expenses, (b) whose operating results are regularly reviewed by the Company’s chief operating decision maker to make decisions about resources to be allocated to the segment and to assess its performance, and (c) for which discrete financial information is available. The Company does not evaluate its operating segments using discrete asset information.
	Effective January 1, 2014, the Company realigned its operating segments due to changes in the Company’s internal financial reporting structure. The Company’s North American Vascular, Anesthesia/Respiratory and Surgical businesses, which previously comprised much of the former Americas reportable segment, are now separate reportable segments.  As a result, the Company now has six reportable segments: Vascular North America, Anesthesia/Respiratory North America, Surgical North America, EMEA, Asia and OEM. Certain operating segments are not material and are therefore included in the “All other” line item in tabular presentations of segment information. Additionally, the Company changed the allocation methodology of certain corporate costs, including manufacturing variances and research and development costs, among its businesses to improve accountability, which resulted in changes to the previously reported segment profitability. All prior comparative periods have been restated to reflect these changes.
	The Company’s Vascular North America, Anesthesia/Respiratory North America, Surgical North America, EMEA and Asia reportable segments design, manufacture and distribute medical devices primarily used in critical care, surgical applications and cardiac care and generally serve two end markets: hospitals and healthcare providers, and home health. The products of these segments are most widely used in the acute care setting for a range of diagnostic and therapeutic procedures and in general and specialty surgical applications. The Company’s OEM segment designs, manufactures and supplies devices and instruments for other medical device manufacturers.
	The following tables present the Company’s segment results for the three and nine months ended September 28, 2014 and September 29, 2013:
		Three Months Ended						Nine Months Ended
		28-Sep-14			29-Sep-13			28-Sep-14			29-Sep-13
		(Dollars in thousands)
	Revenue
	Vascular North America	$	63,792		$	55,058		$	190,485		$	168,478
	Anesthesia/Respiratory North America	54,699			53,842			164,462			170,532
	Surgical North America	36,127			34,147			109,327			108,584
	EMEA	141,146			132,265			446,061			412,525
	Asia	62,035			55,263			174,176			148,040
	OEM	39,174			33,774			108,966			97,222
	All other	60,200			49,447			170,347			140,351
	Consolidated net revenues	$	457,173		$	413,796		$	1,363,824		$	1,245,732
		Three Months Ended						Nine Months Ended
		28-Sep-14			29-Sep-13			28-Sep-14			29-Sep-13
		(Dollars in thousands)
	Operating Profit
	Vascular North America	$	11,870		$	6,042		$	31,250		$	17,394
	Anesthesia/Respiratory North America	9,421			3,541			21,401			18,483
	Surgical North America	12,394			10,333			37,308			37,646
	EMEA	28,810			21,074			85,771			65,542
	Asia	14,785			18,894			44,718			44,961
	OEM	9,651			6,684			24,551			20,778
	All other	12,441			11,071			32,564			22,593
	Total segment operating profit (1)	99,372			77,639			277,563			227,397
	Unallocated expenses (2)	(17,437		)	(11,597		)	(61,856		)	(48,200		)
	Income from continuing operations before interest, loss on extinguishments of debt and taxes	$	81,935		$	66,042		$	215,707		$	179,197
	-1	Segment operating profit includes segment net revenues from external customers reduced by its standard cost of goods sold, adjusted for fixed manufacturing cost absorption variances, selling, general and administrative expenses, research and development expenses and an allocation of corporate expenses. Corporate expenses are allocated among the segments in proportion to the respective amounts of one of several items (such as sales, numbers of employees, and amount of time spent), depending on the category of expense involved.
	-2	Unallocated expenses primarily include manufacturing variances, with the exception of fixed manufacturing cost absorption variances, and restructuring and other impairment charges.
		Three Months Ended						Nine Months Ended
		28-Sep-14			29-Sep-13			28-Sep-14			29-Sep-13
		(Dollars in thousands)
	Depreciation and Amortization
	Vascular North America	$	7,921		$	7,222		$	23,842		$	20,656
	Anesthesia/Respiratory North America	5,321			3,948			13,457			10,663
	Surgical North America	909			2,476			4,944			7,708
	EMEA	9,688			7,035			28,298			20,666
	Asia	2,003			1,134			6,146			3,506
	OEM	1,651			1,123			4,715			3,370
	All other	4,946			4,137			14,852			12,466
	Consolidated depreciation and amortization	$	32,439		$	27,075		$	96,254		$	79,035
	Geographic Data
	The following table provides total net revenues for the three and nine months ended September 28, 2014 and September 29, 2013 and total net property, plant and equipment by geographic region as of September 28, 2014 and December 31, 2013:
		Three Months Ended						Nine Months Ended
		28-Sep-14			29-Sep-13			28-Sep-14			29-Sep-13
		(Dollars in thousands)
	Net revenue (based on selling location)
	United States	$	231,278		$	205,049		$	676,088		$	623,397
	Other Americas	14,440			12,108			44,399			40,786
	Europe	157,797			137,848			500,763			419,062
	All other	53,658			58,791			142,574			162,487
		$	457,173		$	413,796		$	1,363,824		$	1,245,732
		28-Sep-14			31-Dec-13
		(Dollars in thousands)
	Net property, plant and equipment
	United States	$	201,045		$	203,985
	Czech Republic	38,728			41,607
	Malaysia	35,972			29,313
	All other	71,488			50,995
	$	347,233		$	325,900

Condensed_consolidated_guarant

Condensed consolidated guarantor financial information	9 Months Ended
	Sep. 28, 2014
Condensed Consolidated Guarantor Financial Information [Abstract]	'
Condensed consolidated guarantor financial information	'
	Condensed consolidated guarantor financial information
	In June 2011, Teleflex Incorporated (referred to below as “Parent Company”) issued $250 million of 6.875% senior subordinated notes through a registered public offering. The notes are guaranteed, jointly and severally, by certain of the Parent Company’s subsidiaries (each, a “Guarantor Subsidiary” and collectively, the “Guarantor Subsidiaries”). The guarantees are full and unconditional, subject to certain customary release provisions. Each Guarantor Subsidiary is directly or indirectly 100% owned by the Parent Company. The Company’s condensed consolidating statements of income and comprehensive income (loss) for the three and nine months ended September 28, 2014 and September 29, 2013, condensed consolidating balance sheets as of September 28, 2014 and December 31, 2013 and condensed consolidating statements of cash flows for the nine months ended September 28, 2014 and September 29, 2013, provide consolidated information for:
	a.	Parent Company, the issuer of the guaranteed obligations;
	b.	Guarantor Subsidiaries, on a combined basis;
	c.	Non-guarantor subsidiaries, on a combined basis; and
	d.	Parent Company and its subsidiaries on a consolidated basis.
	The same accounting policies as described in Note 1 to the consolidated financial statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2013 are used by the Parent Company and each of its subsidiaries in connection with the condensed consolidated financial information, except for the use by the Parent Company and Guarantor Subsidiaries of the equity method of accounting to reflect ownership interests in subsidiaries which are eliminated upon consolidation.
	Consolidating entries and eliminations in the following condensed consolidated financial statements represent adjustments to (a) eliminate intercompany transactions between or among the Parent Company, the Guarantor Subsidiaries and the Non-guarantor subsidiaries, (b) eliminate the investments in subsidiaries and (c) record consolidating entries.
	The Company adjusted the 2013 condensed consolidating statement of cash flows included within the guarantor financial information to correctly present dividends received from subsidiaries as an operating activity. The corrections had no impact on the consolidated financial information, but resulted only in reclassifications among the parent, guarantor subsidiaries, non-guarantor subsidiaries and eliminations. The Company does not consider the errors to be material to the previously issued consolidated financial statements.
	The following table illustrates the increase/(decrease) to the previously reported amounts for the nine months ended September 29, 2013:
		Nine Months Ended September 29, 2013
		Parent			Guarantor			Non-Guarantor			Eliminations			Condensed
		Company			Subsidiaries			Subsidiaries						Consolidated
		(Dollars in thousands)
	Cash Flows from Operating Activities of Continuing Operations	$	1,200		$	61,134		$	3,737		$	(66,071	)	$	—
	Cash Flows from Financing Activities of Continuing Operations:
	Intercompany transactions	(1,200		)	(43,734		)	44,934			—			—
	Intercompany dividends paid	—			(17,400		)	(48,671		)	66,071			—
	Cash Flows from Financing Activities of Continuing Operations	$	(1,200	)	$	(61,134	)	$	(3,737	)	$	66,071		$	—
	TELEFLEX INCORPORATED AND SUBSIDIARIES
	CONDENSED CONSOLIDATING STATEMENTS OF INCOME AND COMPREHENSIVE INCOME
		Three Months Ended September 28, 2014
		Parent			Guarantor			Non-Guarantor			Eliminations			Condensed
		Company			Subsidiaries			Subsidiaries						Consolidated
		(Dollars in thousands)
	Net revenues	$	—		$	261,346		$	272,083		$	(76,256	)	$	457,173
	Cost of goods sold	—			161,298			136,526			(76,817		)	221,007
	Gross profit	—			100,048			135,557			561			236,166
	Selling, general and administrative expenses	8,978			77,352			52,002			(80		)	138,252
	Research and development expenses	—			12,871			2,000			—			14,871
	Restructuring and other impairment charges	—			148			960			—			1,108
	Income (loss) from continuing operations before interest, and taxes	(8,978		)	9,677			80,595			641			81,935
	Interest expense	37,913			(22,346		)	1,617			—			17,184
	Interest income	—			—			(161		)	—			(161		)
	Income (loss) from continuing operations before taxes	(46,891		)	32,023			79,139			641			64,912
	Taxes (benefit) on income (loss) from continuing operations	(16,761		)	13,984			10,505			1,956			9,684
	Equity in net income of consolidated subsidiaries	85,187			60,295			96			(145,578		)	—
	Income from continuing operations	55,057			78,334			68,730			(146,893		)	55,228
	Operating loss from discontinued operations	(247		)	—			—			—			(247		)
	Taxes (benefit) on loss from discontinued operations	(21		)	—			45			—			24
	Loss from discontinued operations	(226		)	—			(45		)	—			(271		)
	Net income	54,831			78,334			68,685			(146,893		)	54,957
	Less: Income from continuing operations attributable to noncontrolling interests	—			—			126			—			126
	Net income attributable to common shareholders	54,831			78,334			68,559			(146,893		)	54,831
	Other comprehensive loss attributable to common shareholders	(45,201		)	(58,947		)	(43,438		)	102,385			(45,201		)
	Comprehensive income attributable to common shareholders	$	9,630		$	19,387		$	25,121		$	(44,508	)	$	9,630
		Three Months Ended September 29, 2013
		Parent			Guarantor			Non-Guarantor			Eliminations			Condensed
		Company			Subsidiaries			Subsidiaries						Consolidated
		(Dollars in thousands)
	Net revenues	$	—		$	237,949		$	238,254		$	(62,407	)	$	413,796
	Cost of goods sold	—			139,501			130,825			(60,522		)	209,804
	Gross profit	—			98,448			107,429			(1,885		)	203,992
	Selling, general and administrative expenses	14,088			62,701			38,167			272			115,228
	Research and development expenses	—			13,161			2,477			—			15,638
	Restructuring and other impairment charges	828			3,834			2,422			—			7,084
	Income (loss) from continuing operations before interest, loss on extinguishments of debt and taxes	(14,916		)	18,752			64,363			(2,157		)	66,042
	Interest expense	33,492			(21,204		)	1,660			—			13,948
	Interest income	3			(3		)	(144		)	—			(144		)
	Loss on extinguishments of debt	1,250			—			—			—			1,250
	Income (loss) from continuing operations before taxes	(49,661		)	39,959			62,847			(2,157		)	50,988
	Taxes (benefit) on income (loss) from continuing operations	(18,446		)	14,261			9,962			(568		)	5,209
	Equity in net income of consolidated subsidiaries	76,448			48,367			319			(125,134		)	—
Income from continuing operations	45,233			74,065			53,204			(126,723		)	45,779
Operating income (loss) from discontinued operations	364			—			(326		)	—			38
Taxes (benefit) on income (loss) from discontinued operations	(977		)	(170		)	156			—			(991		)
Income (loss) from discontinued operations	1,341			170			(482		)	—			1,029
Net income (loss)	46,574			74,235			52,722			(126,723		)	46,808
Less: Income from continuing operations attributable to noncontrolling interests	—			—			234			—			234
Net income (loss) attributable to common shareholders	46,574			74,235			52,488			(126,723		)	46,574
Other comprehensive income attributable to common shareholders	24,375			30,034			21,442			(51,476		)	24,375
Comprehensive income attributable to common shareholders	$	70,949		$	104,269		$	73,930		$	(178,199	)	$	70,949
	Nine Months Ended September 28, 2014
	Parent			Guarantor			Non-Guarantor			Eliminations			Condensed
	Company			Subsidiaries			Subsidiaries						Consolidated
	(Dollars in thousands)
Net revenues	$	—		$	814,051		$	838,171		$	(288,398	)	$	1,363,824
Cost of goods sold	—			489,694			451,408			(278,691		)	662,411
Gross profit	—			324,357			386,763			(9,707		)	701,413
Selling, general and administrative expenses	30,781			235,322			159,058			231			425,392
Research and development expenses	—			37,766			6,037			—			43,803
Restructuring and other impairment charges	—			8,639			7,872			—			16,511
Income (loss) from continuing operations before interest, and taxes	(30,781		)	42,630			213,796			(9,938		)	215,707
Interest expense	106,794			(62,993		)	4,849			—			48,650
Interest income	—			—			(494		)	—			(494		)
Income (loss) from continuing operations before taxes	(137,575		)	105,623			209,441			(9,938		)	167,551
Taxes (benefit) on income (loss) from continuing operations	(47,891		)	44,737			33,681			(2,303		)	28,224
Equity in net income of consolidated subsidiaries	228,113			160,653			288			(389,054		)	—
Income from continuing operations	138,429			221,539			176,048			(396,689		)	139,327
Operating loss from discontinued operations	(1,866		)	—			—			—			(1,866		)
Taxes (benefit) on loss from discontinued operations	(478		)	—			133			—			(345		)
Loss from discontinued operations	(1,388		)	—			(133		)	—			(1,521		)
Net income	137,041			221,539			175,915			(396,689		)	137,806
Less: Income from continuing operations attributable to noncontrolling interests	—			—			765			—			765
Net income attributable to common shareholders	137,041			221,539			175,150			(396,689		)	137,041
Other comprehensive loss attributable to common shareholders	(38,594		)	(54,326		)	(37,179		)	91,505			(38,594		)
Comprehensive income attributable to common shareholders	$	98,447		$	167,213		$	137,971		$	(305,184	)	$	98,447
	Nine Months Ended September 29, 2013
	Parent			Guarantor			Non-Guarantor			Eliminations			Condensed
	Company			Subsidiaries			Subsidiaries						Consolidated
	(Dollars in thousands)
Net revenues	$	—		$	740,817		$	708,206		$	(203,291	)	$	1,245,732
Cost of goods sold	—			435,937			398,720			(202,927		)	631,730
Gross profit	—			304,880			309,486			(364		)	614,002
Selling, general and administrative expenses	45,915			189,193			123,257			66			358,431
Research and development expenses	—			40,250			6,919			—			47,169
Restructuring and other impairment charges	828			13,112			15,265			—			29,205
Income (loss) from continuing operations before interest, loss on extinguishments of debt and taxes	(46,743		)	62,325			164,045			(430		)	179,197
Interest expense	100,682			(63,348		)	5,232			—			42,566
Interest income	—			(3		)	(455		)	—			(458		)
Loss on extinguishments of debt	1,250			—			—			—			1,250
Income (loss) from continuing operations before taxes	(148,675		)	125,676			159,268			(430		)	135,839
Taxes (benefit) on income (loss) from continuing operations	(54,192		)	42,241			30,701			208			18,958
Equity in net income of consolidated subsidiaries	210,701			114,116			319			(325,136		)	—
Income from continuing operations	116,218			197,551			128,886			(325,774		)	116,881
Operating income (loss) from discontinued operations	(1,788		)	—			42			—			(1,746		)
Taxes (benefit) on income (loss) from discontinued operations	(1,623		)	(170		)	246			—			(1,547		)
Income (loss) from discontinued operations	(165		)	170			(204		)	—			(199		)
Net income (loss)	116,053			197,721			128,682			(325,774		)	116,682
Less: Income from continuing operations attributable to noncontrolling interests	—			—			629			—			629
Net income (loss) attributable to common shareholders	116,053			197,721			128,053			(325,774		)	116,053
Other comprehensive income attributable to common shareholders	(6,335		)	(3,316		)	(5,930		)	9,246			(6,335		)
Comprehensive income attributable to common shareholders	$	109,718		$	194,405		$	122,123		$	(316,528	)	$	109,718
TELEFLEX INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATING BALANCE SHEETS
	September 28, 2014
	Parent			Guarantor			Non-Guarantor			Eliminations			Condensed
	Company			Subsidiaries			Subsidiaries						Consolidated
	(Dollars in thousands)
ASSETS
Current assets
Cash and cash equivalents	$	59,555		$	1,662		$	225,165		$	—		$	286,382
Accounts receivable, net	1,921			11,630			270,387			3,241			287,179
Accounts receivable from consolidated subsidiaries	39,604			2,782,391			270,488			(3,092,483		)	—
Inventories, net	—			210,427			168,218			(25,418		)	353,227
Prepaid expenses and other current assets	15,587			6,826			20,870			—			43,283
Prepaid taxes	34,406			—			16,913			—			51,319
Deferred tax assets	19,912			19,516			8,933			(220		)	48,141
Assets held for sale	2,901			—			4,771			—			7,672
Total current assets	173,886			3,032,452			985,745			(3,114,880		)	1,077,203
Property, plant and equipment, net	3,648			196,101			147,484			—			347,233
Goodwill	—			704,210			647,835			—			1,352,045
Intangibles assets, net	—			713,854			494,398			—			1,208,252
Investments in affiliates	5,676,862			1,356,773			21,252			(7,053,808		)	1,079
Deferred tax assets	34,525			—			5,109			(37,928		)	1,706
Notes receivable and other amounts due from consolidated subsidiaries	975,641			992,775			—			(1,968,416		)	—
Other assets	28,795			7,435			34,044			—			70,274
Total assets	$	6,893,357		$	7,003,600		$	2,335,867		$	(12,175,032	)	$	4,057,792
LIABILITIES AND EQUITY
Current liabilities
Current borrowings	$	360,656		$	—		$	4,700		$	—		$	365,356
Accounts payable	4,291			35,293			31,450			—			71,034
Accounts payable to consolidated subsidiaries	2,730,852			197,409			164,222			(3,092,483		)	—
Accrued expenses	18,088			17,056			42,189			—			77,333
Current portion of contingent consideration	—			2,957			—			—			2,957
Payroll and benefit-related liabilities	17,358			20,742			38,681			—			76,781
Accrued interest	13,831			—			17			—			13,848
Income taxes payable	—			—			26,735			—			26,735
Other current liabilities	475			33,450			8,567			(220		)	42,272
Total current liabilities	3,145,551			306,907			316,561			(3,092,703		)	676,316
Long-term borrowings	700,000			—			—			—			700,000
Deferred tax liabilities	—			477,101			55,710			(37,927		)	494,884
Pension and other postretirement benefit liabilities	46,618			33,962			16,427			—			97,007
Noncurrent liability for uncertain tax positions	13,355			17,476			25,617			—			56,448
Notes payable and other amounts due from consolidated subsidiaries	986,769			897,634			89,801			(1,974,204		)	—
Other liabilities	19,336			17,142			12,743			—			49,221
Total liabilities	4,911,629			1,750,222			516,859			(5,104,834		)	2,073,876
Total common shareholders' equity	1,981,728			5,253,378			1,816,820			(7,070,198		)	1,981,728
Noncontrolling interest	—			—			2,188			—			2,188
Total equity	1,981,728			5,253,378			1,819,008			(7,070,198		)	1,983,916
Total liabilities and equity	$	6,893,357		$	7,003,600		$	2,335,867		$	(12,175,032	)	$	4,057,792
	December 31, 2013
	Parent			Guarantor			Non-Guarantor			Eliminations			Condensed
	Company			Subsidiaries			Subsidiaries						Consolidated
	(Dollars in thousands)
ASSETS
Current assets
Cash and cash equivalents	$	42,749		$	14,500		$	374,735		$	—		$	431,984
Accounts receivable, net	1,822			10,948			279,048			3,472			295,290
Accounts receivable from consolidated subsidiaries	42,865			2,623,314			214,469			(2,880,648		)	—
Inventories, net	—			211,165			138,165			(15,709		)	333,621
Prepaid expenses and other current assets	15,200			6,870			17,740			—			39,810
Prepaid taxes	27,487			—			9,017			—			36,504
Deferred tax assets	20,218			22,472			10,230			(3		)	52,917
Assets held for sale	1,669			3,503			5,256			—			10,428
Total current assets	152,010			2,892,772			1,048,660			(2,892,888		)	1,200,554
Property, plant and equipment, net	14,189			188,455			123,256			—			325,900
Goodwill	—			797,671			556,532			—			1,354,203
Intangibles assets, net	—			962,243			293,354			—			1,255,597
Investments in affiliates	5,489,676			1,478,429			21,382			(6,987,772		)	1,715
Deferred tax assets	35,877			—			4,476			(39,410		)	943
Notes receivable and other amounts due from consolidated subsidiaries	1,049,344			873,105			14,169			(1,936,618		)	—
Other assets	24,574			7,447			38,074			—			70,095
Total assets	$	6,765,670		$	7,200,122		$	2,099,903		$	(11,856,688	)	$	4,209,007
LIABILITIES AND EQUITY
Current liabilities
Notes payable	$	351,587		$	—		$	4,700		$	—		$	356,287
Accounts payable	2,194			45,802			23,971			—			71,967
Accounts payable to consolidated subsidiaries	2,644,296			147,957			88,395			(2,880,648		)	—
Accrued expenses	15,569			21,120			38,179			—			74,868
Current portion of contingent consideration	—			4,131			—			—			4,131
Payroll and benefit-related liabilities	15,976			21,818			35,296			—			73,090
Accrued interest	8,720			—			5			—			8,725
Income taxes payable	—			—			23,821			—			23,821
Other current liabilities	9,646			7,517			5,072			(4		)	22,231
Total current liabilities	3,047,988			248,345			219,439			(2,880,652		)	635,120
Long-term borrowings	930,000			—			—			—			930,000
Deferred tax liabilities	—			496,228			57,896			(39,409		)	514,715
Pension and other postretirement benefit liabilities	57,406			33,777			18,315			—			109,498
Noncurrent liability for uncertain tax positions	11,389			17,241			26,522			—			55,152
Notes payable and other amounts due from consolidated subsidiaries	785,476			957,451			197,173			(1,940,100		)	—
Other liabilities	19,884			16,221			12,401			—			48,506
Total liabilities	4,852,143			1,769,263			531,746			(4,860,161		)	2,292,991
Total common shareholders' equity	1,913,527			5,430,859			1,565,668			(6,996,527		)	1,913,527
Noncontrolling interest	—			—			2,489			—			2,489
Total equity	1,913,527			5,430,859			1,568,157			(6,996,527		)	1,916,016
Total liabilities and equity	$	6,765,670		$	7,200,122		$	2,099,903		$	(11,856,688	)	$	4,209,007
TELEFLEX INCORPORATED AND SUBSIDIARIES
CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS
	Nine Months Ended September 28, 2014
	Parent			Guarantor			Non-Guarantor			Eliminations			Condensed
	Company			Subsidiaries			Subsidiaries						Consolidated
	(Dollars in thousands)
Net cash (used in) provided by operating activities from continuing operations	$	(80,537	)	$	300,960		$	63,715		$	(75,340	)	$	208,798
Cash Flows from Investing Activities of Continuing Operations:
Expenditures for property, plant and equipment	(2,146		)	(22,578		)	(23,496		)	—			(48,220		)
Proceeds from sale of assets and investments	1,669			3,421			161			—			5,251
Payments for businesses and intangibles acquired, net of cash acquired	—			—			(28,535		)	—			(28,535		)
Investments in affiliates	(60		)	20			—			—			(40		)
Intercompany dividends received	—			—			229,782			(229,782		)	—
Net cash (used in) provided by investing activities from continuing operations	(537		)	(19,137		)	177,912			(229,782		)	(71,544		)
Cash Flows from Financing Activities of Continuing Operations:
Proceeds from long-term borrowings	250,000			—			—			—			250,000
Repayment of long-term borrowings	(480,009		)	—			—			—			(480,009		)
Debt issuance fees	(3,689		)	—			—			—			(3,689		)
Proceeds from share based compensation plans and the related tax impacts	2,936			—			—			—			2,936
Payments to noncontrolling interest shareholders	—			—			(1,094		)	—			(1,094		)
Dividends	(42,174		)	—			—			—			(42,174		)
Intercompany transactions	372,762			(294,661		)	(78,101		)	—			—
Intercompany dividends paid	—			—			(305,122		)	305,122			—
Net cash provided by (used in) financing activities from continuing operations	99,826			(294,661		)	(384,317		)	305,122			(274,030		)
Cash Flows from Discontinued Operations:
Net cash used in operating activities	(1,946		)	—			—			—			(1,946		)
Net cash used in discontinued  operations	(1,946		)	—			—			—			(1,946		)
Effect of exchange rate changes on cash and cash equivalents	—			—			(6,880		)	—			(6,880		)
Net increase (decrease) in cash and cash equivalents	16,806			(12,838		)	(149,570		)	—			(145,602		)
Cash and cash equivalents at the beginning of the period	42,749			14,500			374,735			—			431,984
Cash and cash equivalents at the end of the period	$	59,555		$	1,662		$	225,165		$	—		$	286,382
	Nine Months Ended September 29, 2013
	Parent			Guarantor			Non-Guarantor			Eliminations			Condensed
	Company			Subsidiaries			Subsidiaries						Consolidated
	(Dollars in thousands)
Net cash (used in) provided by operating activities from continuing operations	$	(85,753	)	$	147,461		$	140,235		$	(66,071	)	$	135,872
Cash Flows from Investing Activities of Continuing Operations:
Expenditures for property, plant and equipment	(799		)	(42,854		)	(10,987		)	—			(54,640		)
Payments for business intangibles acquired, net of cash acquired	—			(1,820		)	(38,630		)	—			(40,450		)
Investments in affiliates	(50		)	—			—			—			(50		)
Net cash used in investing activities from continuing operations	(849		)	(44,674		)	(49,617		)	—			(95,140		)
Cash Flows from Financing Activities of Continuing Operations:
Proceeds from long-term borrowings	382,000			—			—			—			382,000
Repayment of long-term borrowings	(375,000		)	—			—			—			(375,000		)
Debt extinguishment, issuance and amendment fees	(6,365		)	—			—			—			(6,365		)
Proceeds from share based compensation plans and the related tax impacts	4,740			—			—			—			4,740
Payments to noncontrolling interest shareholders	—			—			(736		)	—			(736		)
Payments for contingent consideration	—			(14,802		)	(1,565		)	—			(16,367		)
Dividends	(41,915		)	—			—			—			(41,915		)
Intercompany transactions	70,932			(72,574		)	1,642			—			—
Intercompany dividends paid	—			(17,400		)	(48,671		)	66,071			—
Net cash provided by (used in) financing activities from continuing operations	34,392			(104,776		)	(49,330		)	66,071			(53,643		)
Cash Flows from Discontinued Operations:													—
Net cash used in operating activities	(1,567		)	—			(600		)	—			(2,167		)
Net cash used in discontinued operations	(1,567		)	—			(600		)	—			(2,167		)
Effect of exchange rate changes on cash and cash equivalents	—			—			4,476			—			4,476
Net (decrease) increase in cash and cash equivalents	(53,777		)	(1,989		)	45,164			—			(10,602		)
Cash and cash equivalents at the beginning of the period	70,860			1,989			264,190			—			337,039
Cash and cash equivalents at the end of the period	$	17,083		$	—		$	309,354		$	—		$	326,437

New_accounting_standards_Polic

New accounting standards (Policies)	9 Months Ended
	Sep. 28, 2014
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]	'
New accounting standards	'
	New accounting standards
	In April 2014, the Financial Accounting Standards Board (FASB) issued guidance for the reporting of discontinued operations. Under the new guidance, only those disposals of components of an entity that represent a strategic shift that has or will have a major effect on an entity's operations and financial results will be reported as discontinued operations in an entity's financial statements. In addition, the new guidance requires additional disclosures for discontinued operations designed to provide users of financial statements with more information about the assets, liabilities, revenues and expenses of discontinued operations. The new guidance also requires disclosures regarding disposals of a significant component of an entity that does not qualify for discontinued operations reporting.This guidance is effective for fiscal years, and interim periods within those years, beginning after December 15, 2014 with early adoption permitted. The Company does not believe the adoption of this guidance will have a material impact on the Company’s results of operations, cash flows or financial position.
	In May 2014, the FASB, in a joint effort with the International Accounting Standards Board, issued new accounting guidance to clarify the principles for recognizing revenue.  The new guidance is designed to enhance the comparability of revenue recognition practices across entities, industries, jurisdictions and capital markets, and will affect any entity that enters into contracts with customers or enters into contracts for the transfer of nonfinancial assets, unless those contracts are within the scope of other standards.  The new guidance establishes principles for reporting information to users of financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from an entity's contracts with customers.  The core principle of the new guidance is that an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods and services. The new guidance is effective prospectively for annual periods beginning after December 15, 2016, and interim periods within those years.  Early application is not permitted. The Company is currently evaluating this guidance to determine the impact on the Company’s results of operations, cash flows, and financial position.
	From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies that are adopted by the Company as of the specified effective date or, in some cases where early adoption is permitted, in advance of the specified effective date. The Company has assessed the recently issued standards that are not yet effective and, unless otherwise discussed, believes these standards will not have a material impact on the Company’s results of operations, cash flows or financial position.

Acquisitions_Tables

Acquisitions (Tables)	9 Months Ended
	Sep. 28, 2014
Business Combinations [Abstract]	'
Fair Values Determination of Assets Acquired and Liabilities Assumed in Acquisition	'
	The following table presents the preliminary fair value determination of the assets acquired and liabilities assumed in the Mayo Healthcare acquisition.
		(Dollars in thousands)
	Assets
	Current assets	$	10,393
	Property, plant and equipment	306
	Customer lists intangible asset	9,335
	Goodwill	15,986
	Total assets acquired	36,020
	Liabilities
	Current liabilities	4,685
	Deferred tax liabilities	2,800
	Liabilities assumed	7,485
	Net assets acquired	$	28,535

Restructuring_and_other_impair1

Restructuring and other impairment charges (Tables)	9 Months Ended
	Sep. 28, 2014
Summary of Current Cost Estimates by Major Type of Cost Associated with 2014 Manufacturing Footprint Realignment Plan	'
	The following table provides a summary of the Company’s current cost estimates by major type of cost associated with the 2014 Manufacturing Footprint Realignment Plan:
	Type of cost	Total estimated amount expected to be incurred
	Termination benefits	$12 million to $15 million
	Facility closure and other exit costs(1)	$2 million to $5 million
	Accelerated depreciation charges	$10 million to $12 million
	Other (2)	$18 million to $21 million
		$42 million to $53 million
	-1	Includes costs to transfer product lines among facilities and outplacement and employee relocation costs.
	-2	Consists of other costs directly related to the Plan, including project management, legal and regulatory costs.
Restructuring and Other Impairment Charges	'
	The restructuring and other impairment charges recognized for the three and nine months ended September 28, 2014 and September 29, 2013 consisted of the following:
	Three Months Ended September 28, 2014
	(in thousands)	Termination Benefits			Facility Closure Costs			Contract Termination Costs			Other Exit Costs		Total
	2014 Manufacturing footprint realignment plan	$	129		$	—		$	—		$	42	$	171
	2014 European restructuring plan	537			1			1			27		566
	Other 2014 restructuring programs	25			—			202			62		289
	LMA restructuring program	—			—			20			—		20
	2013 Restructuring programs	(124		)	—			186			—		62
	Total restructuring and other impairment charges	$	567		$	1		$	409		$	131	$	1,108
	Three Months Ended September 29, 2013
	(in thousands)	Termination Benefits			Facility			Contract Termination Costs			Other Exit Costs		Total
					Closure
					Costs
	LMA restructuring program	$	492		$	162		$	1,097		$	17	$	1,768
	2013 Restructuring programs	891			—			(65		)	—		826
	2012 Restructuring program	559			539			—			—		1,098
	2007 Arrow integration program	—			38			—			—		38
		1,942			739			1,032			17		3,730
	Impairment charges	—			—			—			3,354		3,354
	Total restructuring and other impairment charges	$	1,942		$	739		$	1,032		$	3,371	$	7,084
	Nine Months Ended September 28, 2014
	(in thousands)	Termination Benefits			Facility			Contract Termination Costs			Other Exit Costs		Total
					Closure
					Costs
	2014 Manufacturing footprint realignment plan	$	8,706		$	—		$	—		$	42	$	8,748
	2014 European restructuring plan	8,289			1			306			76		8,672
	Other 2014 restructuring programs	501			—			1,376			193		2,070
	LMA restructuring program	(29		)	(112		)	(3,211		)	—		(3,352		)
	2013 Restructuring programs	361			—			243			22		626
	2012 Restructuring program	(619		)	354			—			—		(265		)
	2011 Restructuring program	—			12			—			—		12
	Total restructuring and other impairment charges	$	17,209		$	255		$	(1,286	)	$	333	$	16,511
	Nine Months Ended September 29, 2013
	(in thousands)	Termination Benefits			Facility Closure Costs			Contract Termination Costs			Other Exit Costs		Total
	LMA restructuring program	$	3,318		$	536		$	4,378		$	132	$	8,364
	2013 Restructuring programs	2,443			—			3,326			2,887		8,656
	2012 Restructuring program	3,225			641			293			5		4,164
	2007 Arrow integration program	—			173			—			—		173
		8,986			1,350			7,997			3,024		21,357
	Impairment charges	—			—			—			7,848		7,848
	Total restructuring and other impairment charges	$	8,986		$	1,350		$	7,997		$	10,872	$	29,205
Reporting Segment	'
Restructuring and Other Impairment Charges	'
	Restructuring and other impairment charges by reportable segment for the three and nine months ended September 28, 2014 and September 29, 2013 are set forth in the following table:
		Three Months Ended						Nine Months Ended
		September 28, 2014			September 29, 2013			September 28, 2014			September 29, 2013
		(Dollars in thousands)
	Restructuring and other impairment charges
	Vascular North America	$	(54	)	$	2,233		$	5,908		$	2,860
	Anesthesia/Respiratory North America	15			332			1,193			3,001
	Surgical North America	—			—			—			7,294
	EMEA	849			2,221			7,164			11,428
	Asia	111			202			708			447
	OEM	—			—			—			588
	All other	187			2,096			1,538			3,587
	Total restructuring and other impairment charges	$	1,108		$	7,084		$	16,511		$	29,205
LMA Restructuring Program	'
Changes in Accrued Liability Associated with Restructuring Program	'
	A reconciliation of the changes in accrued liabilities associated with the LMA Restructuring Program from December 31, 2013 through September 28, 2014 is set forth in the following table:
		Termination Benefits			Facility Closure Costs			Contract Termination Costs			Other Exit Costs		Total
		(Dollars in thousands)
	Balance at December 31, 2013	$	552		$	427		$	3,686		$	16	$	4,681
	Subsequent accruals (reversals)	(29		)	(112		)	(3,211		)	—		(3,352		)
	Cash payments	(533		)	(317		)	(104		)	—		(954		)
	Foreign currency translation	10			2			(14		)	—		(2		)
	Balance at September 28, 2014	$	—		$	—		$	357		$	16	$	373

Inventories_net_Tables

Inventories, net (Tables)	9 Months Ended
	Sep. 28, 2014
Inventory Disclosure [Abstract]	'
Inventories, net	'
	Inventories as of September 28, 2014 and December 31, 2013 consisted of the following:
		28-Sep-14			31-Dec-13
		(Dollars in thousands)
	Raw materials	$	73,170		$	70,209
	Work-in-process	59,282			53,672
	Finished goods	254,120			242,113
		386,572			365,994
	Less: Inventory reserve	(33,345		)	(32,373		)
	Inventories, net	$	353,227		$	333,621

Goodwill_and_other_intangible_1

Goodwill and other intangible assets, net (Tables)	9 Months Ended
	Sep. 28, 2014
Goodwill and Intangible Assets Disclosure [Abstract]	'
Changes in Carrying Amount of Goodwill, by Reporting Segment	'
	The following table provides information relating to changes in the carrying amount of goodwill by reportable segment for the nine months ended September 28, 2014:
		Vascular			Anesthesia/			Surgical			EMEA			Asia			All			Total
		North America			Respiratory			North America									Other
					North America
		(Dollars in thousands)
	Balance as of December 31, 2013
	Goodwill	$	474,044		$	167,195		$	250,506		$	373,417		$	136,946		$	284,223		$	1,686,331
	Accumulated impairment losses	(219,527		)	(107,073		)	—			—			—			(5,528		)	(332,128		)
		254,517			60,122			250,506			373,417			136,946			278,695			1,354,203
	Goodwill related to acquisitions	—			—			—			—			15,986			—			15,986
	Translation adjustment	—			(300		)	—			(17,467		)	(585		)	208			(18,144		)
	Balance at September 28, 2014
	Goodwill	474,044			166,895			250,506			355,950			152,347			284,431			1,684,173
	Accumulated impairment losses	(219,527		)	(107,073		)	—			—			—			(5,528		)	(332,128		)
		$	254,517		$	59,822		$	250,506		$	355,950		$	152,347		$	278,903		$	1,352,045
Components of Intangible Assets	'
	The following table provides information as of September 28, 2014 and December 31, 2013 regarding the gross carrying amount of, and accumulated amortization relating to, intangible assets, net:
		Gross Carrying Amount						Accumulated Amortization
		September 28,			31-Dec-13			September 28,			31-Dec-13
		2014						2014
		(Dollars in thousands)
	Customer relationships	$	631,983		$	628,020		$	(188,261	)	$	(168,223	)
	In-process research and development	68,766			68,786			—			—
	Intellectual property	433,227			435,869			(140,606		)	(118,086		)
	Distribution rights	16,406			16,797			(14,466		)	(14,592		)
	Trade names	403,460			407,879			(2,425		)	(1,148		)
	Noncompete agreements	337			337			(169		)	(42		)
		$	1,554,179		$	1,557,688		$	(345,927	)	$	(302,091	)
Estimated Annual Amortization Expense	'
	stimated annual amortization expense for the remainder of 2014 and the next five succeeding years is as follows (dollars in thousands):
	2014	$	13,700
	2015	54,100
	2016	53,700
	2017	53,300
	2018	53,000
	2019	52,600

Borrowings_Tables

Borrowings (Tables)	9 Months Ended
	Sep. 28, 2014
Debt Disclosure [Abstract]	'
Components of Long-Term Debt	'
	The components of long-term debt at September 28, 2014 and December 31, 2013 are as follows:
		28-Sep-14			31-Dec-13
		(Dollars in thousands)
	Senior Credit Facility:
	Revolving credit facility, at a rate of 1.90% at September 28, 2014, due 7/16/2018	$	200,000		$	680,000
	3.875% Convertible Senior Subordinated Notes due 2017	399,991			400,000
	6.875% Senior Subordinated Notes due 2019	250,000			250,000
	5.25% Senior Notes due 2024	250,000			—
	Total borrowings	1,099,991			1,330,000
	Less: Unamortized debt discount on 3.875% Convertible Senior Subordinated Notes	(39,335		)	(48,413		)
		1,060,656			1,281,587
	Current portion of borrowings	(360,656		)	(351,587		)
		$	700,000		$	930,000
Fair Value of Long-Term Debt	'
	The following table provides the fair value of the Company’s debt as of September 28, 2014, categorized by fair value hierarchy level (see Note 10, “Fair value measurement,” in the Company’s annual report on Form 10-K for the year ended December 31, 2013 for further information):
		Fair value of debt
		(Dollars in thousands)
	Level 1	$	955,567
	Level 2	442,337
	Total	$	1,397,904

Financial_instruments_Tables

Financial instruments (Tables)	9 Months Ended
	Sep. 28, 2014
Derivative Instruments and Hedging Activities Disclosure [Abstract]	'
Fair Values of Derivative Instruments Designated as Hedging Instruments	'
	The following table presents the location and fair values of derivative instruments designated as hedging instruments in the condensed consolidated balance sheet as of September 28, 2014 and December 31, 2013:
		September 28,			December 31,
		2014			2013
		Fair Value			Fair Value
		(Dollars in thousands)
	Asset derivatives:
	Foreign currency forward contracts:
	Prepaid expenses and other current assets	$	959		$	—
	Total asset derivatives	$	959		$	—
	Liability derivatives:
	Foreign currency forward contracts:
	Other current liabilities	$	471		$	—
	Total liability derivatives	$	471		$	—
After Tax Gain/(Loss) Recognized in OCI	'
	The following table provides information as to the gains and losses attributable to derivatives in cash flow hedging relationships that were reported in other comprehensive income (“OCI”) for the three and nine months ended September 28, 2014 and September 29, 2013:
		After Tax Gain/(Loss)
		Recognized in OCI
		Three Months Ended						Nine Months Ended
		28-Sep-14			September 29,			September 28,		September 29,
					2013			2014		2013
		(Dollars in thousands)
	Foreign currency forward contracts	$	60		$	(40	)	$	203	$	(52	)
	Total	$	60		$	(40	)	$	203	$	(52	)
Aggregate Accounts Receivable, Net of Allowance for Doubtful Accounts	'
	The aggregate net current and long-term accounts receivable for Spain, Italy, Greece and Portugal as a percentage of the Company’s net current and long-term accounts receivable at September 28, 2014 and December 31, 2013 are as follows:
		September 28,			December 31,
		2014			2013
		(Dollars in thousands)
	Current and long-term accounts receivable (net of allowances of $8.9 million and $7.9 million at September 28, 2014 and December 31, 2013, respectively) in Spain, Italy, Greece and Portugal (1)	$	87,733		$	97,852
	Percentage of total net current and long-term accounts receivable	29.4		%	31		%
	(1)The long-term portion of accounts receivable, net at September 28, 2014 and December 31, 2013 was $15.5 million and $17.6 million, respectively.

Fair_value_measurement_Tables

Fair value measurement (Tables)	9 Months Ended
	Sep. 28, 2014
Fair Value Disclosures [Abstract]	'
Financial Assets and Liabilities Carried at Fair Value Measured on Recurring Basis	'
	The following tables provide information regarding the financial assets and liabilities measured at fair value on a recurring basis as of September 28, 2014 and December 31, 2013:
		Total carrying			Quoted prices in		Significant other		Significant
		value at			active markets		observable		unobservable
		September 28,			(Level 1)		Inputs (Level 2)		Inputs (Level 3)
		2014
		(Dollars in thousands)
	Investments in marketable securities	$	6,540		$	6,540	$	—	$	—
	Derivative assets	959			—		959		—
	Derivative liabilities	471			—		471		—
	Contingent consideration liabilities	12,643			—		—		12,643
		Total carrying			Quoted prices in		Significant other		Significant
		value at			active markets		observable		unobservable
		December 31, 2013			(Level 1)		Inputs (Level 2)		Inputs (Level 3)
		(Dollars in thousands)
	Investments in marketable securities	$	6,150		$	6,150	$	—	$	—
	Contingent consideration liabilities	20,313			—		—		20,313
Reconciliation of Changes in Level 3 Financial Liabilities Measured at Fair Value on Recurring Basis	'
	The following table provides information regarding changes in Level 3 financial liabilities related to contingent consideration in connection with various Company acquisitions during the nine months ended September 28, 2014:
		Contingent consideration
		2014
		(Dollars in thousands)
	Balance - December 31, 2013	$	20,313
	Revaluations	(7,670		)
	Balance - September 28, 2014	$	12,643
Valuation Technique and Inputs Used to Determine Fair Value of Assets or Liabilities	'
	The following table provides information regarding the valuation techniques and inputs used in determining the fair value of assets or liabilities categorized as Level 3 measurements as of September 28, 2014:
		Valuation Technique		Unobservable Input	Range (Weighted Average)
	Contingent consideration	Discounted cash flow		Discount rate	2.3% - 10% (8.6%)
				Probability of payment	0% - 100% (28.3%)

Changes_in_shareholders_equity1

Changes in shareholders' equity (Tables)	9 Months Ended
	Sep. 28, 2014
Equity [Abstract]	'
Reconciliation of Basic to Diluted Weighted Average Common Shares Outstanding	'
	The following table provides a reconciliation of basic to diluted weighted average shares outstanding:
		Three Months Ended						Nine Months Ended
		September 28, 2014			September 29, 2013			September 28, 2014		September 29, 2013
		(Shares in thousands)
	Basic	41,399			41,132			41,347		41,087
	Dilutive effect of share-based awards	440			383			441		383
	Dilutive effect of 3.875% Convertible Notes and warrants	4,789			1,749			4,468		1,776
	Diluted	46,628			43,264			46,256		43,246
Change in Accumulated Other Comprehensive Income (Loss)	'
	The following tables provide information relating to the changes in accumulated other comprehensive income (loss), net of tax, for the nine months ended September 28, 2014 and September 29, 2013:
		Cash Flow Hedges				Pension and Other Postretirement Benefit Plans			Foreign Currency Translation Adjustment			Accumulated Other Comprehensive Income (Loss)
		(Dollars in thousands)
	Balance as of December 31, 2013	$	—			$	(97,037	)	$	(13,818	)	$	(110,855	)
	Other comprehensive income (loss) before reclassifications	641				131			(41,133		)	(40,361		)
	Amounts reclassified from accumulated other comprehensive income (loss)	(438		)		2,205			—			1,767
	Net current-period other comprehensive income (loss)	203				2,336			(41,133		)	(38,594		)
	Balance at September 28, 2014	$	203			$	(94,701	)	$	(54,951	)	$	(149,449	)
		Cash Flow Hedges				Pension and Other Postretirement Benefit Plans			Foreign Currency Translation Adjustment			Accumulated Other Comprehensive Income (Loss)
		(Dollars in thousands)
	Balance at December 31, 2012	$	(381	)		$	(127,257	)	$	(4,410	)	$	(132,048	)
	Other comprehensive income (loss) before reclassifications	(370		)		(762		)	(9,018		)	(10,150		)
	Amounts reclassified from accumulated other comprehensive income (loss)	318				3,497			—			3,815
	Net current-period other comprehensive income (loss)	(52		)		2,735			(9,018		)	(6,335		)
	Balance at September 29, 2013	$	(433	)		$	(124,522	)	$	(13,428	)	$	(138,383	)
Reclassification of Gain/Losses into Income/Expense, Net of Tax	'
	The following table provides information relating to the reclassifications of losses/(gain) in accumulated other comprehensive income into expense/(income), net of tax, for the three and nine months ended September 28, 2014 and September 29, 2013:
		Three Months Ended							Nine Months Ended
		28-Sep-14				29-Sep-13			28-Sep-14			29-Sep-13
		(Dollars in thousands)
	(Gains) losses on foreign exchange contracts:
	Cost of goods sold	$	(397	)		$	850		$	(526	)	$	154
	Total before tax	(397		)		850			(526		)	154
	Tax benefit	49				(158		)	88			164
	Net of tax	$	(348	)		$	692		$	(438	)	$	318
	Amortization of pension and other postretirement benefit items:
	Actuarial losses/(gains) (1)	$	1,090			$	1,696		$	3,295		$	5,460
	Prior-service costs(1)	(5		)		(4		)	(16		)	(15		)
	Transition obligation(1)	—				1			—			4
	Total before tax	1,085				1,693			3,279			5,449
	Tax expense	(378		)		(604		)	(1,074		)	(1,952		)
	Net of tax	$	707			$	1,089		$	2,205		$	3,497
	Total reclassifications, net of tax	$	359			$	1,781		$	1,767		$	3,815
	-1	These accumulated other comprehensive income components are included in the computation of net benefit cost of pension and other postretirement benefit plans (see Note 12 for additional information).

Taxes_on_income_from_continuin1

Taxes on income from continuing operations (Tables)	9 Months Ended
	Sep. 28, 2014
Income Tax Disclosure [Abstract]	'
Effective Income Tax Rate	'
	Taxes on income from continuing operations
		Three Months Ended		Nine Months Ended
		28-Sep-14	29-Sep-13	28-Sep-14	29-Sep-13
	Effective income tax rate	14.90%	10.20%	16.80%	14.00%

Pension_and_other_postretireme1

Pension and other postretirement benefits (Tables)	9 Months Ended
	Sep. 28, 2014
Compensation and Retirement Disclosure [Abstract]	'
Net Benefit Cost of Pension and Postretirement Benefit Plans	'
	Net benefit cost of pension and postretirement benefit plans consisted of the following:
		Pension						Other Postretirement Benefits					Pension						Other Postretirement Benefits
		Three Months Ended						Three Months Ended					Nine Months Ended						Nine Months Ended
		28-Sep-14			29-Sep-13			28-Sep-14			29-Sep-13		28-Sep-14			29-Sep-13			28-Sep-14			29-Sep-13
		(Dollars in thousands)
	Service cost	$	453		$	432		$	42		$	176	$	1,350		$	1,361		$	318		$	501
	Interest cost	4,548			4,333			434			543		13,517			12,614			1,627			2,084
	Expected return on plan assets	(6,240		)	(5,784		)	—			—		(18,764		)	(17,328		)	—			—
	Net amortization and deferral	1,143			1,556			(58		)	137		3,284			4,380			(5		)	1,069
	Net benefit expense (income)	$	(96	)	$	537		$	418		$	856	$	(613	)	$	1,027		$	1,940		$	3,654

Business_segment_information_T

Business segment information (Tables)	9 Months Ended
	Sep. 28, 2014
Segment Reporting [Abstract]	'
Segment Results	'
	The following tables present the Company’s segment results for the three and nine months ended September 28, 2014 and September 29, 2013:
		Three Months Ended						Nine Months Ended
		28-Sep-14			29-Sep-13			28-Sep-14			29-Sep-13
		(Dollars in thousands)
	Revenue
	Vascular North America	$	63,792		$	55,058		$	190,485		$	168,478
	Anesthesia/Respiratory North America	54,699			53,842			164,462			170,532
	Surgical North America	36,127			34,147			109,327			108,584
	EMEA	141,146			132,265			446,061			412,525
	Asia	62,035			55,263			174,176			148,040
	OEM	39,174			33,774			108,966			97,222
	All other	60,200			49,447			170,347			140,351
	Consolidated net revenues	$	457,173		$	413,796		$	1,363,824		$	1,245,732
		Three Months Ended						Nine Months Ended
		28-Sep-14			29-Sep-13			28-Sep-14			29-Sep-13
		(Dollars in thousands)
	Operating Profit
	Vascular North America	$	11,870		$	6,042		$	31,250		$	17,394
	Anesthesia/Respiratory North America	9,421			3,541			21,401			18,483
	Surgical North America	12,394			10,333			37,308			37,646
	EMEA	28,810			21,074			85,771			65,542
	Asia	14,785			18,894			44,718			44,961
	OEM	9,651			6,684			24,551			20,778
	All other	12,441			11,071			32,564			22,593
	Total segment operating profit (1)	99,372			77,639			277,563			227,397
	Unallocated expenses (2)	(17,437		)	(11,597		)	(61,856		)	(48,200		)
	Income from continuing operations before interest, loss on extinguishments of debt and taxes	$	81,935		$	66,042		$	215,707		$	179,197
	-1	Segment operating profit includes segment net revenues from external customers reduced by its standard cost of goods sold, adjusted for fixed manufacturing cost absorption variances, selling, general and administrative expenses, research and development expenses and an allocation of corporate expenses. Corporate expenses are allocated among the segments in proportion to the respective amounts of one of several items (such as sales, numbers of employees, and amount of time spent), depending on the category of expense involved.
	-2	Unallocated expenses primarily include manufacturing variances, with the exception of fixed manufacturing cost absorption variances, and restructuring and other impairment charges.
		Three Months Ended						Nine Months Ended
		28-Sep-14			29-Sep-13			28-Sep-14			29-Sep-13
		(Dollars in thousands)
	Depreciation and Amortization
	Vascular North America	$	7,921		$	7,222		$	23,842		$	20,656
	Anesthesia/Respiratory North America	5,321			3,948			13,457			10,663
	Surgical North America	909			2,476			4,944			7,708
	EMEA	9,688			7,035			28,298			20,666
	Asia	2,003			1,134			6,146			3,506
	OEM	1,651			1,123			4,715			3,370
	All other	4,946			4,137			14,852			12,466
	Consolidated depreciation and amortization	$	32,439		$	27,075		$	96,254		$	79,035
Schedule Of Revenues And Property Plant Equipment By Geographic Region	'
	The following table provides total net revenues for the three and nine months ended September 28, 2014 and September 29, 2013 and total net property, plant and equipment by geographic region as of September 28, 2014 and December 31, 2013:
		Three Months Ended						Nine Months Ended
		28-Sep-14			29-Sep-13			28-Sep-14			29-Sep-13
		(Dollars in thousands)
	Net revenue (based on selling location)
	United States	$	231,278		$	205,049		$	676,088		$	623,397
	Other Americas	14,440			12,108			44,399			40,786
	Europe	157,797			137,848			500,763			419,062
	All other	53,658			58,791			142,574			162,487
		$	457,173		$	413,796		$	1,363,824		$	1,245,732
Schedule of Disclosure on Geographic Areas, Long-Lived Assets in Individual Foreign Countries by Country	'
		28-Sep-14			31-Dec-13
		(Dollars in thousands)
	Net property, plant and equipment
	United States	$	201,045		$	203,985
	Czech Republic	38,728			41,607
	Malaysia	35,972			29,313
	All other	71,488			50,995
		$	347,233		$	325,900

Condensed_consolidated_guarant1

Condensed consolidated guarantor financial information (Tables)	9 Months Ended
	Sep. 28, 2014
Condensed Consolidated Guarantor Financial Information [Abstract]	'
Condensed Consolidating Financial Statement Adjustments	'
	The following table illustrates the increase/(decrease) to the previously reported amounts for the nine months ended September 29, 2013:
		Nine Months Ended September 29, 2013
		Parent			Guarantor			Non-Guarantor			Eliminations			Condensed
		Company			Subsidiaries			Subsidiaries						Consolidated
		(Dollars in thousands)
	Cash Flows from Operating Activities of Continuing Operations	$	1,200		$	61,134		$	3,737		$	(66,071	)	$	—
	Cash Flows from Financing Activities of Continuing Operations:
	Intercompany transactions	(1,200		)	(43,734		)	44,934			—			—
	Intercompany dividends paid	—			(17,400		)	(48,671		)	66,071			—
	Cash Flows from Financing Activities of Continuing Operations	$	(1,200	)	$	(61,134	)	$	(3,737	)	$	66,071		$	—
Condensed Consolidated Statements of Income (Loss) and Comprehensive Income (Loss)	'
	TELEFLEX INCORPORATED AND SUBSIDIARIES
	CONDENSED CONSOLIDATING STATEMENTS OF INCOME AND COMPREHENSIVE INCOME
		Three Months Ended September 28, 2014
		Parent			Guarantor			Non-Guarantor			Eliminations			Condensed
		Company			Subsidiaries			Subsidiaries						Consolidated
		(Dollars in thousands)
	Net revenues	$	—		$	261,346		$	272,083		$	(76,256	)	$	457,173
	Cost of goods sold	—			161,298			136,526			(76,817		)	221,007
	Gross profit	—			100,048			135,557			561			236,166
	Selling, general and administrative expenses	8,978			77,352			52,002			(80		)	138,252
	Research and development expenses	—			12,871			2,000			—			14,871
	Restructuring and other impairment charges	—			148			960			—			1,108
	Income (loss) from continuing operations before interest, and taxes	(8,978		)	9,677			80,595			641			81,935
	Interest expense	37,913			(22,346		)	1,617			—			17,184
	Interest income	—			—			(161		)	—			(161		)
	Income (loss) from continuing operations before taxes	(46,891		)	32,023			79,139			641			64,912
	Taxes (benefit) on income (loss) from continuing operations	(16,761		)	13,984			10,505			1,956			9,684
	Equity in net income of consolidated subsidiaries	85,187			60,295			96			(145,578		)	—
	Income from continuing operations	55,057			78,334			68,730			(146,893		)	55,228
	Operating loss from discontinued operations	(247		)	—			—			—			(247		)
	Taxes (benefit) on loss from discontinued operations	(21		)	—			45			—			24
	Loss from discontinued operations	(226		)	—			(45		)	—			(271		)
	Net income	54,831			78,334			68,685			(146,893		)	54,957
	Less: Income from continuing operations attributable to noncontrolling interests	—			—			126			—			126
	Net income attributable to common shareholders	54,831			78,334			68,559			(146,893		)	54,831
	Other comprehensive loss attributable to common shareholders	(45,201		)	(58,947		)	(43,438		)	102,385			(45,201		)
	Comprehensive income attributable to common shareholders	$	9,630		$	19,387		$	25,121		$	(44,508	)	$	9,630
		Three Months Ended September 29, 2013
		Parent			Guarantor			Non-Guarantor			Eliminations			Condensed
		Company			Subsidiaries			Subsidiaries						Consolidated
		(Dollars in thousands)
	Net revenues	$	—		$	237,949		$	238,254		$	(62,407	)	$	413,796
	Cost of goods sold	—			139,501			130,825			(60,522		)	209,804
	Gross profit	—			98,448			107,429			(1,885		)	203,992
	Selling, general and administrative expenses	14,088			62,701			38,167			272			115,228
	Research and development expenses	—			13,161			2,477			—			15,638
	Restructuring and other impairment charges	828			3,834			2,422			—			7,084
	Income (loss) from continuing operations before interest, loss on extinguishments of debt and taxes	(14,916		)	18,752			64,363			(2,157		)	66,042
	Interest expense	33,492			(21,204		)	1,660			—			13,948
	Interest income	3			(3		)	(144		)	—			(144		)
	Loss on extinguishments of debt	1,250			—			—			—			1,250
	Income (loss) from continuing operations before taxes	(49,661		)	39,959			62,847			(2,157		)	50,988
	Taxes (benefit) on income (loss) from continuing operations	(18,446		)	14,261			9,962			(568		)	5,209
	Equity in net income of consolidated subsidiaries	76,448			48,367			319			(125,134		)	—
	Income from continuing operations	45,233			74,065			53,204			(126,723		)	45,779
	Operating income (loss) from discontinued operations	364			—			(326		)	—			38
	Taxes (benefit) on income (loss) from discontinued operations	(977		)	(170		)	156			—			(991		)
	Income (loss) from discontinued operations	1,341			170			(482		)	—			1,029
	Net income (loss)	46,574			74,235			52,722			(126,723		)	46,808
	Less: Income from continuing operations attributable to noncontrolling interests	—			—			234			—			234
	Net income (loss) attributable to common shareholders	46,574			74,235			52,488			(126,723		)	46,574
	Other comprehensive income attributable to common shareholders	24,375			30,034			21,442			(51,476		)	24,375
	Comprehensive income attributable to common shareholders	$	70,949		$	104,269		$	73,930		$	(178,199	)	$	70,949
		Nine Months Ended September 28, 2014
		Parent			Guarantor			Non-Guarantor			Eliminations			Condensed
		Company			Subsidiaries			Subsidiaries						Consolidated
		(Dollars in thousands)
	Net revenues	$	—		$	814,051		$	838,171		$	(288,398	)	$	1,363,824
	Cost of goods sold	—			489,694			451,408			(278,691		)	662,411
	Gross profit	—			324,357			386,763			(9,707		)	701,413
	Selling, general and administrative expenses	30,781			235,322			159,058			231			425,392
	Research and development expenses	—			37,766			6,037			—			43,803
	Restructuring and other impairment charges	—			8,639			7,872			—			16,511
Income (loss) from continuing operations before interest, and taxes	(30,781		)	42,630			213,796			(9,938		)	215,707
Interest expense	106,794			(62,993		)	4,849			—			48,650
Interest income	—			—			(494		)	—			(494		)
Income (loss) from continuing operations before taxes	(137,575		)	105,623			209,441			(9,938		)	167,551
Taxes (benefit) on income (loss) from continuing operations	(47,891		)	44,737			33,681			(2,303		)	28,224
Equity in net income of consolidated subsidiaries	228,113			160,653			288			(389,054		)	—
Income from continuing operations	138,429			221,539			176,048			(396,689		)	139,327
Operating loss from discontinued operations	(1,866		)	—			—			—			(1,866		)
Taxes (benefit) on loss from discontinued operations	(478		)	—			133			—			(345		)
Loss from discontinued operations	(1,388		)	—			(133		)	—			(1,521		)
Net income	137,041			221,539			175,915			(396,689		)	137,806
Less: Income from continuing operations attributable to noncontrolling interests	—			—			765			—			765
Net income attributable to common shareholders	137,041			221,539			175,150			(396,689		)	137,041
Other comprehensive loss attributable to common shareholders	(38,594		)	(54,326		)	(37,179		)	91,505			(38,594		)
Comprehensive income attributable to common shareholders	$	98,447		$	167,213		$	137,971		$	(305,184	)	$	98,447
	Nine Months Ended September 29, 2013
	Parent			Guarantor			Non-Guarantor			Eliminations			Condensed
	Company			Subsidiaries			Subsidiaries						Consolidated
	(Dollars in thousands)
Net revenues	$	—		$	740,817		$	708,206		$	(203,291	)	$	1,245,732
Cost of goods sold	—			435,937			398,720			(202,927		)	631,730
Gross profit	—			304,880			309,486			(364		)	614,002
Selling, general and administrative expenses	45,915			189,193			123,257			66			358,431
Research and development expenses	—			40,250			6,919			—			47,169
Restructuring and other impairment charges	828			13,112			15,265			—			29,205
Income (loss) from continuing operations before interest, loss on extinguishments of debt and taxes	(46,743		)	62,325			164,045			(430		)	179,197
Interest expense	100,682			(63,348		)	5,232			—			42,566
Interest income	—			(3		)	(455		)	—			(458		)
Loss on extinguishments of debt	1,250			—			—			—			1,250
Income (loss) from continuing operations before taxes	(148,675		)	125,676			159,268			(430		)	135,839
Taxes (benefit) on income (loss) from continuing operations	(54,192		)	42,241			30,701			208			18,958
Equity in net income of consolidated subsidiaries	210,701			114,116			319			(325,136		)	—
Income from continuing operations	116,218			197,551			128,886			(325,774		)	116,881
Operating income (loss) from discontinued operations	(1,788		)	—			42			—			(1,746		)
Taxes (benefit) on income (loss) from discontinued operations	(1,623		)	(170		)	246			—			(1,547		)
Income (loss) from discontinued operations	(165		)	170			(204		)	—			(199		)
Net income (loss)	116,053			197,721			128,682			(325,774		)	116,682
Less: Income from continuing operations attributable to noncontrolling interests	—			—			629			—			629
Net income (loss) attributable to common shareholders	116,053			197,721			128,053			(325,774		)	116,053
Other comprehensive income attributable to common shareholders	(6,335		)	(3,316		)	(5,930		)	9,246			(6,335		)
Comprehensive income attributable to common shareholders	$	109,718		$	194,405		$	122,123		$	(316,528	)	$	109,718
Condensed Consolidating Balance Sheets	'
	TELEFLEX INCORPORATED AND SUBSIDIARIES
	CONDENSED CONSOLIDATING BALANCE SHEETS
		September 28, 2014
		Parent			Guarantor			Non-Guarantor			Eliminations			Condensed
		Company			Subsidiaries			Subsidiaries						Consolidated
		(Dollars in thousands)
	ASSETS
	Current assets
	Cash and cash equivalents	$	59,555		$	1,662		$	225,165		$	—		$	286,382
	Accounts receivable, net	1,921			11,630			270,387			3,241			287,179
	Accounts receivable from consolidated subsidiaries	39,604			2,782,391			270,488			(3,092,483		)	—
	Inventories, net	—			210,427			168,218			(25,418		)	353,227
	Prepaid expenses and other current assets	15,587			6,826			20,870			—			43,283
	Prepaid taxes	34,406			—			16,913			—			51,319
	Deferred tax assets	19,912			19,516			8,933			(220		)	48,141
	Assets held for sale	2,901			—			4,771			—			7,672
	Total current assets	173,886			3,032,452			985,745			(3,114,880		)	1,077,203
	Property, plant and equipment, net	3,648			196,101			147,484			—			347,233
	Goodwill	—			704,210			647,835			—			1,352,045
	Intangibles assets, net	—			713,854			494,398			—			1,208,252
	Investments in affiliates	5,676,862			1,356,773			21,252			(7,053,808		)	1,079
	Deferred tax assets	34,525			—			5,109			(37,928		)	1,706
	Notes receivable and other amounts due from consolidated subsidiaries	975,641			992,775			—			(1,968,416		)	—
	Other assets	28,795			7,435			34,044			—			70,274
	Total assets	$	6,893,357		$	7,003,600		$	2,335,867		$	(12,175,032	)	$	4,057,792
	LIABILITIES AND EQUITY
	Current liabilities
	Current borrowings	$	360,656		$	—		$	4,700		$	—		$	365,356
	Accounts payable	4,291			35,293			31,450			—			71,034
	Accounts payable to consolidated subsidiaries	2,730,852			197,409			164,222			(3,092,483		)	—
	Accrued expenses	18,088			17,056			42,189			—			77,333
	Current portion of contingent consideration	—			2,957			—			—			2,957
	Payroll and benefit-related liabilities	17,358			20,742			38,681			—			76,781
	Accrued interest	13,831			—			17			—			13,848
	Income taxes payable	—			—			26,735			—			26,735
	Other current liabilities	475			33,450			8,567			(220		)	42,272
	Total current liabilities	3,145,551			306,907			316,561			(3,092,703		)	676,316
	Long-term borrowings	700,000			—			—			—			700,000
	Deferred tax liabilities	—			477,101			55,710			(37,927		)	494,884
	Pension and other postretirement benefit liabilities	46,618			33,962			16,427			—			97,007
	Noncurrent liability for uncertain tax positions	13,355			17,476			25,617			—			56,448
	Notes payable and other amounts due from consolidated subsidiaries	986,769			897,634			89,801			(1,974,204		)	—
	Other liabilities	19,336			17,142			12,743			—			49,221
	Total liabilities	4,911,629			1,750,222			516,859			(5,104,834		)	2,073,876
	Total common shareholders' equity	1,981,728			5,253,378			1,816,820			(7,070,198		)	1,981,728
	Noncontrolling interest	—			—			2,188			—			2,188
	Total equity	1,981,728			5,253,378			1,819,008			(7,070,198		)	1,983,916
	Total liabilities and equity	$	6,893,357		$	7,003,600		$	2,335,867		$	(12,175,032	)	$	4,057,792
		December 31, 2013
		Parent			Guarantor			Non-Guarantor			Eliminations			Condensed
		Company			Subsidiaries			Subsidiaries						Consolidated
		(Dollars in thousands)
	ASSETS
	Current assets
	Cash and cash equivalents	$	42,749		$	14,500		$	374,735		$	—		$	431,984
	Accounts receivable, net	1,822			10,948			279,048			3,472			295,290
	Accounts receivable from consolidated subsidiaries	42,865			2,623,314			214,469			(2,880,648		)	—
	Inventories, net	—			211,165			138,165			(15,709		)	333,621
	Prepaid expenses and other current assets	15,200			6,870			17,740			—			39,810
	Prepaid taxes	27,487			—			9,017			—			36,504
	Deferred tax assets	20,218			22,472			10,230			(3		)	52,917
	Assets held for sale	1,669			3,503			5,256			—			10,428
	Total current assets	152,010			2,892,772			1,048,660			(2,892,888		)	1,200,554
Property, plant and equipment, net	14,189			188,455			123,256			—			325,900
Goodwill	—			797,671			556,532			—			1,354,203
Intangibles assets, net	—			962,243			293,354			—			1,255,597
Investments in affiliates	5,489,676			1,478,429			21,382			(6,987,772		)	1,715
Deferred tax assets	35,877			—			4,476			(39,410		)	943
Notes receivable and other amounts due from consolidated subsidiaries	1,049,344			873,105			14,169			(1,936,618		)	—
Other assets	24,574			7,447			38,074			—			70,095
Total assets	$	6,765,670		$	7,200,122		$	2,099,903		$	(11,856,688	)	$	4,209,007
LIABILITIES AND EQUITY
Current liabilities
Notes payable	$	351,587		$	—		$	4,700		$	—		$	356,287
Accounts payable	2,194			45,802			23,971			—			71,967
Accounts payable to consolidated subsidiaries	2,644,296			147,957			88,395			(2,880,648		)	—
Accrued expenses	15,569			21,120			38,179			—			74,868
Current portion of contingent consideration	—			4,131			—			—			4,131
Payroll and benefit-related liabilities	15,976			21,818			35,296			—			73,090
Accrued interest	8,720			—			5			—			8,725
Income taxes payable	—			—			23,821			—			23,821
Other current liabilities	9,646			7,517			5,072			(4		)	22,231
Total current liabilities	3,047,988			248,345			219,439			(2,880,652		)	635,120
Long-term borrowings	930,000			—			—			—			930,000
Deferred tax liabilities	—			496,228			57,896			(39,409		)	514,715
Pension and other postretirement benefit liabilities	57,406			33,777			18,315			—			109,498
Noncurrent liability for uncertain tax positions	11,389			17,241			26,522			—			55,152
Notes payable and other amounts due from consolidated subsidiaries	785,476			957,451			197,173			(1,940,100		)	—
Other liabilities	19,884			16,221			12,401			—			48,506
Total liabilities	4,852,143			1,769,263			531,746			(4,860,161		)	2,292,991
Total common shareholders' equity	1,913,527			5,430,859			1,565,668			(6,996,527		)	1,913,527
Noncontrolling interest	—			—			2,489			—			2,489
Total equity	1,913,527			5,430,859			1,568,157			(6,996,527		)	1,916,016
Total liabilities and equity	$	6,765,670		$	7,200,122		$	2,099,903		$	(11,856,688	)	$	4,209,007
Condensed Consolidating Statements of Cash Flows	'
	TELEFLEX INCORPORATED AND SUBSIDIARIES
	CONDENSED CONSOLIDATING STATEMENTS OF CASH FLOWS
		Nine Months Ended September 28, 2014
		Parent			Guarantor			Non-Guarantor			Eliminations			Condensed
		Company			Subsidiaries			Subsidiaries						Consolidated
		(Dollars in thousands)
	Net cash (used in) provided by operating activities from continuing operations	$	(80,537	)	$	300,960		$	63,715		$	(75,340	)	$	208,798
	Cash Flows from Investing Activities of Continuing Operations:
	Expenditures for property, plant and equipment	(2,146		)	(22,578		)	(23,496		)	—			(48,220		)
	Proceeds from sale of assets and investments	1,669			3,421			161			—			5,251
	Payments for businesses and intangibles acquired, net of cash acquired	—			—			(28,535		)	—			(28,535		)
	Investments in affiliates	(60		)	20			—			—			(40		)
	Intercompany dividends received	—			—			229,782			(229,782		)	—
	Net cash (used in) provided by investing activities from continuing operations	(537		)	(19,137		)	177,912			(229,782		)	(71,544		)
	Cash Flows from Financing Activities of Continuing Operations:
	Proceeds from long-term borrowings	250,000			—			—			—			250,000
	Repayment of long-term borrowings	(480,009		)	—			—			—			(480,009		)
	Debt issuance fees	(3,689		)	—			—			—			(3,689		)
	Proceeds from share based compensation plans and the related tax impacts	2,936			—			—			—			2,936
	Payments to noncontrolling interest shareholders	—			—			(1,094		)	—			(1,094		)
	Dividends	(42,174		)	—			—			—			(42,174		)
	Intercompany transactions	372,762			(294,661		)	(78,101		)	—			—
	Intercompany dividends paid	—			—			(305,122		)	305,122			—
	Net cash provided by (used in) financing activities from continuing operations	99,826			(294,661		)	(384,317		)	305,122			(274,030		)
	Cash Flows from Discontinued Operations:
	Net cash used in operating activities	(1,946		)	—			—			—			(1,946		)
	Net cash used in discontinued  operations	(1,946		)	—			—			—			(1,946		)
	Effect of exchange rate changes on cash and cash equivalents	—			—			(6,880		)	—			(6,880		)
	Net increase (decrease) in cash and cash equivalents	16,806			(12,838		)	(149,570		)	—			(145,602		)
	Cash and cash equivalents at the beginning of the period	42,749			14,500			374,735			—			431,984
	Cash and cash equivalents at the end of the period	$	59,555		$	1,662		$	225,165		$	—		$	286,382
		Nine Months Ended September 29, 2013
		Parent			Guarantor			Non-Guarantor			Eliminations			Condensed
		Company			Subsidiaries			Subsidiaries						Consolidated
		(Dollars in thousands)
	Net cash (used in) provided by operating activities from continuing operations	$	(85,753	)	$	147,461		$	140,235		$	(66,071	)	$	135,872
	Cash Flows from Investing Activities of Continuing Operations:
	Expenditures for property, plant and equipment	(799		)	(42,854		)	(10,987		)	—			(54,640		)
	Payments for business intangibles acquired, net of cash acquired	—			(1,820		)	(38,630		)	—			(40,450		)
	Investments in affiliates	(50		)	—			—			—			(50		)
	Net cash used in investing activities from continuing operations	(849		)	(44,674		)	(49,617		)	—			(95,140		)
	Cash Flows from Financing Activities of Continuing Operations:
	Proceeds from long-term borrowings	382,000			—			—			—			382,000
	Repayment of long-term borrowings	(375,000		)	—			—			—			(375,000		)
	Debt extinguishment, issuance and amendment fees	(6,365		)	—			—			—			(6,365		)
	Proceeds from share based compensation plans and the related tax impacts	4,740			—			—			—			4,740
	Payments to noncontrolling interest shareholders	—			—			(736		)	—			(736		)
	Payments for contingent consideration	—			(14,802		)	(1,565		)	—			(16,367		)
	Dividends	(41,915		)	—			—			—			(41,915		)
	Intercompany transactions	70,932			(72,574		)	1,642			—			—
	Intercompany dividends paid	—			(17,400		)	(48,671		)	66,071			—
	Net cash provided by (used in) financing activities from continuing operations	34,392			(104,776		)	(49,330		)	66,071			(53,643		)
	Cash Flows from Discontinued Operations:													—
	Net cash used in operating activities	(1,567		)	—			(600		)	—			(2,167		)
	Net cash used in discontinued operations	(1,567		)	—			(600		)	—			(2,167		)
	Effect of exchange rate changes on cash and cash equivalents	—			—			4,476			—			4,476
	Net (decrease) increase in cash and cash equivalents	(53,777		)	(1,989		)	45,164			—			(10,602		)
	Cash and cash equivalents at the beginning of the period	70,860			1,989			264,190			—			337,039
	Cash and cash equivalents at the end of the period	$	17,083		$	—		$	309,354		$	—		$	326,437

Basis_of_presentation_addition

Basis of presentation - additional information (Detail) (Reclassifications, USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 29, 2013
Reclassifications	'
Organization And Summary Of Significant Accounting Policies Disclosure [Line Items]	'
Tax withholding obligations for share based compensation	$2.50

Acquisitions_Additional_Inform

Acquisitions - Additional Information (Detail) (USD $)	3 Months Ended		9 Months Ended			0 Months Ended	3 Months Ended	9 Months Ended		9 Months Ended
	Sep. 28, 2014	Sep. 29, 2013	Sep. 28, 2014	Sep. 29, 2013	Dec. 31, 2013	Feb. 03, 2014	Sep. 28, 2014	Sep. 28, 2014	Feb. 03, 2014	Sep. 28, 2014
						Mayo Healthcare Pty Limited	Mayo Healthcare Pty Limited	Mayo Healthcare Pty Limited	Mayo Healthcare Pty Limited	Mayo Healthcare Pty Limited
										Customer Lists
Business Acquisition [Line Items]	'	'	'	'	'	'	'	'	'	'
Fair value of the consideration at the date of acquisition	'	'	'	'	$307,000,000	'	'	'	$28,500,000	'
Initial payment	'	'	'	'	'	29,000,000	'	'	'	'
Working capital adjustment related to acquisition	'	'	'	'	'	500,000	'	'	'	'
Transaction expenses	'	'	'	'	'	'	'	300,000	'	'
Net revenues	457,173,000	413,796,000	1,363,824,000	1,245,732,000	'	'	6,500,000	19,900,000	'	'
Income (loss) from continuing operations before taxes	$64,912,000	$50,988,000	$167,551,000	$135,839,000	'	'	($700,000)	$3,100,000	'	'
Useful life of intangible assets acquired, years	'	'	'	'	'	'	'	'	'	'10 years

Acquisitions_Fair_Values_Deter

Acquisitions Fair Values Determination of Assets Acquired and Liabilities Assumed in Acquisition (Detail) (USD $)	Sep. 28, 2014	Dec. 31, 2013	Feb. 03, 2014
In Thousands, unless otherwise specified			Mayo Healthcare Pty Limited
Assets	'	'	'
Current assets	'	'	$10,393
Property, plant and equipment	'	'	306
Customer lists intangible asset	'	'	9,335
Goodwill	1,352,045	1,354,203	15,986
Total assets acquired	'	'	36,020
Liabilities	'	'	'
Current liabilities	'	'	4,685
Deferred tax liabilities	'	'	2,800
Liabilities assumed	'	'	7,485
Net assets acquired	'	'	$28,535

Restructuring_and_other_impair2

Restructuring and other impairment charges - additional information (Detail) (USD $)

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

21 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

3 Months Ended

Sep. 28, 2014

Sep. 29, 2013

Sep. 28, 2014

Sep. 29, 2013

Sep. 29, 2013

Sep. 29, 2013

Sep. 29, 2013

Sep. 29, 2013

Sep. 29, 2013

Sep. 29, 2013

Sep. 29, 2013

Sep. 29, 2013

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 29, 2013

Sep. 28, 2014

Sep. 29, 2013

Sep. 28, 2014

Sep. 28, 2014

Sep. 29, 2013

Sep. 28, 2014

Sep. 29, 2013

Sep. 28, 2014

Sep. 29, 2013

Sep. 28, 2014

Sep. 29, 2013

Sep. 28, 2014

Sep. 29, 2013

Sep. 28, 2014

Sep. 29, 2013

Sep. 28, 2014

Sep. 29, 2013

Sep. 28, 2014

Sep. 29, 2013

Sep. 28, 2014

Mar. 31, 2013

Termination benefits

Termination benefits

Contract Termination Costs

Contract Termination Costs

Facility Closure Costs

Facility Closure Costs

Other

Other

2014 Manufacturing Footprint Realignment

2014 Manufacturing Footprint Realignment

2014 Manufacturing Footprint Realignment

2014 Manufacturing Footprint Realignment

2014 Manufacturing Footprint Realignment

2014 Manufacturing Footprint Realignment

2014 Manufacturing Footprint Realignment

2014 Manufacturing Footprint Realignment

2014 Manufacturing Footprint Realignment

2014 Manufacturing Footprint Realignment

2014 Manufacturing Footprint Realignment

2014 Manufacturing Footprint Realignment

2014 Manufacturing Footprint Realignment

2014 Manufacturing Footprint Realignment

2014 Manufacturing Footprint Realignment

2014 Manufacturing Footprint Realignment

2014 Manufacturing Footprint Realignment

2014 Manufacturing Footprint Realignment

2014 Manufacturing Footprint Realignment

2014 Manufacturing Footprint Realignment

2014 Manufacturing Footprint Realignment

2014 Manufacturing Footprint Realignment

2014 European Restructuring Plan

2014 European Restructuring Plan

2014 European Restructuring Plan

2014 European Restructuring Plan

2014 European Restructuring Plan

2014 European Restructuring Plan

2014 European Restructuring Plan

2014 European Restructuring Plan

2014 European Restructuring Plan

2014 European Restructuring Plan

2014 Restructuring Program

2014 Restructuring Program

2014 Restructuring Program

2014 Restructuring Program

2014 Restructuring Program

2014 Restructuring Program

2014 Restructuring Program

2014 Restructuring Program

2014 Restructuring Program

2014 Restructuring Program

2014 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2013 Restructuring Program

2012 Restructuring Charges

In Process Research and Development

Accelerated Depreciation And Other Costs

Accelerated Depreciation And Other Costs

Termination benefits

Termination benefits

Contract Termination Costs

Contract Termination Costs

Facility Closure Costs

Facility Closure Costs

Other

Other

Minimum

Minimum

Minimum

Minimum

Minimum

Maximum

Maximum

Maximum

Maximum

Maximum

Termination benefits

Termination benefits

Contract Termination Costs

Contract Termination Costs

Facility Closure Costs

Facility Closure Costs

Other

Other

Termination benefits

Termination benefits

Contract Termination Costs

Contract Termination Costs

Facility Closure Costs

Facility Closure Costs

Other

Other

Maximum

Termination benefits

Termination benefits

Termination benefits

Termination benefits

Contract Termination Costs

Contract Termination Costs

Contract Termination Costs

Contract Termination Costs

Facility Closure Costs

Facility Closure Costs

Facility Closure Costs

Facility Closure Costs

Other

Other

Other

Other

Axiom

Termination benefits

Facility Closure Costs

Accelerated Depreciation Charges

Other

Termination benefits

Facility Closure Costs

Accelerated Depreciation Charges

Other

Restructuring Cost And Reserve [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Expected restructuring charges

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$42,000,000

$12,000,000

$2,000,000

[1]

$10,000,000

$18,000,000

[2]

$53,000,000

$15,000,000

$5,000,000

[1]

$12,000,000

$21,000,000

[2]

'

$9,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$3,000,000

'

'

$11,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring costs expected cash payment

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

32,000,000

'

'

'

'

40,000,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring expenses

'

'

'

'

'

'

'

'

'

'

'

'

2,100,000

11,600,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Restructuring charges

'

3,730,000

'

21,357,000

1,942,000

8,986,000

1,032,000

7,997,000

739,000

1,350,000

17,000

3,024,000

171,000

8,748,000

1,900,000

2,900,000

129,000

8,706,000

0

0

0

0

42,000

42,000

'

'

'

'

'

'

'

'

'

'

566,000

8,672,000

537,000

8,289,000

1,000

306,000

1,000

1,000

27,000

76,000

289,000

2,070,000

25,000

501,000

202,000

1,376,000

0

0

62,000

193,000

'

62,000

826,000

626,000

8,656,000

'

-124,000

891,000

361,000

2,443,000

186,000

-65,000

243,000

3,326,000

0

0

0

0

0

0

22,000

2,887,000

'

'

Restructuring reserve

'

'

'

'

'

'

'

'

'

'

'

'

8,700,000

8,700,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

3,200,000

3,200,000

'

'

'

'

'

'

'

'

400,000

400,000

'

'

'

'

'

'

'

'

'

1,300,000

'

1,300,000

'

1,300,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

600,000

'

Restructuring charges cumulative

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

10,900,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Impairment charges

$0

$3,354,000

$0

$7,848,000

$0

$0

$0

$0

$0

$0

$3,354,000

$7,848,000

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

$4,500,000

[1]

Includes costs to transfer product lines among facilities and outplacement and employee relocation costs.

[2]

Consists of other costs directly related to the Plan, including project management, legal and regulatory costs.

Restructuring_and_other_impair3

Restructuring and other impairment charges Reconciliation of changes in accrued liabilities associated with restructuring program (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2014	Sep. 29, 2013	Sep. 28, 2014	Sep. 29, 2013
Restructuring Reserve [Roll Forward]	'	'	'	'
Subsequent accruals (reversals)	'	$3,730	'	$21,357
LMA Restructuring Program	'	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'	'
Balance, beginning	'	'	4,681	'
Subsequent accruals (reversals)	20	1,768	-3,352	8,364
Cash payments	'	'	-954	'
Foreign currency translation	'	'	-2	'
Balance, ending	373	'	373	'
Termination Benefits	'	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'	'
Subsequent accruals (reversals)	'	1,942	'	8,986
Termination Benefits | LMA Restructuring Program	'	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'	'
Balance, beginning	'	'	552	'
Subsequent accruals (reversals)	0	492	-29	3,318
Cash payments	'	'	-533	'
Foreign currency translation	'	'	10	'
Balance, ending	0	'	0	'
Facility Closure Costs	'	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'	'
Subsequent accruals (reversals)	'	739	'	1,350
Facility Closure Costs | LMA Restructuring Program	'	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'	'
Balance, beginning	'	'	427	'
Subsequent accruals (reversals)	0	162	-112	536
Cash payments	'	'	-317	'
Foreign currency translation	'	'	2	'
Balance, ending	0	'	0	'
Contract Termination Costs	'	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'	'
Subsequent accruals (reversals)	'	1,032	'	7,997
Contract Termination Costs | LMA Restructuring Program	'	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'	'
Balance, beginning	'	'	3,686	'
Subsequent accruals (reversals)	20	1,097	-3,211	4,378
Cash payments	'	'	-104	'
Foreign currency translation	'	'	-14	'
Balance, ending	357	'	357	'
Other Exit Costs	'	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'	'
Subsequent accruals (reversals)	'	17	'	3,024
Other Exit Costs | LMA Restructuring Program	'	'	'	'
Restructuring Reserve [Roll Forward]	'	'	'	'
Balance, beginning	'	'	16	'
Subsequent accruals (reversals)	0	17	0	132
Cash payments	'	'	0	'
Foreign currency translation	'	'	0	'
Balance, ending	$16	'	$16	'

Restructuring_and_other_impair4

Restructuring and other impairment charges (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 28, 2014	Sep. 29, 2013	Sep. 28, 2014	Sep. 29, 2013
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Restructuring charges	'	$3,730,000	'	$21,357,000
Impairment charges	0	3,354,000	0	7,848,000
Total restructuring and other impairment charges	1,108,000	7,084,000	16,511,000	29,205,000
Termination Benefits	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Restructuring charges	'	1,942,000	'	8,986,000
Impairment charges	'	0	'	0
Total restructuring and other impairment charges	567,000	1,942,000	17,209,000	8,986,000
Facility Closure Costs	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Restructuring charges	'	739,000	'	1,350,000
Impairment charges	'	0	'	0
Total restructuring and other impairment charges	1,000	739,000	255,000	1,350,000
Contract Termination Costs	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Restructuring charges	'	1,032,000	'	7,997,000
Impairment charges	'	0	'	0
Total restructuring and other impairment charges	409,000	1,032,000	-1,286,000	7,997,000
Other Exit Costs	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Restructuring charges	'	17,000	'	3,024,000
Impairment charges	'	3,354,000	'	7,848,000
Total restructuring and other impairment charges	131,000	3,371,000	333,000	10,872,000
2014 Manufacturing Footprint Realignment	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Restructuring charges	171,000	'	8,748,000	'
2014 Manufacturing Footprint Realignment | Termination Benefits	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Restructuring charges	129,000	'	8,706,000	'
2014 Manufacturing Footprint Realignment | Facility Closure Costs	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Restructuring charges	0	'	0	'
2014 Manufacturing Footprint Realignment | Contract Termination Costs	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Restructuring charges	0	'	0	'
2014 Manufacturing Footprint Realignment | Other Exit Costs	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Restructuring charges	42,000	'	42,000	'
2014 European Restructuring Plan	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Restructuring charges	566,000	'	8,672,000	'
2014 European Restructuring Plan | Termination Benefits	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Restructuring charges	537,000	'	8,289,000	'
2014 European Restructuring Plan | Facility Closure Costs	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Restructuring charges	1,000	'	1,000	'
2014 European Restructuring Plan | Contract Termination Costs	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Restructuring charges	1,000	'	306,000	'
2014 European Restructuring Plan | Other Exit Costs	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Restructuring charges	27,000	'	76,000	'
2014 Restructuring Program	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Restructuring charges	289,000	'	2,070,000	'
2014 Restructuring Program | Termination Benefits	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Restructuring charges	25,000	'	501,000	'
2014 Restructuring Program | Facility Closure Costs	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Restructuring charges	0	'	0	'
2014 Restructuring Program | Contract Termination Costs	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Restructuring charges	202,000	'	1,376,000	'
2014 Restructuring Program | Other Exit Costs	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Restructuring charges	62,000	'	193,000	'
LMA Restructuring Program	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Restructuring charges	20,000	1,768,000	-3,352,000	8,364,000
LMA Restructuring Program | Termination Benefits	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Restructuring charges	0	492,000	-29,000	3,318,000
LMA Restructuring Program | Facility Closure Costs	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Restructuring charges	0	162,000	-112,000	536,000
LMA Restructuring Program | Contract Termination Costs	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Restructuring charges	20,000	1,097,000	-3,211,000	4,378,000
LMA Restructuring Program | Other Exit Costs	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Restructuring charges	0	17,000	0	132,000
2013 Restructuring Program	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Restructuring charges	62,000	826,000	626,000	8,656,000
2013 Restructuring Program | Termination Benefits	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Restructuring charges	-124,000	891,000	361,000	2,443,000
2013 Restructuring Program | Facility Closure Costs	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Restructuring charges	0	0	0	0
2013 Restructuring Program | Contract Termination Costs	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Restructuring charges	186,000	-65,000	243,000	3,326,000
2013 Restructuring Program | Other Exit Costs	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Restructuring charges	0	0	22,000	2,887,000
2012 Restructuring Program	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Restructuring charges	'	1,098,000	-265,000	4,164,000
2012 Restructuring Program | Termination Benefits	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Restructuring charges	'	559,000	-619,000	3,225,000
2012 Restructuring Program | Facility Closure Costs	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Restructuring charges	'	539,000	354,000	641,000
2012 Restructuring Program | Contract Termination Costs	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Restructuring charges	'	0	0	293,000
2012 Restructuring Program | Other Exit Costs	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Restructuring charges	'	0	0	5,000
2011 Restructuring Plan	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Restructuring charges	'	'	12,000	'
2011 Restructuring Plan | Termination Benefits	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Restructuring charges	'	'	0	'
2011 Restructuring Plan | Facility Closure Costs	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Restructuring charges	'	'	12,000	'
2011 Restructuring Plan | Contract Termination Costs	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Restructuring charges	'	'	0	'
2011 Restructuring Plan | Other Exit Costs	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Restructuring charges	'	'	0	'
2007 Arrow Integration Program	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Restructuring charges	'	38,000	'	173,000
2007 Arrow Integration Program | Termination Benefits	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Restructuring charges	'	0	'	0
2007 Arrow Integration Program | Facility Closure Costs	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Restructuring charges	'	38,000	'	173,000
2007 Arrow Integration Program | Contract Termination Costs	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Restructuring charges	'	0	'	0
2007 Arrow Integration Program | Other Exit Costs	'	'	'	'
Restructuring Cost And Reserve [Line Items]	'	'	'	'
Restructuring charges	'	$0	'	$0

Restructuring_and_other_impair5

Restructuring and other impairment charges by segment (Detail) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2014	Sep. 29, 2013	Sep. 28, 2014	Sep. 29, 2013
Restructuring and other impairment charges	'	'	'	'
Total restructuring and other impairment charges	$1,108	$7,084	$16,511	$29,205
Vascular North America	'	'	'	'
Restructuring and other impairment charges	'	'	'	'
Total restructuring and other impairment charges	-54	2,233	5,908	2,860
Anesthesia Respiratory North America	'	'	'	'
Restructuring and other impairment charges	'	'	'	'
Total restructuring and other impairment charges	15	332	1,193	3,001
Surgical North America	'	'	'	'
Restructuring and other impairment charges	'	'	'	'
Total restructuring and other impairment charges	0	0	0	7,294
EMEA	'	'	'	'
Restructuring and other impairment charges	'	'	'	'
Total restructuring and other impairment charges	849	2,221	7,164	11,428
Asia	'	'	'	'
Restructuring and other impairment charges	'	'	'	'
Total restructuring and other impairment charges	111	202	708	447
OEM	'	'	'	'
Restructuring and other impairment charges	'	'	'	'
Total restructuring and other impairment charges	0	0	0	588
All Other	'	'	'	'
Restructuring and other impairment charges	'	'	'	'
Total restructuring and other impairment charges	$187	$2,096	$1,538	$3,587

Summary_of_Current_Cost_Estima

Summary of Current Cost Estimates by Major Type of Cost Associated with 2014 Manufacturing Footprint Realignment Plan (Detail) (2014 Manufacturing Footprint Realignment, USD $)	9 Months Ended
In Millions, unless otherwise specified	Sep. 28, 2014
Minimum	'
Restructuring Cost And Reserve [Line Items]	'
Total estimated amount expected to be incurred	$42
Maximum	'
Restructuring Cost And Reserve [Line Items]	'
Total estimated amount expected to be incurred	53
Termination benefits | Minimum	'
Restructuring Cost And Reserve [Line Items]	'
Total estimated amount expected to be incurred	12
Termination benefits | Maximum	'
Restructuring Cost And Reserve [Line Items]	'
Total estimated amount expected to be incurred	15
Facility closure and other exit costs | Minimum	'
Restructuring Cost And Reserve [Line Items]	'
Total estimated amount expected to be incurred	2	[1]
Facility closure and other exit costs | Maximum	'
Restructuring Cost And Reserve [Line Items]	'
Total estimated amount expected to be incurred	5	[1]
Accelerated Depreciation Charges | Minimum	'
Restructuring Cost And Reserve [Line Items]	'
Total estimated amount expected to be incurred	10
Accelerated Depreciation Charges | Maximum	'
Restructuring Cost And Reserve [Line Items]	'
Total estimated amount expected to be incurred	12
Other | Minimum	'
Restructuring Cost And Reserve [Line Items]	'
Total estimated amount expected to be incurred	18	[2]
Other | Maximum	'
Restructuring Cost And Reserve [Line Items]	'
Total estimated amount expected to be incurred	$21	[2]
[1]	Includes costs to transfer product lines among facilities and outplacement and employee relocation costs.
[2]	Consists of other costs directly related to the Plan, including project management, legal and regulatory costs.

Inventories_net_Detail

Inventories, net (Detail) (USD $)	Sep. 28, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Inventory Disclosure [Abstract]	'	'
Raw materials	$73,170	$70,209
Work-in-process	59,282	53,672
Finished goods	254,120	242,113
Inventories, gross	386,572	365,994
Less: Inventory reserve	-33,345	-32,373
Inventories, net	$353,227	$333,621

Goodwill_and_other_intangible_2

Goodwill and other intangible assets, net - additional information (Detail) (USD $)	3 Months Ended		9 Months Ended			3 Months Ended
	Sep. 28, 2014	Sep. 29, 2013	Sep. 28, 2014	Sep. 29, 2013	Sep. 28, 2014	Mar. 31, 2013
					Semprus Technology	Axiom
						In Process Research and Development
Finite-Lived Intangible Assets [Line Items]	'	'	'	'	'	'
In-process research and development impairment	$0	$3,354,000	$0	$7,848,000	'	$4,500,000
Net assets	'	'	'	'	41,000,000	'
Amortization expense of intangible assets	$15,000,000	$12,500,000	$47,053,000	$37,072,000	'	'

Goodwill_and_other_intangible_3

Goodwill and other intangible assets, net Changes in carrying amount of goodwill, by reporting segment (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2014	Dec. 31, 2013
Goodwill [Roll Forward]	'	'
Goodwill	$1,684,173	$1,686,331
Accumulated impairment losses	-332,128	-332,128
Goodwill	1,352,045	1,354,203
Goodwill related to acquisitions	15,986	'
Translation adjustment	-18,144	'
Vascular North America	'	'
Goodwill [Roll Forward]	'	'
Goodwill	474,044	474,044
Accumulated impairment losses	-219,527	-219,527
Goodwill	254,517	254,517
Goodwill related to acquisitions	0	'
Translation adjustment	0	'
Anesthesia Respiratory North America	'	'
Goodwill [Roll Forward]	'	'
Goodwill	166,895	167,195
Accumulated impairment losses	-107,073	-107,073
Goodwill	59,822	60,122
Goodwill related to acquisitions	0	'
Translation adjustment	-300	'
Surgical North America	'	'
Goodwill [Roll Forward]	'	'
Goodwill	250,506	250,506
Accumulated impairment losses	0	0
Goodwill	250,506	250,506
Goodwill related to acquisitions	0	'
Translation adjustment	0	'
EMEA	'	'
Goodwill [Roll Forward]	'	'
Goodwill	355,950	373,417
Accumulated impairment losses	0	0
Goodwill	355,950	373,417
Goodwill related to acquisitions	0	'
Translation adjustment	-17,467	'
Asia	'	'
Goodwill [Roll Forward]	'	'
Goodwill	152,347	136,946
Accumulated impairment losses	0	0
Goodwill	152,347	136,946
Goodwill related to acquisitions	15,986	'
Translation adjustment	-585	'
All Other	'	'
Goodwill [Roll Forward]	'	'
Goodwill	284,431	284,223
Accumulated impairment losses	-5,528	-5,528
Goodwill	278,903	278,695
Goodwill related to acquisitions	0	'
Translation adjustment	$208	'

Goodwill_and_other_intangible_4

Goodwill and other intangible assets, net Components of intangible assets (Details) (USD $)	Sep. 28, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Finite-Lived Intangible Assets [Line Items]	'	'
Gross carrying amount	$1,554,179	$1,557,688
Accumulated amortization	-345,927	-302,091
Customer Relationships	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross carrying amount	631,983	628,020
Accumulated amortization	-188,261	-168,223
In Process Research and Development	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross carrying amount	68,766	68,786
Accumulated amortization	0	0
Intellectual Property	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross carrying amount	433,227	435,869
Accumulated amortization	-140,606	-118,086
Distribution Rights	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross carrying amount	16,406	16,797
Accumulated amortization	-14,466	-14,592
Trade Names	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross carrying amount	403,460	407,879
Accumulated amortization	-2,425	-1,148
Noncompete Agreements	'	'
Finite-Lived Intangible Assets [Line Items]	'	'
Gross carrying amount	337	337
Accumulated amortization	($169)	($42)

Goodwill_and_other_intangible_5

Goodwill and other intangible assets, net Annual amortization expense (Details) (USD $)	Sep. 28, 2014
In Thousands, unless otherwise specified
Goodwill and Intangible Assets Disclosure [Abstract]	'
2014	$13,700
2015	54,100
2016	53,700
2017	53,300
2018	53,000
2019	$52,600

Borrowings_Additional_Informat

Borrowings - Additional Information (Detail) (USD $)

3 Months Ended

9 Months Ended

0 Months Ended

1 Months Ended

9 Months Ended

9 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

Sep. 28, 2014

Sep. 28, 2014

Dec. 31, 2013

Sep. 29, 2013

21-May-14

21-May-14

Sep. 28, 2014

Dec. 31, 2013

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Sep. 28, 2014

Dec. 31, 2013

Sep. 28, 2014

Sep. 28, 2014

Dec. 31, 2013

5.25% Senior Notes due 2024

5.25% Senior Notes due 2024

5.25% Senior Notes due 2024

5.25% Senior Notes due 2024

5.25% Senior Notes due 2024

5.25% Senior Notes due 2024

5.25% Senior Notes due 2024

5.25% Senior Notes due 2024

3.875% Convertible Senior Subordinated Notes

3.875% Convertible Senior Subordinated Notes

6.875% Senior Subordinated Notes due 2019

6.875% Senior Subordinated Notes due 2019

Redemption prior to June 15, 2019

Redemption prior to June 15, 2017

Minimum

Maximum

Debt Instrument [Line Items]

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

5.25% Senior Notes due 2024

$250,000,000

$250,000,000

$0

'

'

$250,000,000

'

'

'

'

'

'

'

'

'

'

Debt instrument, interest payment commencing date

'

'

'

'

'

15-Dec-14

'

'

'

'

'

'

'

'

'

'

Debt instrument, stated interest rate

3.88%

3.88%

3.88%

3.88%

'

5.25%

5.25%

5.25%

'

'

'

'

3.88%

3.88%

6.88%

6.88%

Transaction fees

'

'

'

'

'

4,500,000

'

'

'

'

'

'

'

'

'

'

Proceed from senior notes used to repay revolving line of credit

'

'

'

'

245,000,000

'

'

'

'

'

'

'

'

'

'

'

Percent of redemption price to principal amount any time on or after June 15, 2019

'

'

'

'

'

'

'

'

'

'

100.00%

102.63%

'

'

'

'

Declining percent of redemption price to principal amount on June 15, 2022

'

'

'

'

'

'

0.88%

'

'

'

'

'

'

'

'

'

Debt instrument, earliest date of redemption

'

'

'

'

'

'

15-Jun-19

'

'

'

'

'

'

'

'

'

Redemption price percentage

'

'

'

'

'

'

'

'

100.00%

105.25%

'

'

'

'

'

'

Make-whole premium as percentage of principal amount of 2024 Notes subject to redemption

'

'

'

'

'

'

'

'

1.00%

'

'

'

'

'

'

'

Basis spread

'

'

'

'

'

'

'

'

0.50%

'

'

'

'

'

'

'

Percent of principal amount of notes redeemable

'

'

'

'

'

'

'

'

'

35.00%

'

'

'

'

'

'

Convertible notes, threshold number of trading days to trigger conversion feature

'

'

'

'

'

'

'

'

'

'

'

'

'

'20 days

'

'

Convertible notes, threshold consecutive trading days

'

'

'

'

'

'

'

'

'

'

'

'

'

'30 days

'

'

Convertible notes, threshold percentage of stock price trigger

'

'

'

'

'

'

'

'

'

'

'

'

130.00%

130.00%

'

'

Conversion price, per share

'

'

'

'

'

'

'

'

'

'

'

'

'

$61.32

'

'

Convertible notes, stock price trigger

'

'

'

'

'

'

'

'

'

'

'

'

'

$79.72

'

'

Total long-term debt

$1,060,656,000

$1,060,656,000

$1,281,587,000

'

'

'

'

'

'

'

'

'

'

'

'

'

Line of credit facility interest rate

1.90%

'

'

'

'

'

'

'

'

'

'

'

'

'

'

'

Debt instrument maturity date

'

16-Jul-18

'

'

'

15-Jun-24

15-Jun-24

'

'

'

'

'

'

1-Aug-17

1-Jun-19

1-Jun-19

Borrowings_Components_of_longt

Borrowings Components of long-term debt (Details) (USD $)	Sep. 28, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Debt Instrument [Line Items]	'	'
Revolving credit facility, at a rate of 1.90% at September 28, 2014, due 7/16/2018	$200,000	$680,000
5.25% Senior Notes due 2024	250,000	0
Total borrowings	1,099,991	1,330,000
Less: Unamortized debt discount on 3.875% Convertible Senior Subordinated Notes	-39,335	-48,413
Total long-term debt	1,060,656	1,281,587
Current portion of borrowings	-360,656	-351,587
Long-term borrowings	700,000	930,000
3.875% Convertible Senior Subordinated Notes	'	'
Debt Instrument [Line Items]	'	'
3.875% Convertible Senior Subordinated Notes due 2017	399,991	400,000
6.875% Senior Subordinated Notes due 2019	'	'
Debt Instrument [Line Items]	'	'
6.875% Senior Subordinated Notes due 2019	$250,000	$250,000

Borrowings_Fair_value_of_long_

Borrowings Fair value of long term debt (Details) (USD $)	Sep. 28, 2014
In Thousands, unless otherwise specified
Fair Value Measurements [Line Items]	'
Fair value of debt	$1,397,904
Level 1	'
Fair Value Measurements [Line Items]	'
Fair value of debt	955,567
Level 2	'
Fair Value Measurements [Line Items]	'
Fair value of debt	$442,337

Financial_instruments_addition

Financial instruments - additional information (Detail) (USD $)	3 Months Ended		9 Months Ended
	Sep. 28, 2014	Sep. 29, 2013	Sep. 28, 2014	Sep. 29, 2013	Dec. 31, 2013
Derivatives Fair Value [Line Items]	'	'	'	'	'
Total notional amount for all open foreign currency forward contracts	$20,500,000	'	$20,500,000	'	$0
Amount of gains in accumulated other comprehensive income to be reclassified as expense to the statement of income	200,000	'	200,000	'	'
Allowance for doubtful accounts	10,400,000	'	10,400,000	'	10,700,000
Net revenues	457,173,000	413,796,000	1,363,824,000	1,245,732,000	'
Spain, Italy, Portugal, and Greece	'	'	'	'	'
Derivatives Fair Value [Line Items]	'	'	'	'	'
Net revenues	'	'	$114,800,000	$106,300,000	'

Financial_instruments_Fair_val

Financial instruments Fair values of derivative instruments designated as hedging instruments (Details) (USD $)	Sep. 28, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Derivatives Fair Value [Line Items]	'	'
Total asset derivatives	$959	$0
Total liability derivatives	471	0
Foreign Currency Forward Contract | Prepaid Expenses and Other Current Assets	'	'
Derivatives Fair Value [Line Items]	'	'
Total asset derivatives	959	0
Foreign Currency Forward Contract | Other Current Liabilities	'	'
Derivatives Fair Value [Line Items]	'	'
Total liability derivatives	$471	$0

Financial_instruments_After_ta

Financial instruments After tax (gain)/loss reclassified from accumulated other comprehensive income into income (Details) (Cash Flow Hedging, USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2014	Sep. 29, 2013	Sep. 28, 2014	Sep. 29, 2013
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'
Derivatives qualifying as hedges, net of tax	$60	($40)	$203	($52)
Foreign Currency Forward Contract	'	'	'	'
Derivative Instruments, Gain (Loss) [Line Items]	'	'	'	'
Derivatives qualifying as hedges, net of tax	$60	($40)	$203	($52)

Financial_instruments_Aggregat

Financial instruments Aggregate accounts receivable, net of allowance for doubtful accounts (Details) (Spain, Italy, Portugal, and Greece, USD $)	9 Months Ended		12 Months Ended
	Sep. 28, 2014		Dec. 31, 2013
Spain, Italy, Portugal, and Greece	'		'
Accounts, Notes, Loans and Financing Receivable [Line Items]	'		'
Current and long-term accounts receivable (net of allowances of $8.9 million and $7.9 million at September 28, 2014 and December 31, 2013, respectively) in Spain, Italy, Greece and Portugal (1)	$87,733,000	[1]	$97,852,000	[1]
Percentage of total net current and long-term accounts receivable	29.40%		31.00%
Current and long term accounts receivable, allowances	8,900,000		7,900,000
Long-term portion of accounts receivable, net	$15,500,000		$17,600,000
[1]	The long-term portion of accounts receivable, net at SeptemberB 28, 2014 and December 31, 2013 was $15.5 million and $17.6 million, respectively.

Fair_value_measurement_additio

Fair value measurement - additional information (Detail) (USD $)	Sep. 28, 2014	Dec. 31, 2013	Sep. 28, 2014	Sep. 28, 2014	Sep. 28, 2014	Sep. 29, 2013	Sep. 28, 2014	Sep. 29, 2013
			Minimum	Maximum	Regulatory and Sales Milestones	Regulatory and Sales Milestones	Regulatory and Sales Milestones	Regulatory and Sales Milestones
Fair Value Measurements [Line Items]	'	'	'	'	'	'	'	'
Reversal of contingent consideration liabilities	'	'	'	'	$1,500,000	$4,400,000	$8,200,000	$12,400,000
Fair value of contingent consideration liability associated with future milestone	'	'	0	56,500,000	'	'	'	'
Fair value measurement with unobservable inputs reconciliations liability value	12,643,000	20,313,000	'	'	'	'	'	'
Current Portion Of Contingent Consideration	2,957,000	4,131,000	'	'	'	'	'	'
Other liabilities	$9,600,000	'	'	'	'	'	'	'

Fair_value_measurement_Financi

Fair value measurement Financial assets and liabilities carried at fair value measured on recurring basis (Details) (USD $)	Sep. 28, 2014	Dec. 31, 2013
In Thousands, unless otherwise specified
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]	'	'
Investments in marketable securities	$6,540	$6,150
Derivative assets	959	'
Derivative liabilities	471	'
Contingent consideration liabilities	12,643	20,313
Level 1	'	'
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]	'	'
Investments in marketable securities	6,540	6,150
Derivative assets	0	'
Derivative liabilities	0	'
Contingent consideration liabilities	0	0
Level 2	'	'
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]	'	'
Investments in marketable securities	0	0
Derivative assets	959	'
Derivative liabilities	471	'
Contingent consideration liabilities	0	0
Level 3	'	'
Fair Value Assets And Liabilities Measured On Recurring Basis [Line Items]	'	'
Investments in marketable securities	0	0
Derivative assets	0	'
Derivative liabilities	0	'
Contingent consideration liabilities	$12,643	$20,313

Fair_value_measurement_Reconci

Fair value measurement Reconciliation of changes in three financial liabilities measured at fair value on recurring basis (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2014
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]	'
Beginning balance	$20,313
Revaluations	-7,670
Ending balance	$12,643

Fair_value_measurement_Valuati

Fair value measurement Valuation technique and inputs used to determine fair value of assets or liabilities (Details)	9 Months Ended
	Sep. 28, 2014
Discount Rate	'
Fair Value Assets And Liabilities Measured On Unobservable Inputs [Line Items]	'
Contingent consideration, weighted average	8.60%
Discount Rate | Minimum	'
Fair Value Assets And Liabilities Measured On Unobservable Inputs [Line Items]	'
Contingent consideration	2.30%
Discount Rate | Maximum	'
Fair Value Assets And Liabilities Measured On Unobservable Inputs [Line Items]	'
Contingent consideration	10.00%
Probability Of Payment	'
Fair Value Assets And Liabilities Measured On Unobservable Inputs [Line Items]	'
Contingent consideration, weighted average	32.00%
Probability Of Payment | Minimum	'
Fair Value Assets And Liabilities Measured On Unobservable Inputs [Line Items]	'
Contingent consideration	0.00%
Probability Of Payment | Maximum	'
Fair Value Assets And Liabilities Measured On Unobservable Inputs [Line Items]	'
Contingent consideration	100.00%

Changes_in_shareholders_equity2

Changes in shareholders' equity - additional information (Details) (USD $)	1 Months Ended	3 Months Ended		9 Months Ended
Share data in Millions, except Per Share data, unless otherwise specified	Jun. 30, 2007	Sep. 28, 2014	Sep. 29, 2013	Sep. 28, 2014	Sep. 29, 2013	Dec. 31, 2013
Shareholders Equity [Line Items]	'	'	'	'	'	'
Repurchase of outstanding common stock, authorized amount	$300,000,000	'	'	'	'	'
Per share market price of common stock	'	$61.32	'	$61.32	'	'
Strike price of warrents	'	'	'	$74.65	$74.65	'
Conversion of convertible notes, shares issued upon conversion	'	2	0.3	1.8	0.3	'
Debt instrument, stated interest rate	'	3.88%	3.88%	3.88%	3.88%	3.88%
Equity Option	'	'	'	'	'	'
Shareholders Equity [Line Items]	'	'	'	'	'	'
Weighted average antidilutive which were not included in the calculation of earnings per share	'	6.3	8	6.4	7.9	'
Convertible Note	'	'	'	'	'	'
Shareholders Equity [Line Items]	'	'	'	'	'	'
Weighted average antidilutive which were not included in the calculation of earnings per share	'	2.8	1.4	2.7	1.4	'

Changes_in_shareholders_equity3

Changes in shareholders' equity Reconciliation of basic to diluted weighted average common shares outstanding (Details)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2014	Sep. 29, 2013	Sep. 28, 2014	Sep. 29, 2013
Equity [Abstract]	'	'	'	'
Basic (in shares)	41,399	41,132	41,347	41,087
Dilutive effect of share-based awards (in shares)	440	383	441	383
Dilutive effect of 3.875% Convertible Notes and warrants (in shares)	4,789	1,749	4,468	1,776
Diluted (in shares)	46,628	43,264	46,256	43,246

Changes_in_shareholders_equity4

Changes in shareholders' equity Change in accumulated other comprehensive income , net of tax (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2014	Sep. 29, 2013
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'
Beginning balance, accumulated other comprehensive income (loss)	($110,855)	($132,048)
Other comprehensive income (loss) before reclassifications	-40,361	-10,150
Amounts reclassified from accumulated other comprehensive income (loss)	1,767	3,815
Net current-period other comprehensive income (loss)	-38,594	-6,335
Ending balance, accumulated other comprehensive income (loss)	-149,449	-138,383
Cash Flow Hedges	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'
Beginning balance, accumulated other comprehensive income (loss)	0	-381
Other comprehensive income (loss) before reclassifications	641	-370
Amounts reclassified from accumulated other comprehensive income (loss)	-438	318
Net current-period other comprehensive income (loss)	203	-52
Ending balance, accumulated other comprehensive income (loss)	203	-433
Pension and Other Postretirement Benefits Plans	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'
Beginning balance, accumulated other comprehensive income (loss)	-97,037	-127,257
Other comprehensive income (loss) before reclassifications	131	-762
Amounts reclassified from accumulated other comprehensive income (loss)	2,205	3,497
Net current-period other comprehensive income (loss)	2,336	2,735
Ending balance, accumulated other comprehensive income (loss)	-94,701	-124,522
Foreign Currency Translation Adjustment	'	'
Increase (Decrease) in Stockholders' Equity [Roll Forward]	'	'
Beginning balance, accumulated other comprehensive income (loss)	-13,818	-4,410
Other comprehensive income (loss) before reclassifications	-41,133	-9,018
Amounts reclassified from accumulated other comprehensive income (loss)	0	0
Net current-period other comprehensive income (loss)	-41,133	-9,018
Ending balance, accumulated other comprehensive income (loss)	($54,951)	($13,428)

Changes_in_shareholders_equity5

Changes in shareholders' equity Accumulated other comprehensive income into income expense (Details) (USD $)	3 Months Ended				9 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2014		Sep. 29, 2013		Sep. 28, 2014		Sep. 29, 2013
Accumulated Other Comprehensive Income (Loss) [Line Items]	'		'		'		'
Cost of goods sold	$221,007		$209,804		$662,411		$631,730
Income from continuing operations before taxes	64,912		50,988		167,551		135,839
Tax benefit	-9,684		-5,209		-28,224		-18,958
Income from continuing operations	55,228		45,779		139,327		116,881
Reclassification out of Accumulated Other Comprehensive Income	'		'		'		'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'		'		'		'
Income from continuing operations	359		1,781		1,767		3,815
Reclassification out of Accumulated Other Comprehensive Income | Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges	'		'		'		'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'		'		'		'
Income from continuing operations before taxes	-397		850		-526		154
Tax benefit	49		-158		88		164
Income from continuing operations	-348		692		-438		318
Reclassification out of Accumulated Other Comprehensive Income | Pension and Other Postretirement Benefits Plans	'		'		'		'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'		'		'		'
Income from continuing operations before taxes	1,085		1,693		3,279		5,449
Tax benefit	-378		-604		-1,074		-1,952
Income from continuing operations	707		1,089		2,205		3,497
Actuarial losses/(gains)	1,090	[1]	1,696	[1]	3,295	[1]	5,460	[1]
Prior-service costs	-5	[1]	-4	[1]	-16	[1]	-15	[1]
Transition obligation	0	[1]	1	[1]	0	[1]	4	[1]
Reclassification out of Accumulated Other Comprehensive Income | Commodity Contract | Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges	'		'		'		'
Accumulated Other Comprehensive Income (Loss) [Line Items]	'		'		'		'
Cost of goods sold	($397)		$850		($526)		$154
[1]	These accumulated other comprehensive income components are included in the computation of net benefit cost of pension and other postretirement benefit plans (see Note 12 for additional information).

Taxes_on_income_from_continuin2

Taxes on income from continuing operations- additional information (Details)	3 Months Ended		9 Months Ended
	Sep. 28, 2014	Sep. 29, 2013	Sep. 28, 2014	Sep. 29, 2013
Income Tax Disclosure [Abstract]	'	'	'	'
Effective income tax rate	14.90%	10.20%	16.80%	14.00%

Pension_and_other_postretireme2

Pension and other postretirement benefits - Additional Information (Detail) (USD $)	3 Months Ended	9 Months Ended
In Millions, unless otherwise specified	Sep. 28, 2014	Sep. 28, 2014
Compensation and Retirement Disclosure [Abstract]	'	'
Expected employer contribution for year 2014	'	$9.40
Employer contribution to pension plan	$2.70	$7.40

Pension_and_other_postretireme3

Pension and other postretirement benefits Net benefit cost of pension and postretirement benefit plans (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2014	Sep. 29, 2013	Sep. 28, 2014	Sep. 29, 2013
Pension	'	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'	'
Service cost	$453	$432	$1,350	$1,361
Interest cost	4,548	4,333	13,517	12,614
Expected return on plan assets	-6,240	-5,784	-18,764	-17,328
Net amortization and deferral	1,143	1,556	3,284	4,380
Net benefit expense (income)	-96	537	-613	1,027
Other Postretirement Benefits	'	'	'	'
Defined Benefit Plan Disclosure [Line Items]	'	'	'	'
Service cost	42	176	318	501
Interest cost	434	543	1,627	2,084
Expected return on plan assets	0	0	0	0
Net amortization and deferral	-58	137	-5	1,069
Net benefit expense (income)	$418	$856	$1,940	$3,654

Commitments_and_contingent_lia1

Commitments and contingent liabilities - Additional Information (Detail) (USD $)	Sep. 28, 2014	Dec. 31, 2013	Sep. 28, 2014	Sep. 28, 2014	Sep. 28, 2014	Dec. 31, 2013	Sep. 28, 2014	Dec. 31, 2013	Sep. 28, 2014	Sep. 28, 2014
In Millions, unless otherwise specified			Minimum	Maximum	Accrued Liabilities	Accrued Liabilities	Other Liability	Other Liability	Property, Plant and Equipment	Property, Plant and Equipment
										Build To Suit Lease
Loss Contingencies [Line Items]	'	'	'	'	'	'	'	'	'	'
Estimated fair value of the costs to construct buildings	'	'	'	'	'	'	'	'	$28.20	$28.30
Lease commencement date	'	'	'	'	'	'	'	'	'	1-Sep-13
Waste disposed accrued liability	'	'	'	'	2.2	2.5	5.3	5.8	'	'
Time-frame over which the accrued amounts may be paid out, in years	'	'	'15 years	'20 years	'	'	'	'	'	'
Contingency reserve for litigation	$4.20	$6.80	'	'	'	'	'	'	'	'
Expected construction completion year	'	'	'	'	'	'	'	'	'	'2014-10

Business_segment_information_a

Business segment information - additional information (Details) (USD $)	3 Months Ended				9 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2014		Sep. 29, 2013		Sep. 28, 2014		Sep. 29, 2013		Dec. 31, 2013
					segment
Revenues from External Customers and Long-Lived Assets [Line Items]	'		'		'		'		'
Number of reportable segments	'		'		6		'		'
Revenue	$457,173		$413,796		$1,363,824		$1,245,732		'
Operating profit	81,935		66,042		215,707		179,197		'
Depreciation and amortization	32,439		27,075		96,254		79,035		'
Property, plant and equipment, net	347,233		'		347,233		'		325,900
United States	'		'		'		'		'
Revenues from External Customers and Long-Lived Assets [Line Items]	'		'		'		'		'
Revenue	231,278		205,049		676,088		623,397		'
Property, plant and equipment, net	201,045		'		201,045		'		203,985
Other Americas	'		'		'		'		'
Revenues from External Customers and Long-Lived Assets [Line Items]	'		'		'		'		'
Revenue	14,440		12,108		44,399		40,786		'
Europe	'		'		'		'		'
Revenues from External Customers and Long-Lived Assets [Line Items]	'		'		'		'		'
Revenue	157,797		137,848		500,763		419,062		'
Czech Republic	'		'		'		'		'
Revenues from External Customers and Long-Lived Assets [Line Items]	'		'		'		'		'
Property, plant and equipment, net	38,728		'		38,728		'		41,607
Malaysia	'		'		'		'		'
Revenues from External Customers and Long-Lived Assets [Line Items]	'		'		'		'		'
Property, plant and equipment, net	35,972		'		35,972		'		29,313
All Other	'		'		'		'		'
Revenues from External Customers and Long-Lived Assets [Line Items]	'		'		'		'		'
Revenue	53,658		58,791		142,574		162,487		'
Property, plant and equipment, net	71,488		'		71,488		'		50,995
Operating Segments	'		'		'		'		'
Revenues from External Customers and Long-Lived Assets [Line Items]	'		'		'		'		'
Operating profit	99,372	[1]	77,639	[1]	277,563	[1]	227,397	[1]	'
Unallocated expenses	'		'		'		'		'
Revenues from External Customers and Long-Lived Assets [Line Items]	'		'		'		'		'
Operating profit	-17,437	[2]	-11,597	[2]	-61,856	[2]	-48,200	[2]	'
Vascular North America	'		'		'		'		'
Revenues from External Customers and Long-Lived Assets [Line Items]	'		'		'		'		'
Revenue	63,792		55,058		190,485		168,478		'
Depreciation and amortization	7,921		7,222		23,842		20,656		'
Vascular North America | Operating Segments	'		'		'		'		'
Revenues from External Customers and Long-Lived Assets [Line Items]	'		'		'		'		'
Operating profit	11,870		6,042		31,250		17,394		'
Anesthesia Respiratory North America	'		'		'		'		'
Revenues from External Customers and Long-Lived Assets [Line Items]	'		'		'		'		'
Revenue	54,699		53,842		164,462		170,532		'
Depreciation and amortization	5,321		3,948		13,457		10,663		'
Anesthesia Respiratory North America | Operating Segments	'		'		'		'		'
Revenues from External Customers and Long-Lived Assets [Line Items]	'		'		'		'		'
Operating profit	9,421		3,541		21,401		18,483		'
Surgical North America	'		'		'		'		'
Revenues from External Customers and Long-Lived Assets [Line Items]	'		'		'		'		'
Revenue	36,127		34,147		109,327		108,584		'
Depreciation and amortization	909		2,476		4,944		7,708		'
Surgical North America | Operating Segments	'		'		'		'		'
Revenues from External Customers and Long-Lived Assets [Line Items]	'		'		'		'		'
Operating profit	12,394		10,333		37,308		37,646		'
EMEA	'		'		'		'		'
Revenues from External Customers and Long-Lived Assets [Line Items]	'		'		'		'		'
Revenue	141,146		132,265		446,061		412,525		'
Depreciation and amortization	9,688		7,035		28,298		20,666		'
EMEA | Operating Segments	'		'		'		'		'
Revenues from External Customers and Long-Lived Assets [Line Items]	'		'		'		'		'
Operating profit	28,810		21,074		85,771		65,542		'
Asia	'		'		'		'		'
Revenues from External Customers and Long-Lived Assets [Line Items]	'		'		'		'		'
Revenue	62,035		55,263		174,176		148,040		'
Depreciation and amortization	2,003		1,134		6,146		3,506		'
Asia | Operating Segments	'		'		'		'		'
Revenues from External Customers and Long-Lived Assets [Line Items]	'		'		'		'		'
Operating profit	14,785		18,894		44,718		44,961		'
OEM	'		'		'		'		'
Revenues from External Customers and Long-Lived Assets [Line Items]	'		'		'		'		'
Revenue	39,174		33,774		108,966		97,222		'
Depreciation and amortization	1,651		1,123		4,715		3,370		'
OEM | Operating Segments	'		'		'		'		'
Revenues from External Customers and Long-Lived Assets [Line Items]	'		'		'		'		'
Operating profit	9,651		6,684		24,551		20,778		'
All Other	'		'		'		'		'
Revenues from External Customers and Long-Lived Assets [Line Items]	'		'		'		'		'
Revenue	60,200		49,447		170,347		140,351		'
Depreciation and amortization	4,946		4,137		14,852		12,466		'
All Other | Operating Segments	'		'		'		'		'
Revenues from External Customers and Long-Lived Assets [Line Items]	'		'		'		'		'
Operating profit	$12,441		$11,071		$32,564		$22,593		'
[1]	Segment operating profit includes segment net revenues from external customers reduced by its standard cost of goods sold, adjusted for fixed manufacturing cost absorption variances, selling, general and administrative expenses, research and development expenses and an allocation of corporate expenses. Corporate expenses are allocated among the segments in proportion to the respective amounts of one of several items (such as sales, numbers of employees, and amount of time spent), depending on the category of expense involved.
[2]	Unallocated expenses primarily include manufacturing variances, with the exception of fixed manufacturing cost absorption variances, and restructuring and other impairment charges.

Condensed_consolidated_guarant2

Condensed consolidated guarantor financial information - additional information (Detail) (USD $)	Sep. 28, 2014	Dec. 31, 2013	Sep. 29, 2013	Jun. 26, 2011
In Thousands, unless otherwise specified				6.875% Senior Subordinated Notes due 2019
Condensed Financial Statements Captions [Line Items]	'	'	'	'
6.875% Senior Subordinated Notes due 2019	'	'	'	$250,000
Debt instrument, stated interest rate	3.88%	3.88%	3.88%	6.88%
Ownership percentage of subsidiaries	100.00%	'	'	'

Condensed_consolidated_guarant3

Condensed consolidated guarantor financial information Adjustments to condensed consolidating statements of cash flows within guarantor financial information (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2014	Sep. 29, 2013
Condensed Cash Flow Statements, Captions [Line Items]	'	'
Net cash provided by operating activities from continuing operations	$208,798	$135,872
Intercompany transactions	0	0
Intercompany dividends paid	0	0
Net cash used in financing activities from continuing operations	-274,030	-53,643
Scenario, Adjustment	'	'
Condensed Cash Flow Statements, Captions [Line Items]	'	'
Intercompany transactions	'	0
Intercompany dividends paid	'	0
Scenario, Adjustment | Before Adjustment	'	'
Condensed Cash Flow Statements, Captions [Line Items]	'	'
Net cash provided by operating activities from continuing operations	'	0
Scenario, Adjustment | After Adjustment	'	'
Condensed Cash Flow Statements, Captions [Line Items]	'	'
Net cash used in financing activities from continuing operations	'	0
Consolidation, Eliminations	'	'
Condensed Cash Flow Statements, Captions [Line Items]	'	'
Net cash provided by operating activities from continuing operations	-75,340	-66,071
Intercompany transactions	0	0
Intercompany dividends paid	-305,122	-66,071
Net cash used in financing activities from continuing operations	305,122	66,071
Consolidation, Eliminations | Scenario, Adjustment	'	'
Condensed Cash Flow Statements, Captions [Line Items]	'	'
Intercompany transactions	'	0
Intercompany dividends paid	'	66,071
Consolidation, Eliminations | Scenario, Adjustment | Before Adjustment	'	'
Condensed Cash Flow Statements, Captions [Line Items]	'	'
Net cash provided by operating activities from continuing operations	'	-66,071
Consolidation, Eliminations | Scenario, Adjustment | After Adjustment	'	'
Condensed Cash Flow Statements, Captions [Line Items]	'	'
Net cash used in financing activities from continuing operations	'	66,071
Parent Company	'	'
Condensed Cash Flow Statements, Captions [Line Items]	'	'
Net cash provided by operating activities from continuing operations	-80,537	-85,753
Intercompany transactions	372,762	70,932
Intercompany dividends paid	0	0
Net cash used in financing activities from continuing operations	99,826	34,392
Parent Company | Scenario, Adjustment	'	'
Condensed Cash Flow Statements, Captions [Line Items]	'	'
Intercompany transactions	'	-1,200
Intercompany dividends paid	'	0
Parent Company | Scenario, Adjustment | Before Adjustment	'	'
Condensed Cash Flow Statements, Captions [Line Items]	'	'
Net cash provided by operating activities from continuing operations	'	1,200
Parent Company | Scenario, Adjustment | After Adjustment	'	'
Condensed Cash Flow Statements, Captions [Line Items]	'	'
Net cash used in financing activities from continuing operations	'	-1,200
Guarantor Subsidiaries	'	'
Condensed Cash Flow Statements, Captions [Line Items]	'	'
Net cash provided by operating activities from continuing operations	300,960	147,461
Intercompany transactions	-294,661	-72,574
Intercompany dividends paid	0	17,400
Net cash used in financing activities from continuing operations	-294,661	-104,776
Guarantor Subsidiaries | Scenario, Adjustment	'	'
Condensed Cash Flow Statements, Captions [Line Items]	'	'
Intercompany transactions	'	-43,734
Intercompany dividends paid	'	-17,400
Guarantor Subsidiaries | Scenario, Adjustment | Before Adjustment	'	'
Condensed Cash Flow Statements, Captions [Line Items]	'	'
Net cash provided by operating activities from continuing operations	'	61,134
Guarantor Subsidiaries | Scenario, Adjustment | After Adjustment	'	'
Condensed Cash Flow Statements, Captions [Line Items]	'	'
Net cash used in financing activities from continuing operations	'	-61,134
Non-Guarantor Subsidiaries	'	'
Condensed Cash Flow Statements, Captions [Line Items]	'	'
Net cash provided by operating activities from continuing operations	63,715	140,235
Intercompany transactions	-78,101	1,642
Intercompany dividends paid	305,122	48,671
Net cash used in financing activities from continuing operations	-384,317	-49,330
Non-Guarantor Subsidiaries | Scenario, Adjustment	'	'
Condensed Cash Flow Statements, Captions [Line Items]	'	'
Intercompany transactions	'	44,934
Intercompany dividends paid	'	-48,671
Non-Guarantor Subsidiaries | Scenario, Adjustment | Before Adjustment	'	'
Condensed Cash Flow Statements, Captions [Line Items]	'	'
Net cash provided by operating activities from continuing operations	'	3,737
Non-Guarantor Subsidiaries | Scenario, Adjustment | After Adjustment	'	'
Condensed Cash Flow Statements, Captions [Line Items]	'	'
Net cash used in financing activities from continuing operations	'	($3,737)

Condensed_consolidated_guarant4

Condensed consolidated guarantor financial information Condensed consolidating statements of income and comprehensive income (Details) (USD $)	3 Months Ended		9 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2014	Sep. 29, 2013	Sep. 28, 2014	Sep. 29, 2013
Condensed Income Statements, Captions [Line Items]	'	'	'	'
Net revenues	$457,173	$413,796	$1,363,824	$1,245,732
Cost of goods sold	221,007	209,804	662,411	631,730
Gross profit	236,166	203,992	701,413	614,002
Selling, general and administrative expenses	138,252	115,228	425,392	358,431
Research and development expenses	14,871	15,638	43,803	47,169
Restructuring and other impairment charges	1,108	7,084	16,511	29,205
Income from continuing operations before interest, loss on extingushments of debt and taxes	81,935	66,042	215,707	179,197
Interest expense	17,184	13,948	48,650	42,566
Interest income	-161	-144	-494	-458
Loss on extinguishments of debt	0	1,250	0	1,250
Income from continuing operations before taxes	64,912	50,988	167,551	135,839
Taxes (benefit) on income (loss) from continuing operations	9,684	5,209	28,224	18,958
Equity in net income of consolidated subsidiaries	0	0	0	0
Income from continuing operations	55,228	45,779	139,327	116,881
Operating loss from discontinued operations	-247	38	-1,866	-1,746
Taxes (benefit) on loss from discontinued operations	24	-991	-345	-1,547
Income (loss) from discontinued operations	-271	1,029	-1,521	-199
Net income	54,957	46,808	137,806	116,682
Less: Income from continuing operations attributable to noncontrolling interests	126	234	765	629
Net income attributable to common shareholders	54,831	46,574	137,041	116,053
Other comprehensive loss attributable to common shareholders	-45,201	24,375	-38,594	-6,335
Comprehensive income attributable to common shareholders	9,630	70,949	98,447	109,718
Consolidation, Eliminations	'	'	'	'
Condensed Income Statements, Captions [Line Items]	'	'	'	'
Net revenues	-76,256	-62,407	-288,398	-203,291
Cost of goods sold	-76,817	-60,522	-278,691	-202,927
Gross profit	561	-1,885	-9,707	-364
Selling, general and administrative expenses	-80	272	231	66
Research and development expenses	0	0	0	0
Restructuring and other impairment charges	0	0	0	0
Income from continuing operations before interest, loss on extingushments of debt and taxes	641	-2,157	-9,938	-430
Interest expense	0	'	0	0
Interest income	0	0	0	0
Loss on extinguishments of debt	'	0	'	0
Income from continuing operations before taxes	641	-2,157	-9,938	-430
Taxes (benefit) on income (loss) from continuing operations	1,956	-568	-2,303	208
Equity in net income of consolidated subsidiaries	-145,578	-125,134	-389,054	-325,136
Income from continuing operations	-146,893	-126,723	-396,689	-325,774
Operating loss from discontinued operations	0	0	0	0
Taxes (benefit) on loss from discontinued operations	0	0	0	0
Income (loss) from discontinued operations	0	0	0	0
Net income	-146,893	-126,723	-396,689	-325,774
Less: Income from continuing operations attributable to noncontrolling interests	0	0	0	0
Net income attributable to common shareholders	-146,893	-126,723	-396,689	-325,774
Other comprehensive loss attributable to common shareholders	102,385	-51,476	91,505	9,246
Comprehensive income attributable to common shareholders	-44,508	-178,199	-305,184	-316,528
Parent Company	'	'	'	'
Condensed Income Statements, Captions [Line Items]	'	'	'	'
Net revenues	0	0	0	0
Cost of goods sold	0	0	0	0
Gross profit	0	0	0	0
Selling, general and administrative expenses	8,978	14,088	30,781	45,915
Research and development expenses	0	0	0	0
Restructuring and other impairment charges	0	828	0	828
Income from continuing operations before interest, loss on extingushments of debt and taxes	-8,978	-14,916	-30,781	-46,743
Interest expense	37,913	33,492	106,794	100,682
Interest income	0	3	0	0
Loss on extinguishments of debt	'	1,250	'	1,250
Income from continuing operations before taxes	-46,891	-49,661	-137,575	-148,675
Taxes (benefit) on income (loss) from continuing operations	-16,761	-18,446	-47,891	-54,192
Equity in net income of consolidated subsidiaries	85,187	76,448	228,113	210,701
Income from continuing operations	55,057	45,233	138,429	116,218
Operating loss from discontinued operations	-247	364	-1,866	-1,788
Taxes (benefit) on loss from discontinued operations	-21	-977	-478	-1,623
Income (loss) from discontinued operations	-226	1,341	-1,388	-165
Net income	54,831	46,574	137,041	116,053
Less: Income from continuing operations attributable to noncontrolling interests	0	0	0	0
Net income attributable to common shareholders	54,831	46,574	137,041	116,053
Other comprehensive loss attributable to common shareholders	-45,201	24,375	-38,594	-6,335
Comprehensive income attributable to common shareholders	9,630	70,949	98,447	109,718
Guarantor Subsidiaries	'	'	'	'
Condensed Income Statements, Captions [Line Items]	'	'	'	'
Net revenues	261,346	237,949	814,051	740,817
Cost of goods sold	161,298	139,501	489,694	435,937
Gross profit	100,048	98,448	324,357	304,880
Selling, general and administrative expenses	77,352	62,701	235,322	189,193
Research and development expenses	12,871	13,161	37,766	40,250
Restructuring and other impairment charges	148	3,834	8,639	13,112
Income from continuing operations before interest, loss on extingushments of debt and taxes	9,677	18,752	42,630	62,325
Interest expense	-22,346	-21,204	-62,993	-63,348
Interest income	0	-3	0	-3
Loss on extinguishments of debt	'	0	'	0
Income from continuing operations before taxes	32,023	39,959	105,623	125,676
Taxes (benefit) on income (loss) from continuing operations	13,984	14,261	44,737	42,241
Equity in net income of consolidated subsidiaries	60,295	48,367	160,653	114,116
Income from continuing operations	78,334	74,065	221,539	197,551
Operating loss from discontinued operations	0	0	0	0
Taxes (benefit) on loss from discontinued operations	0	-170	0	-170
Income (loss) from discontinued operations	0	170	0	170
Net income	78,334	74,235	221,539	197,721
Less: Income from continuing operations attributable to noncontrolling interests	0	0	0	0
Net income attributable to common shareholders	78,334	74,235	221,539	197,721
Other comprehensive loss attributable to common shareholders	-58,947	30,034	-54,326	-3,316
Comprehensive income attributable to common shareholders	19,387	104,269	167,213	194,405
Non-Guarantor Subsidiaries	'	'	'	'
Condensed Income Statements, Captions [Line Items]	'	'	'	'
Net revenues	272,083	238,254	838,171	708,206
Cost of goods sold	136,526	130,825	451,408	398,720
Gross profit	135,557	107,429	386,763	309,486
Selling, general and administrative expenses	52,002	38,167	159,058	123,257
Research and development expenses	2,000	2,477	6,037	6,919
Restructuring and other impairment charges	960	2,422	7,872	15,265
Income from continuing operations before interest, loss on extingushments of debt and taxes	80,595	64,363	213,796	164,045
Interest expense	1,617	1,660	4,849	5,232
Interest income	-161	-144	-494	-455
Loss on extinguishments of debt	'	0	'	0
Income from continuing operations before taxes	79,139	62,847	209,441	159,268
Taxes (benefit) on income (loss) from continuing operations	10,505	9,962	33,681	30,701
Equity in net income of consolidated subsidiaries	96	319	288	319
Income from continuing operations	68,730	53,204	176,048	128,886
Operating loss from discontinued operations	0	-326	0	42
Taxes (benefit) on loss from discontinued operations	45	156	133	246
Income (loss) from discontinued operations	-45	-482	-133	-204
Net income	68,685	52,722	175,915	128,682
Less: Income from continuing operations attributable to noncontrolling interests	126	234	765	629
Net income attributable to common shareholders	68,559	52,488	175,150	128,053
Other comprehensive loss attributable to common shareholders	-43,438	21,442	-37,179	-5,930
Comprehensive income attributable to common shareholders	$25,121	$73,930	$137,971	$122,123

Condensed_consolidated_guarant5

Condensed consolidated guarantor financial information Condensed consolidating balance sheets (Details) (USD $)	Sep. 28, 2014	Dec. 31, 2013	Sep. 29, 2013	Dec. 31, 2012
In Thousands, unless otherwise specified
Current assets	'	'	'	'
Cash and cash equivalents	$286,382	$431,984	$326,437	$337,039
Accounts receivable, net	287,179	295,290	'	'
Accounts receivable from consolidated subsidiaries	0	0	'	'
Inventories, net	353,227	333,621	'	'
Prepaid expenses and other current assets	43,283	39,810	'	'
Prepaid taxes	51,319	36,504	'	'
Deferred tax assets	48,141	52,917	'	'
Assets held for sale	7,672	10,428	'	'
Total current assets	1,077,203	1,200,554	'	'
Property, plant and equipment, net	347,233	325,900	'	'
Goodwill	1,352,045	1,354,203	'	'
Intangible assets, net	1,208,252	1,255,597	'	'
Investments in affiliates	1,079	1,715	'	'
Deferred tax assets	1,706	943	'	'
Notes receivable and other amounts due from consolidated subsidiaries	0	0	'	'
Other assets	70,274	70,095	'	'
Total assets	4,057,792	4,209,007	'	'
Current liabilities	'	'	'	'
Current borrowings	365,356	356,287	'	'
Accounts payable	71,034	71,967	'	'
Accounts payable to consolidated subsidiaries	0	0	'	'
Accrued expenses	77,333	74,868	'	'
Current portion of contingent consideration	2,957	4,131	'	'
Payroll and benefit-related liabilities	76,781	73,090	'	'
Accrued interest	13,848	8,725	'	'
Income taxes payable	26,735	23,821	'	'
Other current liabilities	42,272	22,231	'	'
Total current liabilities	676,316	635,120	'	'
Long-term borrowings	700,000	930,000	'	'
Deferred tax liabilities	494,884	514,715	'	'
Pension and other postretirement benefit liabilities	97,007	109,498	'	'
Noncurrent liability for uncertain tax positions	56,448	55,152	'	'
Notes payable and other amounts due from consolidated subsidiaries	0	0	'	'
Other liabilities	49,221	48,506	'	'
Total liabilities	2,073,876	2,292,991	'	'
Total common shareholders' equity	1,981,728	1,913,527	'	'
Noncontrolling interest	2,188	2,489	'	'
Total equity	1,983,916	1,916,016	1,862,262	1,781,537
Total liabilities and equity	4,057,792	4,209,007	'	'
Consolidation, Eliminations	'	'	'	'
Current assets	'	'	'	'
Cash and cash equivalents	0	0	0	0
Accounts receivable, net	3,241	3,472	'	'
Accounts receivable from consolidated subsidiaries	-3,092,483	-2,880,648	'	'
Inventories, net	-25,418	-15,709	'	'
Prepaid expenses and other current assets	0	0	'	'
Prepaid taxes	0	0	'	'
Deferred tax assets	-220	-3	'	'
Assets held for sale	0	0	'	'
Total current assets	-3,114,880	-2,892,888	'	'
Property, plant and equipment, net	0	0	'	'
Goodwill	0	0	'	'
Intangible assets, net	0	0	'	'
Investments in affiliates	-7,053,808	-6,987,772	'	'
Deferred tax assets	-37,928	-39,410	'	'
Notes receivable and other amounts due from consolidated subsidiaries	-1,968,416	-1,936,618	'	'
Other assets	0	0	'	'
Total assets	-12,175,032	-11,856,688	'	'
Current liabilities	'	'	'	'
Current borrowings	0	0	'	'
Accounts payable	0	0	'	'
Accounts payable to consolidated subsidiaries	-3,092,483	-2,880,648	'	'
Accrued expenses	0	0	'	'
Current portion of contingent consideration	0	0	'	'
Payroll and benefit-related liabilities	0	0	'	'
Accrued interest	0	0	'	'
Income taxes payable	0	0	'	'
Other current liabilities	-220	-4	'	'
Total current liabilities	-3,092,703	-2,880,652	'	'
Long-term borrowings	0	0	'	'
Deferred tax liabilities	-37,927	-39,409	'	'
Pension and other postretirement benefit liabilities	0	0	'	'
Noncurrent liability for uncertain tax positions	0	0	'	'
Notes payable and other amounts due from consolidated subsidiaries	-1,974,204	-1,940,100	'	'
Other liabilities	0	0	'	'
Total liabilities	-5,104,834	-4,860,161	'	'
Total common shareholders' equity	-7,070,198	-6,996,527	'	'
Noncontrolling interest	0	0	'	'
Total equity	-7,070,198	-6,996,527	'	'
Total liabilities and equity	-12,175,032	-11,856,688	'	'
Parent Company	'	'	'	'
Current assets	'	'	'	'
Cash and cash equivalents	59,555	42,749	17,083	70,860
Accounts receivable, net	1,921	1,822	'	'
Accounts receivable from consolidated subsidiaries	39,604	42,865	'	'
Inventories, net	0	0	'	'
Prepaid expenses and other current assets	15,587	15,200	'	'
Prepaid taxes	34,406	27,487	'	'
Deferred tax assets	19,912	20,218	'	'
Assets held for sale	2,901	1,669	'	'
Total current assets	173,886	152,010	'	'
Property, plant and equipment, net	3,648	14,189	'	'
Goodwill	0	0	'	'
Intangible assets, net	0	0	'	'
Investments in affiliates	5,676,862	5,489,676	'	'
Deferred tax assets	34,525	35,877	'	'
Notes receivable and other amounts due from consolidated subsidiaries	975,641	1,049,344	'	'
Other assets	28,795	24,574	'	'
Total assets	6,893,357	6,765,670	'	'
Current liabilities	'	'	'	'
Current borrowings	360,656	351,587	'	'
Accounts payable	4,291	2,194	'	'
Accounts payable to consolidated subsidiaries	2,730,852	2,644,296	'	'
Accrued expenses	18,088	15,569	'	'
Current portion of contingent consideration	0	0	'	'
Payroll and benefit-related liabilities	17,358	15,976	'	'
Accrued interest	13,831	8,720	'	'
Income taxes payable	0	0	'	'
Other current liabilities	475	9,646	'	'
Total current liabilities	3,145,551	3,047,988	'	'
Long-term borrowings	700,000	930,000	'	'
Deferred tax liabilities	0	0	'	'
Pension and other postretirement benefit liabilities	46,618	57,406	'	'
Noncurrent liability for uncertain tax positions	13,355	11,389	'	'
Notes payable and other amounts due from consolidated subsidiaries	986,769	785,476	'	'
Other liabilities	19,336	19,884	'	'
Total liabilities	4,911,629	4,852,143	'	'
Total common shareholders' equity	1,981,728	1,913,527	'	'
Noncontrolling interest	0	0	'	'
Total equity	1,981,728	1,913,527	'	'
Total liabilities and equity	6,893,357	6,765,670	'	'
Guarantor Subsidiaries	'	'	'	'
Current assets	'	'	'	'
Cash and cash equivalents	1,662	14,500	0	1,989
Accounts receivable, net	11,630	10,948	'	'
Accounts receivable from consolidated subsidiaries	2,782,391	2,623,314	'	'
Inventories, net	210,427	211,165	'	'
Prepaid expenses and other current assets	6,826	6,870	'	'
Prepaid taxes	0	0	'	'
Deferred tax assets	19,516	22,472	'	'
Assets held for sale	0	3,503	'	'
Total current assets	3,032,452	2,892,772	'	'
Property, plant and equipment, net	196,101	188,455	'	'
Goodwill	704,210	797,671	'	'
Intangible assets, net	713,854	962,243	'	'
Investments in affiliates	1,356,773	1,478,429	'	'
Deferred tax assets	0	0	'	'
Notes receivable and other amounts due from consolidated subsidiaries	992,775	873,105	'	'
Other assets	7,435	7,447	'	'
Total assets	7,003,600	7,200,122	'	'
Current liabilities	'	'	'	'
Current borrowings	0	0	'	'
Accounts payable	35,293	45,802	'	'
Accounts payable to consolidated subsidiaries	197,409	147,957	'	'
Accrued expenses	17,056	21,120	'	'
Current portion of contingent consideration	2,957	4,131	'	'
Payroll and benefit-related liabilities	20,742	21,818	'	'
Accrued interest	0	0	'	'
Income taxes payable	0	0	'	'
Other current liabilities	33,450	7,517	'	'
Total current liabilities	306,907	248,345	'	'
Long-term borrowings	0	0	'	'
Deferred tax liabilities	477,101	496,228	'	'
Pension and other postretirement benefit liabilities	33,962	33,777	'	'
Noncurrent liability for uncertain tax positions	17,476	17,241	'	'
Notes payable and other amounts due from consolidated subsidiaries	897,634	957,451	'	'
Other liabilities	17,142	16,221	'	'
Total liabilities	1,750,222	1,769,263	'	'
Total common shareholders' equity	5,253,378	5,430,859	'	'
Noncontrolling interest	0	0	'	'
Total equity	5,253,378	5,430,859	'	'
Total liabilities and equity	7,003,600	7,200,122	'	'
Non-Guarantor Subsidiaries	'	'	'	'
Current assets	'	'	'	'
Cash and cash equivalents	225,165	374,735	309,354	264,190
Accounts receivable, net	270,387	279,048	'	'
Accounts receivable from consolidated subsidiaries	270,488	214,469	'	'
Inventories, net	168,218	138,165	'	'
Prepaid expenses and other current assets	20,870	17,740	'	'
Prepaid taxes	16,913	9,017	'	'
Deferred tax assets	8,933	10,230	'	'
Assets held for sale	4,771	5,256	'	'
Total current assets	985,745	1,048,660	'	'
Property, plant and equipment, net	147,484	123,256	'	'
Goodwill	647,835	556,532	'	'
Intangible assets, net	494,398	293,354	'	'
Investments in affiliates	21,252	21,382	'	'
Deferred tax assets	5,109	4,476	'	'
Notes receivable and other amounts due from consolidated subsidiaries	0	14,169	'	'
Other assets	34,044	38,074	'	'
Total assets	2,335,867	2,099,903	'	'
Current liabilities	'	'	'	'
Current borrowings	4,700	4,700	'	'
Accounts payable	31,450	23,971	'	'
Accounts payable to consolidated subsidiaries	164,222	88,395	'	'
Accrued expenses	42,189	38,179	'	'
Current portion of contingent consideration	0	0	'	'
Payroll and benefit-related liabilities	38,681	35,296	'	'
Accrued interest	17	5	'	'
Income taxes payable	26,735	23,821	'	'
Other current liabilities	8,567	5,072	'	'
Total current liabilities	316,561	219,439	'	'
Long-term borrowings	0	0	'	'
Deferred tax liabilities	55,710	57,896	'	'
Pension and other postretirement benefit liabilities	16,427	18,315	'	'
Noncurrent liability for uncertain tax positions	25,617	26,522	'	'
Notes payable and other amounts due from consolidated subsidiaries	89,801	197,173	'	'
Other liabilities	12,743	12,401	'	'
Total liabilities	516,859	531,746	'	'
Total common shareholders' equity	1,816,820	1,565,668	'	'
Noncontrolling interest	2,188	2,489	'	'
Total equity	1,819,008	1,568,157	'	'
Total liabilities and equity	$2,335,867	$2,099,903	'	'

Condensed_consolidated_guarant6

Condensed consolidated guarantor financial information Condensed consolidating statements of cash flows (Details) (USD $)	9 Months Ended
In Thousands, unless otherwise specified	Sep. 28, 2014	Sep. 29, 2013
Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]	'	'
Net cash (used in) provided by operating activities from continuing operations	$208,798	$135,872
Net Cash Provided by (Used in) Investing Activities [Abstract]	'	'
Expenditures for property, plant and equipment	-48,220	-54,640
Proceeds from sale of assets and investments	5,251	0
Payments for businesses and intangibles acquired, net of cash acquired	-28,535	-40,450
Investments in affiliates	-40	-50
Intercompany dividends received	0	'
Net cash used in investing activities from continuing operations	-71,544	-95,140
Cash Flows from Financing Activities of Continuing Operations:	'	'
Proceeds from long-term borrowings	250,000	382,000
Repayment of long-term borrowings	-480,009	-375,000
Debt issuance fees	-3,689	-6,365
Proceeds from share based compensation plans and the related tax impacts	2,936	4,740
Payments to Noncontrolling Interests	-1,094	-736
Payments for contingent consideration	0	-16,367
Dividends	-42,174	-41,915
Intercompany transactions	0	0
Intercompany dividends paid	0	0
Net cash used in financing activities from continuing operations	-274,030	-53,643
Cash Flows from Discontinued Operations:	'	'
Net cash used in operating activities	-1,946	-2,167
Net cash used in discontinued operations	-1,946	-2,167
Effect of exchange rate changes on cash and cash equivalents	-6,880	4,476
Net increase (decrease) in cash and cash equivalents	-145,602	-10,602
Cash and cash equivalents at the beginning of the period	431,984	337,039
Cash and cash equivalents at the end of the period	286,382	326,437
Consolidation, Eliminations	'	'
Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]	'	'
Net cash (used in) provided by operating activities from continuing operations	-75,340	-66,071
Net Cash Provided by (Used in) Investing Activities [Abstract]	'	'
Expenditures for property, plant and equipment	0	0
Proceeds from sale of assets and investments	0	'
Payments for businesses and intangibles acquired, net of cash acquired	0	0
Investments in affiliates	0	0
Intercompany dividends received	-229,782	'
Net cash used in investing activities from continuing operations	-229,782	0
Cash Flows from Financing Activities of Continuing Operations:	'	'
Proceeds from long-term borrowings	0	0
Repayment of long-term borrowings	0	0
Debt issuance fees	0	0
Proceeds from share based compensation plans and the related tax impacts	0	0
Payments to Noncontrolling Interests	0	0
Payments for contingent consideration	'	0
Dividends	0	0
Intercompany transactions	0	0
Intercompany dividends paid	305,122	66,071
Net cash used in financing activities from continuing operations	305,122	66,071
Cash Flows from Discontinued Operations:	'	'
Net cash used in operating activities	0	0
Net cash used in discontinued operations	0	0
Effect of exchange rate changes on cash and cash equivalents	0	0
Net increase (decrease) in cash and cash equivalents	0	0
Cash and cash equivalents at the beginning of the period	0	0
Cash and cash equivalents at the end of the period	0	0
Parent Company	'	'
Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]	'	'
Net cash (used in) provided by operating activities from continuing operations	-80,537	-85,753
Net Cash Provided by (Used in) Investing Activities [Abstract]	'	'
Expenditures for property, plant and equipment	-2,146	-799
Proceeds from sale of assets and investments	1,669	'
Payments for businesses and intangibles acquired, net of cash acquired	0	0
Investments in affiliates	-60	-50
Intercompany dividends received	0	'
Net cash used in investing activities from continuing operations	-537	-849
Cash Flows from Financing Activities of Continuing Operations:	'	'
Proceeds from long-term borrowings	250,000	382,000
Repayment of long-term borrowings	-480,009	-375,000
Debt issuance fees	-3,689	-6,365
Proceeds from share based compensation plans and the related tax impacts	2,936	4,740
Payments to Noncontrolling Interests	0	0
Payments for contingent consideration	'	0
Dividends	-42,174	-41,915
Intercompany transactions	372,762	70,932
Intercompany dividends paid	0	0
Net cash used in financing activities from continuing operations	99,826	34,392
Cash Flows from Discontinued Operations:	'	'
Net cash used in operating activities	-1,946	-1,567
Net cash used in discontinued operations	-1,946	-1,567
Effect of exchange rate changes on cash and cash equivalents	0	0
Net increase (decrease) in cash and cash equivalents	16,806	-53,777
Cash and cash equivalents at the beginning of the period	42,749	70,860
Cash and cash equivalents at the end of the period	59,555	17,083
Guarantor Subsidiaries	'	'
Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]	'	'
Net cash (used in) provided by operating activities from continuing operations	300,960	147,461
Net Cash Provided by (Used in) Investing Activities [Abstract]	'	'
Expenditures for property, plant and equipment	-22,578	-42,854
Proceeds from sale of assets and investments	3,421	'
Payments for businesses and intangibles acquired, net of cash acquired	0	-1,820
Investments in affiliates	20	0
Intercompany dividends received	0	'
Net cash used in investing activities from continuing operations	-19,137	-44,674
Cash Flows from Financing Activities of Continuing Operations:	'	'
Proceeds from long-term borrowings	0	0
Repayment of long-term borrowings	0	0
Debt issuance fees	0	0
Proceeds from share based compensation plans and the related tax impacts	0	0
Payments to Noncontrolling Interests	0	0
Payments for contingent consideration	'	-14,802
Dividends	0	0
Intercompany transactions	-294,661	-72,574
Intercompany dividends paid	0	-17,400
Net cash used in financing activities from continuing operations	-294,661	-104,776
Cash Flows from Discontinued Operations:	'	'
Net cash used in operating activities	0	0
Net cash used in discontinued operations	0	0
Effect of exchange rate changes on cash and cash equivalents	0	0
Net increase (decrease) in cash and cash equivalents	-12,838	-1,989
Cash and cash equivalents at the beginning of the period	14,500	1,989
Cash and cash equivalents at the end of the period	1,662	0
Non-Guarantor Subsidiaries	'	'
Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]	'	'
Net cash (used in) provided by operating activities from continuing operations	63,715	140,235
Net Cash Provided by (Used in) Investing Activities [Abstract]	'	'
Expenditures for property, plant and equipment	-23,496	-10,987
Proceeds from sale of assets and investments	161	'
Payments for businesses and intangibles acquired, net of cash acquired	-28,535	-38,630
Investments in affiliates	0	0
Intercompany dividends received	229,782	'
Net cash used in investing activities from continuing operations	177,912	-49,617
Cash Flows from Financing Activities of Continuing Operations:	'	'
Proceeds from long-term borrowings	0	0
Repayment of long-term borrowings	0	0
Debt issuance fees	0	0
Proceeds from share based compensation plans and the related tax impacts	0	0
Payments to Noncontrolling Interests	-1,094	-736
Payments for contingent consideration	'	-1,565
Dividends	0	0
Intercompany transactions	-78,101	1,642
Intercompany dividends paid	-305,122	-48,671
Net cash used in financing activities from continuing operations	-384,317	-49,330
Cash Flows from Discontinued Operations:	'	'
Net cash used in operating activities	0	-600
Net cash used in discontinued operations	0	-600
Effect of exchange rate changes on cash and cash equivalents	-6,880	4,476
Net increase (decrease) in cash and cash equivalents	-149,570	45,164
Cash and cash equivalents at the beginning of the period	374,735	264,190
Cash and cash equivalents at the end of the period	$225,165	$309,354